Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН)

Список литературы/REFERENCES

  1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart fail- ure: executive summary (update 2005). European Heart Journal. 2005;26 (11):1115–40. DOI:10.1093/eurheartj/ehi204
  2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikows- ki P, Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treat- ment of acute and chronic heart failure 2008: The Task Force for the Di- agnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the Eu- ropean Society of Intensive Care Medicine (ESICM). European Heart Journal. 2008;29 (19):2388–442. DOI:10.1093/eurheartj/ehn309
  3. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagno- sis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaborati. Europe- an Journal of Heart Failure. 2012;14 (8):803–69. DOI:10.1093/eur- jhf/hfs105
  4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiol-ogy (ESC) Developed with the special contribution of the Heart Fail- ure Association (HFA) of the ESC. European Heart Journal. 2016;37 (27):2129–200. DOI:10.1093/eurheartj/ehw128
  5. Hunt SA, American College of Cardiology, American Heart Associa- tion Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Fail- ure). ACC/AHA 2005 guideline update for the diagnosis and manage- ment of chronic heart failure in the adult: a report of the American Col- lege of Cardiology/American Heart Association Task Force on Prac- tice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Car- diol. 2005;46 (6):e1–82. DOI:10.1016/j. jacc. 2005.08.022
  6. Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Gani- ats TG et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Associ- ation Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119 (14):1977–2016. DOI:10.1161/CIRCULA- TIONAHA. 109.192064
  7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/Ameri- can Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62 (16):e147–239. DOI:10.1016/j. jacc. 2013.05.019
  8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmaco- logical Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134 (13):e282–93. DOI:10.1161/CIR. 0000000000000435
  9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136 (6):e137–61. DOI:10.1161/CIR. 0000000000000509
  10. Heart Failure Society Of America null. HFSA 2006 Comprehen- sive Heart Failure Practice Guideline. J Card Fail. 2006;12 (1):e1–2. DOI:10.1016/j. cardfail. 2005.11.005
  11. Heart Failure Society of America. HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure. 2010;16 (6):e1– 194. DOI:10.1016/j. cardfail. 2010.04.004
  12. Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016; (8):7–13. [Fomin I. V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian journal of cardiology. 2016;8:7–13.] DOI:10.15829/1560-4 071-2016-8-7-13
  13. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА – ХСН (Часть II). Журнал Сердечная Недостаточность. 2006;7 (3):112–5. [Fomin I. V., Belenkov Yu. N., Mareev V. Yu., Ageev F. T., Badin Yu. V. et al. Prevalence of chronic heart failure in European part of Russian Federation – Data of AGE- CHF (Part II). Russian Heart Failure Journal. 2006;7 (1):112–5.]
  14. Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. Хроническая сердечная недостаточность. -М.: ГЭОТАР-Медиа; 2010. с. 7–77. [Fo- min I. V. Epidemiologiya hronicheskoj serdechnoj nedostatochnosti v Rossijskoj Federacii. Hronicheskaya serdechnaya nedostatochnost’. – M.: GEOTAR-Media; 2010. p. 7–77.] ISBN: 978-5-9704-1472-9
  15. Поляков Д. С., Фомин И. В., Валикулова Ф. Ю., Вайсберг А. Р., Краием Н., Бадин Ю. В. и др. Эпидемиологическая программа ЭПОХА – ХСН: декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА – Д – ХСН). Журнал Сердечная Недостаточность. 2016;17 (5):299– 305. [Polyakov D. S., Fomin I. V., Valikulova F. Yu., Vaysberg A. R., Kraiem N., Badin Yu. V. et al. The EPOCH-CHF epidemiological pro- gram: decompensated chronic heart failure in real-life clinical practice (EPOCH-D–CHF). Russian Heart Failure Journal. 2016;17 (5):299– 305] DOI:10.18087/rhfj. 2016.5.2239
  16. Козиолова Н. А., Никонова Ю. Н., Шилова Я. Э., Агафонов А. В., Полянская Е. А. Характеристика хронической сердечной недостаточности на фоне перманентной формы фибрилляции предсердий. Журнал Сердечная Недостаточность. 2013;14 (1):14– 21. [Koziolova N. A., Nikonova Yu. N., Shilova Ya. E., Agafonov A. V., Polianskaya E. A. Description of chronic heart failure against the back- ground of permanent atrial fibrillation. Russian Heart Failure Journal. 2013;14 (1):14–21.] DOI:10.18087/rhfj. 2013.1.1806
  17. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93 (9):1137–46. DOI:10.1136/hrt. 2003.025270
  18. Артемьева Е. Г., Маленкова В. Ю., Фролова Е. В. Распространен ность артериальной гипертензии при хронической сердечной недостаточности в Чувашской Республике. Медицинский альманах. 2011; (16):51–4. [Artemieva E. G., Malenkova V. Yu., Fro- lova E. V. The prevalence of arterial hypertension at chronic cardiac in- sufficiency in Chuvash Republic. Medical almanac. 2011;16:51–4.]
  19. Сергеева Е. М., Малишевский М. В., Васина А. А., Мищенко Т. А., Кузьмина Ю. С., Раемгулов Р. А. Лечение хронической сердечной недостаточности в первичном звене муниципального здравоохранения в г. Тюмени. Медицинская наука и образование Урала. 2015;16 (4):32–4. [Sergeeva E. M., Malishevsky M. V., Vasi- na A. A., Mishchenko T. A., Kuzmina Y. S., Raemgulov R. A. Chron- ic heart failure treatment in primary municipal health services in Tyu- men. Medical science and education of the Ural. 2015;16 (4):32–4.]
  20. Шакирова Р. М., Галявич А. С., Камалов Г. М. Распространен- ность сердечно-сосудистых заболеваний и сахарного диабета в Республике Татарстан и их взаимосвязь с симптомами хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2005;6 (2):72–3. [Shakirova R. M., Galyav- ich A. S., Kamalov G. M. Prevalence of cardiovascular diseasesand di- abetes mellitus and their relationshipwith symptoms of chronic heart failurein the Republic of Tatarstan. Russian Heart Failure Journal. 2005;6 (2):72–3.]
  21. Смирнова Е. А. Изучение распространенности и этиологии хронической сердечной недостаточности в Рязанской области. Российский кардиологический журнал. 2010; (2):78–83. [Smirno- va E. A. Prevalence and etiology of chronic heart failure in Ryazan Re- gion. Russian journal of cardiology. 2010;2:78–83.]
  22. Бабанская Е. Б., Меньшикова Л. В., Дац Л. С. Эпидемиология хронической сердечной недостаточности в городе Иркутске. Бюллетень ВСНЦ СО РАМН. 2012; (5–1):25–8. [Babanskaya E. B., Menshikovа L. V., Dats L. S. Epidemiology of chronic heart failure in Ir- kutsk. Byulleten’ Vostochno-Sibirskogo nauchnogo centra SO RAMN. 2012;5–1:25–8.]
  23. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Mane- mann SM, Jiang R et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA In- ternal Medicine. 2015;175 (6):996. DOI:10.1001/jamainternmed. 2015.0924
  24. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with pre- served ejection fraction. New England Journal of Medicine. 2006;355 (3):251–9. DOI:10.1056/NEJMoa052256
  25. Фомин И. В., Бадин Ю. В., Поляков Д. С., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. и др. Предгипертония: как часто встречается данное состояние сердечно-сосудистой системы у граждан Европейской части России (данные исследования ЭПОХА-АГ, 2002–2007 гг.). Современные технологии в медицине. 2013;5 (2):38–46. [Fomin I. V., Badin Y. V., Polyakov D. S., Belen- kov Y. N., Mareev V. Y., Ageev F. Т. et al. Prehypertension: how of- ten this cardiovascular condition occurs in citizens of European Rus- sia (EPOCH-AH, 2002–2007). Sovremennye tehnologii v medicine 2013; 5 (2): 38–46]
  26. Троицкая Е. А., Котовская Ю. В., Кобалава Ж. Д. Прогностическое значение высокой межвизитной вариабельности систолического артериального давления у больных с хронической сердечной недостаточностью со сниженной фракцией выброса. Материалы IV всероссийской конференции «Противоречия современной кардиологии: спорные и нерешенные вопросы». МIСЕ Partner; 2015. с. 138. [Troickaya E. A., Kotovskaya Yu. V., Kobalava Zh. D. Prog- nosticheskoe znachenie vysokoj mezhvizitnoj variabel’nosti sistol- icheskogo arterial’nogo davleniya u bol’nyh s hronicheskoj serdech- noj nedostatochnost’yu so snizhennoj frakciej vybrosa. Materialy IV vserossijskoj konferencii “Protivorechiya sovremennoj kardiologii: spornye i nereshennye voprosy.” MISE Partner; 2015. p. 138.]
  27. Капанадзе Л. Г., Герасимова В. В., Мареев Ю. В., Рогоза А. Н., Мареев В. Ю. Факторы, влияющие на 5-летнюю выживаемость больных легкой и умеренной ХСН: роль уровня офисного АД и показателей суточного профиля АД в прогнозе заболевания. Журнал Сердечная Недостаточность. 2013;14 (6):353–61. [Kapanadze L. G., Gerasimova V. V., Mareev Yu. V., Rogoza A. N., Mareev V. Yu. Factors influencing 5-year survival in patients with mild and moderate CHF: Role of office BP and parametersof 24-h BP profile in disease prognosis. Russian Heart Failure Journal. 2013;14 (6):353–61.]
  28. Глезер М. Г., Чесникова А. И., Гиляревский С. Р., Перепеч Н. Б., Асташкин Е. И., Лопатин Ю. М. и др. Снижение частоты сердечных сокращений у больных ишемической болезнью с хронической сердечной недостаточностью – цель и средства. Кардиология. 2014;54 (4):109–20. [Glezer M. G., Chesnikova A. I., Gilyarevsky S. R., Perepech N. B., Astashkin E. I., Lopatin Yu. M., Vasyuk Yu. A. Decrease in heart rate in patients with coronary artery disease and chronic heart failure – the purpose and means. Kardiolo- giia. 2014;54 (4):109–20.]
  29. Фомин И. В., Поляков Д. С. β-адреноблокаторы: нереализованность задач или неготовность врачей в Российской Федерации к оптимизации лечения? Системные гипертензии. 2014;11 (1):56– 63. [Fomin I. V., Polyakov D. S. β-Blockers: the lack of taskimplemen- tation or the unwillingness of doctors in the Russian Federation to op- timize the treatment? System hypertension. 2014;11 (1):56–63.]
  30. Cleland J. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe Part 1: pa- tient characteristics and diagnosis. European Heart Journal. 2003;24 (5):442–63. DOI:10.1016/S0195-668X (02) 00823–0
  31. Жиров И. В., Романова Н. В., Терещенко С. Н., Осмоловс- кая Ю. Ф. Эпидемиология и особенности терапии хронической сердечной недостаточности в сочетании с фибрилляцией предсердий. Кардиология. 2015; (3):91–6. [Zhirov I. V., Ro- manova N. V., Tereshchenko S. N., Osmolovskaya Yu. F. Epidemi- ology and management of heart failure patients with atrial fibril- lation. Kardiologiia. 2015;55 (3):91–6.] DOI:10.18565 /cardio. 2015.3.91–96
  32. Козиолова Н. А. Закономерности формирования хронической сердечной недостаточности у больных ишемической болезнью сердца и хронической обструктивной болезнью легких на фоне множественной коморбидной патологии. Журнал Сердечная Недостаточность. 2016;17 (3):151–63. [Koziolova N. A., Masalki- na O. V., Kozlova E. V. Regularities in development of chronic heart failure in patients with ischemic heart disease and chronic obstruc- tive pulmonary disease associated with multiple comorbidity. Russian Heart Failure Journal. 2016;17 (3):151–163]
  33. Ефремова Е. В., Шутов А. М. Коморбидность и прогноз больных при хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2014;15 (5):294–300. [Efremova E. V., Shutov A. M. Comorbidity and prognosis in patients with chronic heart failure. Russian Heart Failure Journal. 2014;15 (5): 294–300]
  34. Мареев Ю. В., Мареев В. Ю. Характеристика и лечение пациентов с ХСН, госпитализированных в стационар. Кардиология. 2017;57 (S4):20–30. [Mareev Yu. V., Mareev V. Yu. Characteristics and treat- ment of hospitalized patients with CHF. Kardiologiia. 2017;17 (S4):20–30. DOI:10.18087/cardio. 2433]
  35. Арутюнов А. Г., Рылова А. К., Арутюнов Г. П. Регистр госпитализированных пациентов с декомпенсацией крово- обращения (Павловский регистр). Сообщение 1. Современ- ная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал Сердечная Недостаточность. 2014;15 (1):23–32. [Arutyunov A. G., Rylova A. K., Arutyunov G. P. Registry of hospitalized patients with circulatorydecompensation (Pavlov Registry). Report 1. Current clin- ical characteristics of a patient with circulatory decompensation. Clin- ical phenotypes of patients. Russian Heart Failure Journal. 2014;15 (1):23–32.]
  36. Арутюнов А. Г., Драгунов Д. О., Арутюнов Г. П., Рылова А. К., Пашкевич Д. Д., Витер К. В. и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015;55 (5):12– 21. [Arutyunov A. G., Dragunov D. O., Arutyunov G. P., Rylova A. K., Pashkevich D. D., Viter K. V. et al. First open study of syndrome of acute decompensation of heart failure and concomitant diseases in Russian Federation: independent registry ORAKUL. Kardiologiia. 2015;55 (5):12–21.] DOI:10.18565/cardio. 2015.5.12–21
  37. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Сравнительная характеристика больных ХСН в зависимости от величины фрак- ции выброса по результатам Российского многоцентрового исследования ЭПОХА-О-ХСН: снова о проблеме ХСН с сохраненной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2006;7 (4):164–71. [Mareev V. Yu., Danielyan M. O., Belenkov Yu. N. Comparative characteristicsof pa- tients with CHF in relationto the value of injection fraction by da- ta from the Russian multicenter study EPOCH-A-CHF: once more about the problem of CHF with preserved left ventricular systolic function. Russian Heart Failure Journal. 2006;7 (4):164–171]
  38. Ощепкова Е. В., Лазарева Н. В., Салтыкова Д. Ф., Терещен- ко С. Н. Первые результаты Российского регистра хронической сердечной недостаточности. Кардиология. 2015;55 (5):22–8. [Osh- chepkova E. V., Lazareva N. V., Satlykova D. F., Tereshchenko S. N. The first results of the Russian register of chronic heart failure. Kardiologi- ia. 2015;55 (5):22–8.]
  39. Арутюнов А. Г., Рылова А. К., Арутюнов Г. П. Регистр госпита- лизированных пациентов с декомпенсацией кровообращения (регистр Павловской больницы). Сообщение 2. Клиническое значение и прогностическая роль некоторых параметров, опреде- ляемых при физикальном и инструментальном обследовании пациентов с декомпенсацией кровообращения. Журнал Сердечная Недостаточность. 2014;15 (2):67–75. [Arutyunov A. G., Rylo- va A. K., Arutyunov G. P. Registry of hospitalized patients with de- compensated circulation («Pavlov’s hospital registr»). Report 2. Clin- ical significance and prognostic role of some parameters determined during physical and instrumental examination of patients with decom- pensated circulationRussian Heart Failure Journal. 2014;15 (2):67– 75.] DOI:10.18087/rhfj. 2014.2.1934
  40. Cleland JG, Swedberg K, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Fol- lath F et al. The Euro Heart Failure Survey of the EUROHEART sur- vey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics Universi- ty of York. Eur J Heart Fail. 2000;2 (2):123–32.
  41. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю., Беленков Ю. Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4–7. [Ageev F. T., Danielyan M. O., Mareev V. Y. et al. Patients with chronic heart fail- ure in the Russian ambulatory practice: contingent features, diagnosis and treatment (studies of AGE-O-CHF). Russian Heart Failure Jour- nal. 2004;5 (1):4–7.]
  42. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal. 2011;32 (6):670–9. DOI:10.1093/eurheartj/ehq426
  43. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al. How to diagnose diastolic heart failure: a con- sensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiog- raphy Associations of the European Society of Cardiology. Euro- pean Heart Journal. 2007;28 (20):2539–50. DOI:10.1093/eur- heartj/ehm037
  44. Marwick TH, Raman SV, Carrió I, Bax JJ. Recent Developments in Heart Failure Imaging. JACC: Cardiovascular Imaging. 2010;3 (4):429–39. DOI:10.1016/j. jcmg. 2010.02.002
  45. Paterson DI, OMeara E, Chow BJ, Ukkonen H, Beanlands RS. Recent advances in cardiac imaging for patients with heart failure: Current Opinion in Cardiology. 2011;26 (2):132–43. DOI:10.1097/HCO. 0b013e32834380e7
  46. McMurray JJV. Systolic Heart Failure. New England Journal of Medi- cine. 2010;362 (3):228–38. DOI:10.1056/NEJMcp0909392
  47. Chen J, Normand S-LT, Wang Y, Krumholz HM. National and Re- gional Trends in Heart Failure Hospitalization and Mortality Rates for Medicare Beneficiaries, 1998–2008. JAMA. 2011;306 (15):1669. DOI:10.1001/jama. 2011.1474
  48. Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND et al. Hospitalizations After Heart Failure Diagnosis. Jour- nal of the American College of Cardiology. 2009;54 (18):1695–702. DOI:10.1016/j. jacc. 2009.08.019
  49. Khot UN, Jia G, Moliterno DJ, Lincoff AM, Khot MB, Harrington RA et al. Prognostic Importance of Physical Examination for Heart Fail- ure in Non – ST-Elevation Acute Coronary Syndromes: The En- during Value of Killip Classification. JAMA. 2003;290 (16):2174. DOI:10.1001/jama. 290.16.2174
  50. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. As- sessing diagnosis in heart failure: which features are any use? QJM. 1997;90 (5):335–9. PMID:9205668
  51. Mant J, Doust J, Roalfe A, Barton P, Cowie M, Glasziou P et al. Sys- tematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technology Assessment [Internet]. 2009 [cited on Febrary 1, 2018];13 (32). DOI:10.3310/hta13320
  52. Oudejans I, Mosterd A, Bloemen JA, Valk MJ, van Velzen E, Wield- ers JP et al. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Europe- an Journal of Heart Failure. 2011;13 (5):518–27. DOI:10.1093/eur- jhf/hfr021
  53. Fonseca C. Diagnosis of heart failure in primary care. Heart Failure Re- views. 2006;11 (2):95–107. DOI:10.1007/s10741-006-9481-0
  54. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KGM et al. The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart Failure. Circulation. 2011;124 (25):2865–73. DOI:10.1161/CIRCU- LATIONAHA. 111.019216
  55. Rutten FH. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005;331 (7529):1379–0. DOI:10.1136/bmj. 38664.661181.55
  56. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, Mc- Murray JJV. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Fail- ure. 2009;11 (2):130–9. DOI:10.1093/eurjhf/hfn013
  57. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, Mc- Cord J et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. American Heart Jour- nal. 2006;151 (5):999–1005. DOI:10.1016/j. ahj. 2005.10.011
  58. Беленков Ю. Н., Мареев В. Ю. Принципы рационального лечения хронической сердечной недостаточности. -М.: Медиа Медика; 2000. 266 с. [Belenkov Yu. N., Mareev v. Yu. Principles of rational treat- ment of chronic heart failure. – M.: Media-medika; 2000. – 266p.]
  59. Мареев В. Ю., Даниелян М. О. Оптимизация применения БЕталока ЗОК у больных ХСН в повседневной врачебной практикЕ. Дизайн и результаты исследования БЕЗЕ. Журнал Сердечная Недостаточность. 2005;6 (6):251–7. [Mareev V. Yu., Daniely- an M. O. Optimizing the use of BEtaloc ZOK in patients with CHF in routine medical practicE. Design and results of the study BEZE. Rus- sian Heart Failure Journal. 2005;6 (6):251–7]
  60. Мареев В. Ю. Организация исследования и характеристика больных в исследовании «ФАСОН». Журнал Сердечная Недо- статочность. 2002;3 (2):97–8. [Mareev V. Yu. Design and patient characteristics in the study «FASON». Russian Heart Failure Jour- nal. 2002;3 (2):97–8]
  61. Мареев Ю. В., Герасимова В. В., Горюнова Т. В., Петрухина А. А., Даниелян М. О., Капанадзе Л. Г. и др. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13 (5):255–66. [Mareev Yu. V., Gerasimo- va V. V., Goriunova T. V., Petrukhina A. A., Danielian M. O., Kap- anadze L. G. et al. Factors defining the prognosis in chronic heart fail- ure: role of the QRS width and morphology. Russian Heart Failure Journal. 2012;13 (5):255–66.]
  62. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chan- drasekaran K et al. Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography. Journal of the American Society of Echocardiogra- phy. 2010;23 (7):685–713. DOI:10.1016/j. echo. 2010.05.010
  63. Dokainish H, Nguyen JS, Bobek J, Goswami R, Lakkis NM. Assess- ment of the American Society of Echocardiography-European Asso- ciation of Echocardiography guidelines for diastolic function in pa- tients with depressed ejection fraction: an echocardiographic and in- vasive haemodynamic study. European Journal of Echocardiography. 2011;12 (11):857–64. DOI:10.1093/ejechocard/jer157
  64. Kirkpatrick JN, Vannan MA, Narula J, Lang RM. Echocardiography in Heart Failure. Journal of the American College of Cardiology. 2007;50 (5):381–96. DOI:10.1016/j. jacc. 2007.03.048
  65. Lancellotti P, Moura L, Pierard LA, Agricola E, Popescu BA, Tri- bouilloy C et al. European Association of Echocardiography recom- mendations for the assessment of valvular regurgitation. Part 2: mi- tral and tricuspid regurgitation (native valve disease). European Jour- nal of Echocardiography. 2010;11 (4):307–32. DOI:10.1093/ejecho- card/jeq031
  66. Lancellotti P, Tribouilloy C, Hagendorff A, Moura L, Popescu BA, Agricola E et al. European Association of Echocardiography recom- mendations for the assessment of valvular regurgitation. Part 1: aortic and pulmonary regurgitation (native valve disease). European Jour- nal of Echocardiography. 2010;11 (3):223–44. DOI:10.1093/ejecho- card/jeq030
  67. Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lan- cellotti P et al. European Association of Echocardiography recommen- dations for training, competence, and quality improvement in echocar- diography. European Journal of Echocardiography. 2009;10 (8):893– 905. DOI:10.1093/ejechocard/jep151
  68. Nagueh SF, Bhatt R, Vivo RP, Krim SR, Sarvari SI, Russell K et al. Echo- cardiographic Evaluation of Hemodynamics in Patients With Decom- pensated Systolic Heart Failure. Circulation: Cardiovascular Imaging. 2011;4 (3):220–7. DOI:10.1161/CIRCIMAGING. 111.963496
  69. Sicari R, Nihoyannopoulos P, Evangelista A, Kasprzak J, Lancellotti P, Poldermans D et al. Stress echocardiography expert consensus state- ment: European Association of Echocardiography (EAE) (a registered branch of the ESC). European Journal of Echocardiography. 2008;9 (4):415–37. DOI:10.1093/ejechocard/jen175
  70. Davie AP, Francis CM, Love MP, Caruana L, Starkey IR, Shaw TRD et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312 (7025):222–222. DOI:10.1136/bmj. 312.7025.222
  71. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased sys- tolic function in patients with heart failure. The American Journal of Medicine. 2002;112 (6):437–45. DOI:10.1016/S0002–9343 (02) 01048–3
  72. Khunti K, Squire I, Abrams KR, Sutton AJ. Accuracy of a 12-lead elec- trocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. European Journal of Heart Failure. 2004;6 (5):571–6. DOI:10.1016/j. ejheart. 2004.03.013
  73. Madias JE. Why Recording of an Electrocardiogram Should be Re- quired in Every Inpatient and Outpatient Encounter of Patients with Heart Failure: ECG IN HEART FAILURE. Pacing and Clini- cal Electrophysiology. 2011;34 (8):963–7. DOI:10.1111/j. 1540– 8159.2011.03131. x
  74. Schwitter J. Extending the Frontiers of Cardiac Magnetic Reso- nance. Circulation. 2008;118 (2):109–12. DOI:10.1161/CIRCU- LATIONAHA. 108.790139
  75. Gebker R, Schwitter J, Fleck E, Nagel E. How We Perform Myo- cardial Perfusion With Cardiovascular Magnetic Resonance. Jour- nal of Cardiovascular Magnetic Resonance. 2007;9 (3):539–47. DOI:10.1080/10976640600897286
  76. Beller GA, Heede RC. SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive As- sessment of Myocardial Perfusion and Myocardial Viability. Jour- nal of Cardiovascular Translational Research. 2011;4 (4):416–24. DOI:10.1007/s12265-011-9290-2
  77. Leong DP, De Pasquale CG, Selvanayagam JB. Heart Failure With Normal Ejection Fraction: The Complementary Roles of Echocar- diography and CMR Imaging. JACC: Cardiovascular Imaging. 2010;3 (4):409–20. DOI:10.1016/j. jcmg. 2009.12.011
  78. Myerson SG. Valvular and Hemodynamic Assessment with CMR. Heart Failure Clinics. 2009;5 (3):389–400. DOI:10.1016/j. hfc. 2009.02.004
  79. Raman SV, Simonetti OP. The CMR Examination in Heart Failure. Heart Failure Clinics. 2009;5 (3):283–300. DOI:10.1016/j. hfc. 2009.02.002
  80. Sheikine Y, Di Carli MF. Integrated PET/CT in the assessment of etio- logy and viability in ischemic heart failure. Current Heart Failure Re- ports. 2008;5 (3):136–42. DOI:10.1007/s11897-008-0022-0
  81. Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Got- tlieb I et al. Diagnostic Performance of Coronary Angiography by 64-Row CT. New England Journal of Medicine. 2008;359 (22):2324– 36. DOI:10.1056/NEJMoa0806576
  82. Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M et al. F-18-Fluorodeoxyglucose Positron Emission Tomography Im- aging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. Journal of the Ameri- can College of Cardiology. 2007;50 (20):2002–12. DOI:10.1016/j. jacc. 2007.09.006
  83. Ewald B, Ewald D, Thakkinstian A, Attia J. Meta-analysis of B type na- triuretic peptide and N-terminal pro B natriuretic peptide in the diag- nosis of clinical heart failure and population screening for left ventric- ular systolic dysfunction. Internal Medicine Journal. 2008;38 (2):101– 13. DOI:10.1111/j. 1445–5994.2007.01454. x
  84. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A Systematic Re- view of the Diagnostic Accuracy of Natriuretic Peptides for Heart Failure. Archives of Internal Medicine. 2004;164 (18):1978. DOI:10.1001/archinte. 164.18.1978
  85. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, Mc- Donagh T et al. The diagnostic accuracy of plasma BNP and NTproB- NP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. European Journal of Heart Failure. 2005;7 (4):537–41. DOI:10.1016/j. ejheart. 2005.01.022
  86. Maisel A, Mueller C, Adams K, Anker SD, Aspromonte N, Cle- land JGF et al. State of the art: Using natriuretic peptide levels in clin- ical practice. European Journal of Heart Failure. 2008;10 (9):824–39. DOI:10.1016/j. ejheart. 2008.07.014
  87. Fuat A, Murphy JJ, Hungin APS, Curry J, Mehrzad AA, Hethering- ton A et al. The diagnostic accuracy and utility of a B-type natriuret- ic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract. 2006;56 (526):327–33. PMID:16638247
  88. Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Red- field MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. Journal of Cardiac Failure. 2000;6 (3):194– 200. DOI:10.1054/jcaf. 2000.9676
  89. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole- Wilson PA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. The Lancet. 1997;350 (9088):1349–53. DOI:10.1016/S0140–6736 (97) 06031–5
  90. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001;111 (4):274–9. PMID:11566457
  91. Kelder JC, Cowie MR, McDonagh TA, Hardman SMC, Grobbee DE, Cost B et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97 (12):959–63. DOI:10.1136/hrt. 2010.220426
  92. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clini- cal Utility of Three B-Type Natriuretic Peptide Assays for the Ini- tial Diagnostic Assessment of New Slow-Onset Heart Failure. Jour- nal of Cardiac Failure. 2011;17 (9):729–34. DOI:10.1016/j. cardfail. 2011.04.013
  93. Gustafsson F, Steensgaard-Hansen F, Badskjær J, Poulsen AH, Corell P, Hildebrandt P. Diagnostic and Prognostic Performance of N-Terminal ProBNP in Primary Care Patients With Suspected Heart Failure. Jour- nal of Cardiac Failure. 2005;11 (5):S15–20. DOI:10.1016/j. cardfail. 2005.04.022
  94. Nielsen OW, Rasmussen V, Christensen NJ, Hansen JF. Neuroendo- crine testing in community patients with heart disease: plasma N-ter- minal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability. Scandinavian Journal of Clinical and Laboratory Investigation. 2004;64 (7):619–28. DOI:10.1080/00365510410002878
  95. Porapakkham P. B-Type Natriuretic Peptide – Guided Heart Failure Therapy: A Meta-analysis. Archives of Internal Medicine. 2010;170 (6):507. DOI:10.1001/archinternmed. 2010.35
  96. Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P, et al. Recommendations for chamber quantification☆. European Jour- nal of Echocardiography. 2006;7 (2):79–108. DOI:10.1016/j. euje. 2005.12.014
  97. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность ХСН в Европейской части Российской Федерации – данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006;7 (1):4–7. [Fomin I. V., Belen- kov Yu. N., Mareev V. Yu., Ageev F. T., Badin Yu. V., Galyavich A. S. et al. Prevalence of CHF in European part of the Russian Federation: da- ta from EPOCH-CHF. Russian Heart Failure Journal. 2006;7 (1):4– 7.]
  98. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascu- lar Imaging. Journal of the American Society of Echocardiography. 2015;28 (1):1–39. e14. DOI:10.1016/j. echo. 2014.10.003
  99. Lang RM, Badano LP, Tsang W, Adams DH, Agricola E, Buck T et al. EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography. European Heart Jour- nal – Cardiovascular Imaging. 2012;13 (1):1–46. DOI:10.1093/ehj- ci/jer316
  100. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smis- eth OA et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. European Journal of Echo- cardiography. 2008;10 (2):165–93. DOI:10.1093/ejechocard/jep007
  101. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, Quiñones MA. Doppler Tissue Imaging: A Noninvasive Technique for Evaluation of Left Ventricular Relaxation and Estimation of Filling Pressures. Journal of the American College of Cardiology. 1997;30 (6):1527– 33. DOI:10.1016/S0735–1097 (97) 00344–6
  102. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvard- sen T et al. Recommendations for the evaluation of left ventricular di- astolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Car- diovascular Imaging. J Am Soc Echocardiogr. 2016;29 (4):277–314. DOI:10.1016/j. echo. 2016.01.011
  103. Schwitter J, Arai AE. Assessment of cardiac ischaemia and viability: role of cardiovascular magnetic resonance. European Heart Journal. 2011;32 (7):799–809. DOI:10.1093/eurheartj/ehq481
  104. Kilner PJ, Geva T, Kaemmerer H, Trindade PT, Schwitter J, Webb GD. Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology. European Heart Journal. 2010;31 (7):794–805. DOI:10.1093/eurheartj/ehp586
  105. CMR Update. Schwitter J, редактор. -Zürich: Schwitter; 2008. 239 p. ISBN: 978-3-033-01674-3
  106. Bruder O, Schneider S, Nothnagel D, Pilz G, Lombardi M, Sinha A et al. Acute Adverse Reactions to Gadolinium-Based Contrast Agents in CMR. JACC: Cardiovascular Imaging. 2011;4 (11):1171–6. DOI:10.1016/j. jcmg. 2011.06.019
  107. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A Scientific Statement from the American Heart Association, the American College of Cardiology, and the Eu- ropean Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Soci- ety of Cardiology. European Heart Journal. 2007;28 (24):3076–93. DOI:10.1093/eurheartj/ehm456
  108. Arena R, Myers J, Guazzi M. Cardiopulmonary Exercise Test- ing Is a Core Assessment for Patients With Heart Failure. Con- gestive Heart Failure. 2011;17 (3):115–9. DOI:10.1111/j. 1751– 7133.2011.00216. x
  109. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P et al. Genetic counselling and testing in cardiomyopathies: a position state- ment of the European Society of Cardiology Working Group on Myo- cardial and Pericardial Diseases. European Heart Journal. 2010;31 (22):2715–26. DOI:10.1093/eurheartj/ehq271
  110. Wedel H, McMurray JJV, Lindberg M, Wikstrand J, Cleland JGF, Cor- nel JH et al. Predictors of fatal and non-fatal outcomes in the Con- trolled Rosuvastatin Multinational Trial in Heart Failure (CORO- NA): incremental value of apolipoprotein A-1, high-sensitivity C-reac- tive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure. 2009;11 (3):281–91. DOI:10.1093/eur- jhf/hfn046
  111. Allen LA, Felker GM, Pocock S, McMurray JJV, Pfeffer MA, Swed- berg K et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Fail- ure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. European Journal of Heart Failure. 2009;11 (2):170–7. DOI:10.1093/eurjhf/hfn031
  112. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. The Lancet. 2009;374 (9689):543–50. DOI:10.1016/S0140–6736 (09) 61378–7
  113. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJV, Pfeffer MA, et al. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. Journal of the American College of Cardiology. 2007;50 (1):40–7. DOI:10.1016/j. jacc. 2007.02.067
  114. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swed- berg KB et al. Predictors of mortality and morbidity in patients with chronic heart failure. European Heart Journal. 2006;27 (1):65–75. DOI:10.1093/eurheartj/ehi555
  115. Komajda M, Carson PE, Hetzel S, McKelvie R, McMurray J, Ptaszyns- ka A et al. Factors Associated With Outcome in Heart Failure With Pre- served Ejection Fraction: Findings From the Irbesartan in Heart Fail- ure With Preserved Ejection Fraction Study (I-PRESERVE). Circula- tion: Heart Failure. 2011;4 (1):27–35. DOI:10.1161/CIRCHEART- FAILURE. 109.932996
  116. Ketchum ES, Levy WC. Establishing Prognosis in Heart Failure: A Multimarker Approach. Progress in Cardiovascular Diseases. 2011;54 (2):86–96. DOI:10.1016/j. pcad. 2011.03.003
  117. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michel- son EL et al. Effects of candesartan on mortality and morbidity in pa- tients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362 (9386):759–66.
  118. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121 (12):1393–405. DOI:10.1161/CIRCULATIONAHA. 109.909614
  119. Whitman IR, Agarwal V, Nah G, Dukes JW, Vittinghoff E, Dewland TA et al. Alcohol Abuse and Cardiac Disease. Journal of the American College of Cardiology. 2017;69 (1):13–24. DOI:10.1016 /j. jacc. 2016.10.048
  120. AlFaleh H, Elasfar AA, Ullah A, AlHabib KF, Hersi A, Mimish L et al. Worsening heart failure in «real-world» clinical practice: predictors and prognostic impact: WHF in «real-world» clinical practice. European Journal of Heart Failure. 2017;19 (8):987–95. DOI:10.1002/ejhf. 515
  121. Voors AA, Ouwerkerk W, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P et al. Development and validation of multivariable mo- dels to predict mortality and hospitalization in patients with heart fail- ure: Mortality and hospitalization models in heart failure. European Journal of Heart Failure. 2017;19 (5):627–34. DOI:10.1002/ejhf. 785
  122. Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J et al. Risk Prediction in Patients With Heart Failure. JACC: Heart Failure. 2014;2 (5):440–6. DOI:10.1016/j. jchf. 2014.04.008
  123. Мареев В. Ю. Фармакоэкономическая оценка использования иАПФ в амбулаторном лечении больных сердечной недостаточ- ностью (ФАСОН). ЖСН. 2002;3 (1):38–9. [Mareev V. Yu. Phar- macoeconomic evaluation of the use of ACE-I in ambulatory patients with heart failure (FASON). Russian Heart Failure Journal. 2002;3 (1):38–9.]
  124. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88 (1):107–15. DOI:10.1161/01. CIR. 88.1.107
  125. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Ef- fect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364 (9438):937–52. DOI:10.1016/S0140– 6736 (04) 17018–9
  126. Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, et al. The effect of statin therapy on heart failure events: a collabora- tive meta-analysis of unpublished data from major randomized trials. European Heart Journal. 2015;36 (24):1536–46. DOI:10.1093/eur- heartj/ehv072
  127. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW et al. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia. New England Journal of Medicine. 1995;333 (20):1301–8. DOI:10.1056/NEJM199511163332001
  128. Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J et al. Blood- Pressure and Cholesterol Lowering in Persons without Cardiovascu- lar Disease. New England Journal of Medicine. 2016;374 (21):2032– 43. DOI:10.1056/NEJMoa1600177
  129. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359 (21):2195–207. DOI:10.1056/NEJMoa0807646
  130. Blood-Pressure and Cholesterol Lowering in the HOPE-3 Tri- al. New England Journal of Medicine. 2016;375 (12):1190–4. DOI:10.1056/NEJMc1608916
  131. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P et al. Blood- Pressure Lowering in Intermediate-Risk Persons without Cardiovascu- lar Disease. New England Journal of Medicine. 2016;374 (21):2009– 20. DOI:10.1056/NEJMoa1600175
  132. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men – morbidity, risk factors and prognosis. Journal of Internal Medicine. 2001;249 (3):253–61. DOI:10.1046/j. 1365–2796.2001.00801. x
  133. Authors/Task Force Members, Fuster V, Ryden LE, Cannom DS, Cri- jns HJ, Curtis AB et al. ACC/AHA/ESC 2006 guidelines for the man- agement of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardi- ology Committee for Practice Guidelines (Writing Committee to Re- vise the 2001 Guidelines for the Management of Patients with Atri- al Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. European Heart Journal. 2006;27 (16):1979–2030. DOI:10.1093/eurheartj/ehl176
  134. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Первые результаты национального эпидемиологического исследования. Эпидемиологическое Обследование больных ХСН в реальной практике (по Обращаемости) ЭПОХА-О-ХСН. Журнал Сердечная Недостаточность. 2003;4 (3):116–20. [Mareev V. Yu., Danielyan M. O., Belenkov Yu. N. The first results of the national epi- demiological study. Epidemiological Examination of patients with CHF in real practice (on the Marketability) EPOHA-O-CHF. Rus- sian Heart Failure Journal. 2003;4 (3):116–20.]
  135. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA: The Journal of the American Medical Associa- tion. 1996;275 (20):1571–6. DOI:10.1001/jama. 275.20.1571
  136. Effects Morbidity of Treatment on in Hypertension: II. Results in Patients With Diastolic Blood Pressure Averaging 90 Through 114 mm Hg. JAMA. 1970;213 (7):1143. DOI:10.1001 /jama. 1970.03170330025003
  137. Kostis JB. Prevention of heart failure by antihypertensive drug treat- ment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA: The Journal of the American Medical Association. 1997;278 (3):212–6. DOI:10.1001 / jama. 278.3.212
  138. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure low- ering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pres- sure levels – updated overview and meta-analyses of randomized trials. Journal of Hypertension. 2016;34 (4):613–22. DOI:10.1097/HJH. 0000000000000881
  139. Baker DW. Prevention of heart failure. Journal of Cardiac Failure. 2002;8 (5):333–46. DOI:10.1054/jcaf. 2002.0805333
  140. The SPRINT Research Group. A Randomized Trial of Intensive ver- sus Standard Blood-Pressure Control. New England Journal of Medi- cine. 2015;373 (22):2103–16. DOI:10.1056/NEJMoa1511939
  141. Whelton PK, Carey RM, Aronow WS, Casey DE, Col- lins KJ, Dennison Himmelfarb C et al. 2017 ACC/AHA/AA- PA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guide- line for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Journal of the American College of Car- diology. 2018;71 (19):e127–248. DOI:10.1016/j. jacc. 2017.11.006
  142. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowe- ring treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283 (15):1967–75. PMID:10789664
  143. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hans- son L et al. Outcomes in hypertensive patients at high cardiovascu- lar risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. The Lancet. 2004;363 (9426):2022–31. DOI:10.1016/S0140–6736 (04) 16451–9
  144. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, et al. Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. New England Journal of Medicine. 2008;359 (12):1225–37. DOI:10.1056/NEJMoa0804593
  145. Randomised trial of a perindopril-based blood-pressure-lower- ing regimen among 6105 individuals with previous stroke or tran- sient ischaemic attack. The Lancet. 2001;358 (9287):1033–41. DOI:10.1016/S0140–6736 (01) 06178–5
  146. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitras- cu D et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358 (18):1887–98. DOI:10.1056/NEJMoa0801369
  147. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspi- rin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet. 1998;351 (9118):1755–62. DOI:10.1016/S0140–6736 (98) 04311–6
  148. Tight blood pressure control and risk of macrovascular and microvas- cular complications in type 2 diabetes: UKPDS 38. UK Prospective Di- abetes Study Group. BMJ. 1998;317 (7160):703–13. PMID:9732337
  149. Arima H, Hart RG, Colman S, Chalmers J, Anderson C, Rodgers A, et al. Perindopril-based blood pressure-lowering reduces major vascu- lar events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2005;36 (10):2164–9. DOI:10.1161/01. STR. 0000181115.59173.42
  150. Izzo JL, Gradman AH. Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Medi- cal Clinics of North America. 2004;88 (5):1257–71. DOI:10.1016/j. mcna. 2004.06.002
  151. Чазова И. Е., Ратова Л. Г., Бойцов С. А., Небиеридзе Д. В., Кар- пов Ю. А., Белоусов Ю.Б. и др. Диагностика и лечение артериаль- ной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные Гипертензии. 2010; (3):5–26. [Chazova I. E., Ratova L. G., Boitsov S. A., Nebieri- dze D. V., Karpov Yu. A et al. Recommendations for the management of arterial hypertension Russian Medical Society of Arterial Hyper- tension and Society of Cardiology of the Russian Federation. System hypertension. 2010;3:5–26.]
  152. Чазова И. Е., Ощепкова Е. В., Жернакова Ю. В., Архипов М. В., Барбараш О. Л., Галявич А.С. и др. Клинические рекомендации Диагностика и лечение артериальной гипертонии. Кардиоло- гический вестник. 2015; X (1):3–30. [Chazova I. E., Oshepko- va E. V., Zhernakova Yu. V., Karpov Yu. A., Arkhipov M. V., Bar- barash O. L. et al. Clinical guidelines Diagnostics and treatment of ar- terial hypertension. Cardiology bulletin. 2015; X (1):3–30.]
  153. Мареев В. Ю., Беленков Ю. Н., Агеев Ф. Т., Фомин И. В., Хохлов Р. А., Галявич А. С. Первые результаты Российского эпидемиологического исследования по ХСН (ЭПОХА- ХСН). Журнал Сердечная Недостаточность. 2003;4 (1):17– 8. [Mareev V. Yu., Belenkov Yu. N., Ageev F. T., Fomin I. V., Cho- chlov R. A., Galiavich A. S. et al. The first results of Russian epidemio- logical studies with CHF (EPOCHA-CHF). Russian Heart Failure Journal. 2003;4 (1):17–8.]
  154. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Agu- ilar JC et al. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442– 63. PMID:12633546
  155. Fox KM, EURopean trial On reduction of cardiac events with Perin- dopril in stable coronary Artery disease Investigators. Efficacy of pe- rindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet. 2003;362 (9386):782–8.
  156. Effects of an Angiotensin-Converting – Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine. 2000;342 (3):145–53. DOI:10.1056/NEJM200001203 420301
  157. Angiotensin-Converting – Enzyme Inhibition in Stable Coronary Ar- tery Disease. New England Journal of Medicine. 2004;351 (20):2058– 68. DOI:10.1056/NEJMoa042739
  158. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine. 2008;358 (15):1547–59. DOI:10.1056/NEJMoa0801317
  159. Effects of the angiotensin-receptor blocker telmisartan on cardiovascu- lar events in high-risk patients intolerant to angiotensin-converting en- zyme inhibitors: a randomised controlled trial. The Lancet. 2008;372 (9644):1174–83. DOI:10.1016/S0140–6736 (08) 61242–8
  160. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine. 2008;359 (23):2456–67. DOI:10.1056/NEJMoa0805450
  161. The Norwegian Multicenter Study Group. Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction. New England Journal of Medicine. 1981;304 (14):801–7. DOI:10.1056/NEJM198104023041401
  162. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol af- ter acute myocardial infarction in patients with congestive heart failure. Circulation. 1986;73 (3):503–10. DOI:10.1161/01. CIR. 73.3.503
  163. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction: Results of the Sur- vival and Ventricular Enlargement Trial. New England Journal of Medi- cine. 1992;327 (10):669–77. DOI:10.1056/NEJM199209033271001
  164. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate sin- gly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della So- pravvivenza nell’infarto Miocardico. Lancet. 1994;343 (8906):1115– 22. PMID:7910229
  165. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. The Lancet. 1995;345 (8951):669–85. DOI:10.1016/S0140–6736 (95) 90865-X
  166. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau J-L, Køber L, Mag- gioni AP et al. Valsartan, Captopril, or Both in Myocardial Infarc- tion Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine. 2003;349 (20):1893–906. DOI:10.1056/NEJMoa032292
  167. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine. 2003;348 (14):1309–21. DOI:10.1056/NEJ- Moa030207
  168. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B et al. Additive beneficial effects of beta-blockers to angiotensin-con- verting enzyme inhibitors in the Survival and Ventricular Enlarge- ment (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997;29 (2):229–36. PMID:9014971
  169. Kjekshus J, Pedersen TR, Olsson AG, Færgeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. Journal of Cardiac Failure. 1997;3 (4):249–54. DOI:10.1016/S1071–9164 (97) 90022–1
  170. Lewis SJ. Effect of Pravastatin on Cardiovascular Events in Older Pa- tients with Myocardial Infarction and Cholesterol Levels in the Aver- age Range: Results of the Cholesterol and Recurrent Events (CARE) Trial. Annals of Internal Medicine. 1998;129 (9):681. DOI:10.7326/ 0003-4819-129-9-199811010-00002
  171. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine. 1998;339 (19):1349–57. DOI:10.1056/NEJM199811053391902
  172. Jones CG, Cleland JG. Meeting report – the LIDO, HOPE, MOXCON and WASH studies: heart outcomes prevention evaluation: the War- farin/Aspirin Study of Heart Failure. European Journal of Heart Fail- ure. 1999;1:425–431.
  173. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JGF, Ezekowitz M et al. Randomized trial of warfarin, aspirin, and clopi- dogrel in patients with chronic heart failure: the Wafarin and Anti- platelet Therapy in Chronic Heart failure (WATCH) trial. Circula- tion. 2009;119 (12):1616–24. DOI:10.1161/CIRCULATIONAHA. 108.801753
  174. Homma S, Thompson JLP, Sanford AR, Mann DL, Sacco RL, Levin B et al. Benefit of Warfarin Compared With Aspirin in Pa- tients With Heart Failure in Sinus Rhythm: A Subgroup Analysis of WARCEF, a Randomized Controlled Trial. Circulation: Heart Failure. 2013;6 (5):988–97. DOI:10.1161 / CIRCHEARTFAIL- URE. 113.000372
  175. Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR et al. Warfarin and aspirin in patients with heart fail- ure and sinus rhythm. New England Journal of Medicine. 2012;366 (20):1859–69. DOI:10.1056/NEJMoa1202299
  176. Акчурин Р. С., Васюк Ю. А., Карпов Ю. А. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2008;7 (6 S-4):1–37. [Akchurin R. S., Vasyuk Yu. A., Karpov Yu. A., Lupanov V. P., Marce- vich S. Yu., Pozdnyakov Yu. M. et al. National recommendations about diagnostics and treatment of stable stenocardia. Cardiovascular The- rapy and Prevention. 2008;7 (6 S-4):1–37.]
  177. Ежов М. В., Сергиенко И. В., Аронов Д. М., Арабидзе Г. Г., Ахмеджанов Н. М., Бажан С. С. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр. Атеросклероз и дислипидемии. 2017; (3):5–22. [Ezhov M. V., Ser- gienko I. V., Aronov D. M., Arabidze G. G., Akhmedzhanov N. M., Ba- zhan S. S. et al. Diagnostics and correction of lipid metabolism dis- orders for the prevention and treatment of atherosclerosis. Revision VI. Journal of Atherosclerosis and Dyslipidemias. 2017;3:5–22.]
  178. Levy D. The Progression From Hypertension to Congestive Heart Failure. JAMA: The Journal of the American Medical Association. 1996;275 (20):1557. DOI:10.1001/jama. 1996.03530440037034
  179. Мареев В. Ю., Беленков Ю. Н. Хроническая сердечная недостаточность и инсулиннезависимый сахарный диабет: случайная связь или закономерность. Терапевтический архив. 2003;75 (10):1–10. [Mareev V. Yu., Belenkov Yu. N. Chronic heart failure and insulin-dependent diabetes mellitus random relationship or pattern. Therapeutic arkhive. 2003;75 (10):1–10.]
  180. Ильина А. В., Мареев В. Ю., Герасимова В. В., Джахангиров Т. Ш., Беленков Ю. Н. Эффективность терапии иАПФ фозиноприлом больных с ХСН в сочетании с СД 2 типа (по материалам исследования ФАСОН). Журнал Сердечная Недостаточность. 2005;6 (5):181–5. [Iljina A. V., Mareev V. Yu., Gerasimova V. V., Dzhakhangirov T. Sh., Belenkov Yu. N. Efficacy of therapy with the ACEI fosinopril in patients with CHF combined with type 2 DM (by data of FASON study). Russian Heart Failure Journal. 2005;6 (5):181–5.]
  181. Krumholz HM, Chen Y-T, Wang Y, Vaccarino V, Radford MJ, Hor- witz RI. Predictors of readmission among elderly survivors of admis- sion with heart failure. American Heart Journal. 2000;139 (1):72–7. DOI:10.1016/S0002–8703 (00) 90311–9
  182. Shindler DM, Kostis JB, Yusuf S, Quinones MA, Pitt B, Stewart D et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and regi- stry. The American Journal of Cardiology. 1996;77 (11):1017–20. DOI:10.1016/S0002–9149 (97) 89163–1
  183. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The Effect of Angio- tensin-Converting-Enzyme Inhibition on Diabetic Nephropathy. New England Journal of Medicine. 1993;329 (20):1456–62. DOI:10.1056 /NEJM199311113292004
  184. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO- HOPE substudy. Heart Outcomes Prevention Evaluation Study Inves- tigators. Lancet. 2000;355 (9200):253–9. PMID:10675071
  185. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2001;345 (12):861–9. DOI:10.1056/NEJMoa011161
  186. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau J-L, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropa- thy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138 (7):542–9. PMID:12667024
  187. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373 (22):2117– 28. DOI:10.1056/NEJMoa1504720
  188. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine. 2017;377 (7):644–57. DOI:10.1056/NEJMoa1611925
  189. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW et al. Lower Risk of Heart Failure and Death in Patients Initiated on So- dium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Low- ering DrugsClinical Perspective: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium- Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136 (3):249– 59. DOI:10.1161/CIRCULATIONAHA. 117.029190
  190. Effect of intensive blood-glucose control with metformin on com- plications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352 (9131):854–65. PMID:9742977
  191. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Im- proved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28 (10):2345–51.
  192. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. European Journal of Heart Failure. 2008;10 (7):703– 8. DOI:10.1016/j. ejheart. 2008.05.013
  193. Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK et al. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chro- nic Liver Disease: A Systematic Review. Annals of Internal Medicine. 2017;166 (3):191. DOI:10.7326/M16–1901
  194. Лапина Ю. В., Нарусов О. Ю., Мареев В. Ю. Рациональная Эффективная Многокомпонентная терапия в БОрьбе с Сахарным Диабетом у больных ХСН (РЭМБО – СД ХСН). Хрони- ческая сердечная недостаточность как фактор риска развития инсулинорезистентности и нарушений углеводного обмена. Журнал Сердечная Недостаточность. 2007;8 (4):164–70. [Lap- ina Yu. V., Narusov O. Yu., Mareev V. Yu., Shestakova M. V., Liton- ova G. N., Baklanova N. A., Belenkov Yu. N. «RAtional, efficient, Multicomponent therapy in a Battle for Overcoming Diabetes Mellitus in patients with CHF» (RAMBO-DM CHF). Chronic heart failure as a risk factor for insulin resistance and disorders of carbohydrate metabolism. Russian Heart Failure Journal. 2007;8 (4):164–70]
  195. Lipska KJ. Metformin Use in Patients With Historical Contra- indications. Annals of Internal Medicine. 2017;166 (3):225. DOI:10.7326/M16–2712
  196. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospec- tive cohort study using UK general practice research database. BMJ. 2009;339 (dec031):b4731 – b4731. DOI:10.1136/bmj. b4731
  197. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Sciri- ca BM. Glucose-lowering drugs or strategies and cardiovascular out- comes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. The Lancet Diabetes & Endocrinology. 2015;3 (5):356–66. DOI:10.1016/S2213–8587 (15) 00044–3
  198. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Di- abetes. New England Journal of Medicine. 2015;373 (3):232–42. DOI:10.1056/NEJMoa1501352
  199. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine. 2013;369 (14):1327–35. DOI:10.1056/NEJMoa1305889
  200. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine. 2013;369 (14):1317–26. DOI:10.1056/NEJMoa1307684
  201. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016;375 (4):311–22. DOI:10.1056/NEJMoa1603827
  202. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 2015;373 (23):2247–57. DOI:10.1056/NEJMoa1509225
  203. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375 (19):1834– 44. DOI:10.1056/NEJMoa1607141
  204. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Trials. JAMA. 2007;298 (10):1180. DOI:10.1001/jama. 298.10.1180
  205. Komajda M, McMurray JJV, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ et al. Heart failure events with rosiglitazone in type 2 dia- betes: data from the RECORD clinical trial. European Heart Journal. 2010;31 (7):824–31. DOI:10.1093/eurheartj/ehp604
  206. Rahman A, Kittikulsuth W, Fujisawa Y, Sufiun A, Rafiq K, Hitomi H, et al. Effects of diuretics on sodium-dependent glucose cotransport- er 2 inhibitor-induced changes in blood pressure in obese rats suffe- ring from the metabolic syndrome: Journal of Hypertension. 2016;34 (5):893–906. DOI:10.1097/HJH. 0000000000000871
  207. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glyce- mic Control by Diet and Exercise: A randomized, double-blind, pla- cebo-controlled, phase 3 trial. Diabetes Care. 2010;33 (10):2217–24. DOI:10.2337/dc10–0612
  208. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of Dapa- gliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypogly- cemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. Diabetes Care. 2012;35 (7):1473–8. DOI:10.2337/dc11–1693
  209. Del Prato S, Nauck M, Durán-Garcia S, Maffei L, Rohwedder K, Theuerkauf A et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes, Obesity and Me- tabolism. 2015;17 (6):581–90. DOI:10.1111/dom. 12459
  210. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovas- cular effects of dapagliflozin in patients with type 2 diabetes and dif- ferent risk categories: a meta-analysis. Cardiovascular Diabetology. 2016;15 (1). DOI:10.1186/s12933-016-0356-y
  211. Kalra S, Jain A, Ved J, Unnikrishnan A. Sodium-glucose cotrans- porter 2 inhibition and health benefits: The Robin Hood effect. In- dian Journal of Endocrinology and Metabolism. 2016;20 (5):725. DOI:10.4103/2230–8210.183826
  212. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. Jour- nal of Diabetes Investigation. 2016;7 (2):135–8. DOI:10.1111/jdi. 12401
  213. Verma S, McMurray JJV, Cherney DZI. The Metabolodiuretic Prom- ise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. JAMA Cardiology. 2017;2 (9):939. DOI:10.1001/jamacardio. 2017.1891
  214. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guy- ton RA et al. 2014 AHA/ACC guideline for the management of pa- tients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63 (22):2438– 88. DOI:10.1016/j. jacc. 2014.02.537
  215. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Pa- tients Who Cannot Undergo Surgery. New England Journal of Medi- cine. 2010;363 (17):1597–607. DOI:10.1056/NEJMoa1008232
  216. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine. 2011;364 (23):2187–98. DOI:10.1056/NEJMoa1103510
  217. Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR et al. Two-Year Outcomes after Transcatheter or Surgical Aor- tic-Valve Replacement. New England Journal of Medicine. 2012;366 (18):1686–95. DOI:10.1056/NEJMoa1200384
  218. Bach DS, Bolling SF. Improvement Following Correction of Secondary Mitral Regurgitation in End-Stage Cardiomyopathy With Mitral An- nuloplasty. The American Journal of Cardiology. 1996;78 (8):966–9. DOI:10.1016/S0002–9149 (96) 00481-X
  219. Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Top- ic N et al. Long-term vasodilator therapy of chronic aortic insufficien- cy. A randomized double-blinded, placebo-controlled clinical trial. Circulation. 1988;78 (1):92–103. DOI:10.1161/01. CIR. 78.1.92
  220. Scognamiglio R, Rahimtoola SH, Fasoli G, Nistri S, Volta SD. Nifedi- pine in Asymptomatic Patients with Severe Aortic Regurgitation and Normal Left Ventricular Function. New England Journal of Medicine. 1994;331 (11):689–94. DOI:10.1056/NEJM199409153311101
  221. Мареев В. Ю., Даниелян М. О. Недостаточность митрального клапана в практике терапевта. РМЖ. 1999; (15):706–10. [Mareev V. Yu., Danielyan M. O. Mitral valve insufficiency in the prac- tice of the therapist. RMJ. 1999;15:706–10.]
  222. Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS et al. Per- cutaneous Repair or Surgery for Mitral Regurgitation. New England Journal of Medicine. 2011;364 (15):1395–406. DOI:10.1056/NEJ- Moa1009355
  223. Kenchaiah S, Evans JC, Levy D, Wilson PWF, Benjamin EJ, Lar- son MG et al. Obesity and the Risk of Heart Failure. New England Journal of Medicine. 2002;347 (5):305–13. DOI:10.1056 /NEJ- Moa020245
  224. Walsh CR, Larson MG, Evans JC, Djousse L, Ellison RC, Vasan RS, et al. Alcohol Consumption and Risk for Congestive Heart Failure in the Framingham Heart Study. Annals of Internal Medicine. 2002;136 (3):181. DOI:10.7326/0003-4819-136-3-200202050-00005
  225. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate al- cohol consumption and risk of heart failure among older persons. JA- MA. 2001;285 (15):1971–7. PMID:11308433
  226. Vinogradova NG, Zhirkova MM, Fomin IV, Polyakov DS, Fomin IV, Federal State Budgetary Educational Institution of Higher Educa- tion, «Nizhny Novgorod State Medical Academy» of the Ministry of Health of the Russian Federation et al. Efficacy of therapy for chro- nic heart failure at the outpatient stage in the conditions of a munici- pal center for CHF. Russian Heart Failure Journal. 2017;17 (4):270– 8. DOI:10.18087/rhfj. 2017.4.2355
  227. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sut- ton GC et al. The epidemiology of heart failure. European Heart Jour- nal. 1997;18 (2):208–25. DOI:10.1093/oxfordjournals. eurheartj. a015223
  228. Wolfel EE. Can we predict and prevent the onset of acute de- compensated heart failure? Circulation. 2007;116 (14):1526–9. DOI:10.1161/CIRCULATIONAHA. 107.729608
  229. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;154 (2):260–6. DOI:10.1016/j. ahj. 2007.01.041
  230. Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJV, Granger CB et al. Influence of Nonfatal Hospitalization for Heart Failure on Sub- sequent Mortality in Patients With Chronic Heart Failure. Circula- tion. 2007;116 (13):1482–7. DOI:10.1161/CIRCULATIONAHA. 107.696906
  231. van der Wal MHL, van Veldhuisen DJ, Veeger NJGM, Rutten FH, Jaarsma T. Compliance with non-pharmacological recommenda- tions and outcome in heart failure patients. European Heart Journal. 2010;31 (12):1486–93. DOI:10.1093/eurheartj/ehq091
  232. Arutyunov AG, Dragunov DO, Arutyunov GP, Sokolova AV. Impact of the dosing of basic drugs on the risk of rehospitalization in patients with chronic heart failure. Terapevticheskii arkhiv. 2016;88 (1):29. DOI:10.17116/terarkh201688129–34
  233. Formiga F, Chivite D, Manito N, Casas S, Llopis F, Pujol R. Hos- pitalization due to acute heart failure. Role of the precipitating fac- tors. International Journal of Cardiology. 2007;120 (2):237–41. DOI:10.1016/j. ijcard. 2006.10.004
  234. Мареев В. Ю., Беграмбекова Ю. Л., Даниелян М. О., Агеев Ф. Т., Гиляревский С. Р., Беленков Ю. Н. и др. Какие вопросы задаются и на какие вопросы способны ответить исследования по немеди- каментозному лечению пациентов с сердечной недостаточностью. Уроки исследования ШАНС. Журнал Сердечная Недостаточность. 2014;15 (6):383–96. [Mareev V. Yu., Begrambekova Yu. L., Daniely- an M. O. et al. What questions are asked and answered by studies of non-drug treatment in patients with heart failure. Lessons from the CHANCE study. Russian Heart Failure Journal. 2014;15 (6):383–396]
  235. Lainscak M, Blue L, Clark AL, Dahlström U, Dickstein K, Ekman I et al. Self-care management of heart failure: practical recommenda- tions from the Patient Care Committee of the Heart Failure Associa- tion of the European Society of Cardiology. European Journal of Heart Failure. 2011;13 (2):115–26. DOI:10.1093/eurjhf/hfq219
  236. Schou M, Gustafsson F, Videbaek L, Tuxen C, Keller N, Handberg J et al. Extended heart failure clinic follow-up in low-risk patients: a ran- domized clinical trial (NorthStar). European Heart Journal. 2013;34 (6):432–42. DOI:10.1093/eurheartj/ehs235
  237. Gelbrich G, Störk S, Kreißl-Kemmer S, Faller H, Prettin C, Heus- chmann PU et al. Effects of structured heart failure disease man- agement on mortality and morbidity depend on patients’ mood: re- sults from the Interdisciplinary Network for Heart Failure Study: Effects of structured HF management depend on patients’ mood. European Journal of Heart Failure. 2014;16 (10):1133–41. DOI:10.1002 /ejhf. 150
  238. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb- Peploe KM et al. Wasting as independent risk factor for mortali- ty in chronic heart failure. The Lancet. 1997;349 (9058):1050–3. DOI:10.1016/S0140–6736 (96) 07015–8
  239. Anker SD. Inflammatory mediators in chronic heart failure: an over- view. Heart. 2004;90 (4):464–70. DOI:10.1136/hrt. 2002.007005
  240. von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a the- rapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85 (1):173–83. PMID:12163222
  241. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chron- ic heart failure and its therapeutic implications. Journal of Cardiac Fail- ure. 2003;9 (3):219–26. DOI:10.1054/jcaf. 2003.23
  242. Alsafwah S, Laguardia SP, Arroyo M, Dockery BK, Bhattacharya SK, Ahokas RA et al. Congestive heart failure is a systemic illness: a role for minerals and micronutrients. Clin Med Res. 2007;5 (4):238–43. DOI:10.3121/cmr. 2007.737
  243. Арутюнов Г. П., Костюкевич О. И., Былова Н. А. Распространен- ность, клиническая значимость гипотрофии и эффективность нутритивной поддержки у пациентов, страдающих хронической сердечной недостаточностью. Экспериментальная и клиническая гастроэнтерология. 2009; (2):22–33. [Arutyunov G. P., Kostyuke- vich O. I., Bylova N. A. Prevalence, clinical significance of hypotro- phy and effectiveness of nutritional support in patients with chron- ic heart failure. Experimental and Clinical Gastroenterology Journal. 2009;2:22–33.]
  244. Witte KKA, Nikitin NP, Parker AC, von Haehling S, Volk H-D, An- ker SD et al. The effect of micronutrient supplementation on quali- ty-of-life and left ventricular function in elderly patients with chron- ic heart failure. European Heart Journal. 2005;26 (21):2238–44. DOI:10.1093/eurheartj/ehi442
  245. Doukky R, Avery E, Mangla A, Collado FM, Ibrahim Z, Poulin M-F, et al. Impact of Dietary Sodium Restriction on Heart Failure Out- comes. JACC: Heart Failure. 2016;4 (1):24–35. DOI:10.1016/j. jchf. 2015.08.007
  246. Paterna S, Gaspare P, Fasullo S, Sarullo FM, Di Pasquale P. Normal- sodium diet compared with low-sodium diet in compensated conges- tive heart failure: is sodium an old enemy or a new friend? Clinical Sci- ence. 2008;114 (3):221–30. DOI:10.1042/CS20070193
  247. Lennie TA, Song EK, Wu J-R, Chung ML, Dunbar SB, Pressler SJ et al. Three gram sodium intake is associated with longer event-free surviv- al only in patients with advanced heart failure. Journal of Cardiac Fail- ure. 2011;17 (4):325–30. DOI:10.1016/j. cardfail. 2010.11.008
  248. Damgaard M, Norsk P, Gustafsson F, Kanters JK, Christensen NJ, Bie P et al. Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. American Journal of Phys- iology-Regulatory, Integrative and Comparative Physiology. 2006;290 (5):R1294–301. DOI:10.1152/ajpregu. 00738.2005
  249. Nehra A, Jackson G, Miner M, Billups KL, Burnett AL, Buvat J et al. The Princeton III Consensus Recommendations for the Manage- ment of Erectile Dysfunction and Cardiovascular Disease. Mayo Clinic Proceedings. 2012;87 (8):766–78. DOI:10.1016/j. mayocp. 2012.06.015
  250. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Bur- nett AL et al. Sexual Dysfunction and Cardiac Risk (the Second Prin- ceton Consensus Conference). The American Journal of Cardiology. 2005;96 (2):313–21. DOI:10.1016/j. amjcard. 2005.03.065
  251. Webster LJ, Michelakis ED, Davis T, Archer SL. Use of Sildenafil for Safe Improvement of Erectile Function and Quality of Life in Men With New York Heart Association Classes II and III Conges- tive Heart Failure: A Prospective, Placebo-Controlled, Double-blind Crossover Trial. Archives of Internal Medicine. 2004;164 (5):514. DOI:10.1001/archinte. 164.5.514
  252. Freitas D, Athanazio R, Almeida D, Dantas N, Reis F. Sildenafil im- proves quality of life in men with heart failure and erectile dysfunc- tion. International Journal of Impotence Research. 2006;18 (2):210– 2. DOI:10.1038/sj. ijir. 3901385
  253. Belardinelli R, Lacalaprice F, Faccenda E, Purcaro A, Perna G. Effects of short-term moderate exercise training on sexual function in male pa- tients with chronic stable heart failure. International Journal of Cardi- ology. 2005;101 (1):83–90. DOI:10.1016/j. ijcard. 2004.05.020
  254. Беграмбекова Ю. Л., Дробижев М. Ю., Мареев В. Ю., Кик- та С. В. Можно ли сказать что-то новое о депрессиях у больных хронической сердечной недостаточностью? Журнал Сердечная Недостаточность. 2015;16 (6):360–7. [Begrambekova Yu. L., Drobi- zhev M. Yu., Mareev V. Yu., Kikta S. V. Is it possible to say something new about depressions in patients with chronic heart failure? Russian Heart Failure Journal. 2015;16 (6):360–367] DOI:10.18087/rhfj. 2015.6.2161
  255. Дробижев М. Ю., Беграмбекова Ю. Л., Мареев В. Ю., Кикта С. В. Влияние депрессии и тревоги на клинические исходы у больных ХСН. Журнал Сердечная Недостаточность. 2016;17 (2):91–8. [Drobizhev M. Yu., Begrambekova Yu. L., Mareev V. Yu., Kikta S. V. Effects of depression and anxiety on clinical outcomes in patients with CHF. Russian Heart Failure Journal. 2016;17 (2):91– 98.] DOI:10.18087/rhfj. 2016.2.2206
  256. Piepoli MF, Crisafulli A. Pathophysiology of human heart failure: importance of skeletal muscle myopathy and reflexes. Experimen- tal Physiology. 2014;99 (4):609–15. DOI:10.1113 / expphysiol. 2013.074310
  257. Poole DC, Hirai DM, Copp SW, Musch TI. Muscle oxygen transport and utilization in heart failure: implications for exercise (in) tolerance. AJP: Heart and Circulatory Physiology. 2012;302 (5):H1050–63. DOI:10.1152/ajpheart. 00943.2011
  258. De Sousa E, Veksler V, Bigard X, Mateo P, Ventura-Clapier R. Heart failure affects mitochondrial but not myofibrillar intrinsic pro- perties of skeletal muscle. Circulation. 2000;102 (15):1847–53. PMID:11023942
  259. Ribeiro JP, Chiappa GR, Callegaro CC. The contribution of inspira- tory muscles function to exercise limitation in heart failure: patho- physiological mechanisms. Rev Bras Fisioter. 2012;16 (4):261–7. PMID:22801449
  260. Exercise training meta-analysis of trials in patients with chron- ic heart failure (ExTraMATCH). BMJ. 2004;328 (7433):189–0. DOI:10.1136/bmj. 37938.645220. EE
  261. Davies EJ, Moxham T, Rees K, Singh S, Coats AJS, Ebrahim S et al. Exercise training for systolic heart failure: Cochrane systematic re- view and meta-analysis. European Journal of Heart Failure. 2010;12 (7):706–15. DOI:10.1093/eurjhf/hfq056
  262. Smart N, Marwick TH. Exercise training for patients with heart fail- ure: a systematic review of factors that improve mortality and mor- bidity. The American Journal of Medicine. 2004;116 (10):693–706. DOI:10.1016/j. amjmed. 2003.11.033
  263. Pandey A, Parashar A, Kumbhani DJ, Agarwal S, Garg J, Kitzman D, et al. Exercise training in patients with heart failure and preserved ejec- tion fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8 (1):33–40. DOI:10.1161 /CIRCHEARTFAILURE. 114.001615
  264. Isnard R, Pousset F, Trochu J-N, Chafirovskaı̈a O, Carayon A, Gol- mard J-L et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart fail- ure. The American Journal of Cardiology. 2000;86 (4):417–21. DOI:10.1016/S0002–9149 (00) 00957–7
  265. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L et al. Clinical Recommendations for Cardiopulmonary Exercise Testing Da- ta Assessment in Specific Patient Populations. Circulation. 2012;126 (18):2261–74. DOI:10.1161/CIR. 0b013e31826fb946
  266. Scardovi AB, Coletta C, De Maria R, Perna S, Aspromonte N, Feola M, et al. The cardiopulmonary exercise test is safe and reliable in elderly patients with chronic heart failure: Journal of Cardiovascular Medicine. 2007;8 (8):608–12. DOI:10.2459/01. JCM. 0000281698.53983.4e
  267. Corrà U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA et al. Role of cardiopulmonary exercise testing in clini- cal stratification in heart failure. A position paper from the Commit- tee on Exercise Physiology and Training of the Heart Failure Associ- ation of the European Society of Cardiology: Cardiopulmonary ex- ercise testing and prognosis in HF. European Journal of Heart Fail- ure. 2018;20 (1):3–15. DOI:10.1002/ejhf. 979
  268. Bellet RN, Adams L, Morris NR. The 6-minute walk test in outpatient cardiac rehabilitation: validity, reliability and responsiveness – a sys- tematic review. Physiotherapy. 2012;98 (4):277–86. DOI:10.1016/j. physio. 2011.11.003
  269. ATS Statement: Guidelines for the Six-Minute Walk Test. American Journal of Respiratory and Critical Care Medicine. 2002;166 (1):111– 7. DOI:10.1164/ajrccm. 166.1. at1102
  270. Арутюнов Г. П. Вопросы немедикаментозного лечения пациентов, страдающих сердечной недостаточностью. Журнал Сердечная Недостаточность. 2001;2 (1):35–6. [Arutyunov G. P. Issues of non- drug treatment of patients suffering from heart failure. Russian Heart Failure Journal. 2001;2 (1):35–6.]
  271. Осипова И. В. «Свободный выбор нагрузки» физических тренировок – эффективный метод лечения хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2001;2 (4):176–80. [Osipova I. V. «Free choice of exercise load» is an effec- tive method of treatment of chronic heart failure. Russian Heart Fail- ure Journal. 2001;2 (4):176–80.]
  272. Ribeiro JP, Chiappa GR, Neder JA, Frankenstein L. Respiratory mus- cle function and exercise intolerance in heart failure. Curr Heart Fail Rep. 2009;6 (2):95–101. PMID:19486593
  273. Dall’Ago P, Chiappa GRS, Guths H, Stein R, Ribeiro JP. Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized trial. J Am Coll Cardiol. 2006;47 (4):757– 63. DOI:10.1016/j. jacc. 2005.09.052
  274. Callegaro CC, Martinez D, Ribeiro PAB, Brod M, Ribeiro JP. Aug- mented peripheral chemoreflex in patients with heart failure and inspi- ratory muscle weakness. Respir Physiol Neurobiol. 2010;171 (1):31– 5. DOI:10.1016/j. resp. 2010.01.009
  275. Kolesnikova EA, Arutyunov GP, Rylova AK, Lobzeva VI, Rylova NV. Respiratory muscle trainings as a way of physical rehabilitation for old patients with complicated myocardial infarction. European Heart Journal. 2013;34 (suppl 1):P5786 – P5786. DOI:10.1093/eur- heartj/eht310. P5786
  276. Арутюнов Г. П., Рылова Н. В., Колесникова Е. А., Рыло- ва А. К. Тренировки дыхательной мускулатуры в программе реа- билитации больных с ХСН III–IV ФК и легочной гипертензией. CardioСоматика. 2011; (S1):8. [Arutyunov G. P., Rylova N. V., Kole- snikova E. A., Rylova A. K. Respiratory muscle training in the reha- bilitation program of patients with HSN III–IV FC and pulmonary hypertension. CardioSomatika. 2011; S1:8.]
  277. Арутюнов Г. П., Колесникова Е. А., Рылова А. К. Современные подходы к реабилитации больных с хронической сердечной недостаточностью. CardioСоматика. 2010; (1):20–4. [Arutyu- nov G. P., Kolesnikova E. A., Rylova A. K. Current approaches to re- habilitation of patients with chronic heart failure. CardioSomatika. 2010;1:20–4.]
  278. Mancini DM, Henson D, La Manca J, Donchez L, Levine S. Benefit of selective respiratory muscle training on exercise capacity in patients with chronic congestive heart failure. Circulation. 1995;91 (2):320– 9. PMID:7805234
  279. Arutyunov GP, Kolesnikova EA, Begrambekova YL, Orlova IA, Ry- lova AK, Aronov DM et al. Exercise training in chronic heart fail- ure: practical guidance of the Russian Heart Failure Society. Rus- sian Heart Failure Journal. 2017;18 (1):41–66. DOI:10.18087/rhfj. 2017.1.2339
  280. Shah P, Pellicori P, Macnamara A, Urbinati A, Clark AL. Is Swimming Safe in Heart Failure? A Systematic Review: Cardiology in Review. 2017;25 (6):321–5. DOI:10.1097/CRD. 0000000000000154
  281. Vanhees L. Effect of exercise training in patients with an implan- table cardioverter defibrillator. European Heart Journal. 2004;25 (13):1120–6. DOI:10.1016/j. ehj. 2004.04.034
  282. Belardinelli R, Capestro F, Misiani A, Scipione P, Georgiou D. Mo- derate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure pa- tients with implantable cardioverter defibrillators and cardiac resyn- chronization therapy: European Journal of Cardiovascular Preven- tion & Rehabilitation. 2006;13 (5):818–25. DOI:10.1097/01. hjr. 0000230104.93771.7d
  283. Piccini JP, Hellkamp AS, Whellan DJ, Ellis SJ, Keteyian SJ, Kraus WE et al. Exercise Training and Implantable Cardioverter-Defibrillator Shocks in Patients With Heart Failure. JACC: Heart Failure. 2013;1 (2):142–8. DOI:10.1016/j. jchf. 2013.01.005
  284. Feldman AM, Silver MA, Francis GS, de Lame P-A, Parmley WW. Treating Heart Failure With Enhanced External Counterpulsation (EECP): Design of the Prospective Evaluation of EECP in Heart Fail- ure (PEECH) Trial. Journal of Cardiac Failure. 2005;11 (3):240–5. DOI:10.1016/j. cardfail. 2004.10.001
  285. Габрусенко С. А., Малахов В. В., Сергиенко И. В., Бугрий М. Е., Саидова М. А., Кухарчук В. В. и др. Новые возможности в лечении больных сердечной недостаточностью. Метод наружной контр- пульсации. Кардиология. 2008;48 (9):10–6. [Gabrusenko S. A., Malakhov V. V., Sergienko I. V., Bugriy M. E., Saidova M. A., Kukhar- chuk V. V., Belenkov Yu. N. Novel Possibilities in the Treatment of Pa- tients With Heart Failure. The Method of External Counterpulsation. Kardiologiia. 2008;48 (9):10–6.]
  286. Soran O, Fleishman B, Demarco T, Grossman W, Schneider VM, Manzo K et al. Enhanced External Counterpulsation in Patients With Heart Failure: A Multicenter Feasibility Study. Conges- tive Heart Failure. 2002;8 (4):204–27. DOI:10.1111 / j. 1527– 5299.2002.01731. x
  287. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardio- logy (ESC) Developed with the special contribution of the Heart Fail- ure Association (HFA) of the ESC. European Journal of Heart Failure. 2016;18 (8):891–975. DOI:10.1002/ejhf. 592
  288. Florea VG, Rector TS, Anand IS, Cohn JN. Heart Failure With Im- proved Ejection Fraction: Clinical Characteristics, Correlates of Re- covery, and SurvivalCLINICAL PERSPECTIVE: Results From the Valsartan Heart Failure Trial. Circulation: Heart Failure. 2016;9 (7):e003123. DOI:10.1161/CIRCHEARTFAILURE. 116.003123
  289. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejec- tion fraction. Eur Heart J. 2016;37 (5):455–62. DOI:10.1093/eur- heartj/ehv464
  290. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018; DOI:10.1002/ejhf. 1149
  291. Garg R, Yusuf S. Overview of randomized trials of angiotensin-con- verting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273 (18):1450–6.
  292. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Влияние терапии на прогноз и выживаемость больных с хронической сердечной недостаточностью. Русский медицинский журнал. 1999;2:9–12. [Mareev V. Yu., Danielyan M. O., Belenkov Yu. N. Effect of therapy on prognosis and survival of patients with chronic heart failure. Russian Medical Journal. 1999;2:9–12.]
  293. Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglio- ne M et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dys- function according to race, gender, and diabetic status: a meta-analy- sis of major clinical trials. J Am Coll Cardiol. 2003;41 (9):1529–38. PMID:12742294
  294. Keyhan G, Chen S-F, Pilote L. Angiotensin-converting enzyme inhibi- tors and survival in women and men with heart failure. European Jour- nal of Heart Failure. 2007;9 (6–7):594–601. DOI:10.1016/j. ejheart. 2007.03.004
  295. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Васюк Ю. А., Глезер М. Г., Кобалава Ж. Д. и др. Применение диклофенака и целебрекса у па- циентов с артериальной гипертонией и болями в нижней части спины на фоне гипотензивной терапии аккупро или норваском (исследование ДОЦЕНТ). Журнал Сердечная Недостаточность. 2005;6 (5):204–208. [Mareev V. Yu., Ageev F. T., Arutyunov G. P., Vasyuk Yu. A., Glezer M. G., Kobalava Zh. D., Tereshchenko S. N. The use of DiclOfenac and Celebrex in patients with arterial hypErtension, osteoarthrosis and lower back paiNsduring the antihypertensive The- rapywith accupro or norvasc (DOCENT study). Russian Heart Fail- ure Journal. 2005;6 (5):204–8.]
  296. Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE. Local fore- arm vasodilation with intra-arterial administration of enalaprilat in hu- mans. Clinical Pharmacology and Therapeutics. 1991;50 (3):314–21. DOI:10.1038/clpt. 1991.142
  297. Bleumink GS, Feenstra J, Sturkenboom MCJM, Stricker BHC. Non- steroidal anti-inflammatory drugs and heart failure. Drugs. 2003;63 (6):525–34.
  298. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. Journal of the American College of Cardiology. 1992;20 (7):1549–55. DOI:10.1016/0735– 1097 (92) 90449-W
  299. Мареев В. Ю. Взаимодействие лекарственных средств при лечении больных с сердечно-сосудистыми заболеваниями. Ингибиторы АПФ и аспирин. Есть ли повод для тревоги? Сердце: журнал для практикующих врачей. 2002;1 (4):161–168. [Mareev V. Yu. Drug interactionsin treatment of patients with cardiovascular diseases. ACE inhibitors and aspirin. Is there a reason for concerns? Russian Heart Journal. 2002;1 (4):161–8.]
  300. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Kons- tam MA. Antiplatelet Agents and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction (SOLVD) Trial. Jour- nal of the American College of Cardiology. 1998;31 (2):419–25. DOI:10.1016/S0735–1097 (97) 00502–0
  301. Nguyen KN, Aursnes I, Kjekshus J. Interaction Between Enalapril and Aspirin on Mortality After Acute Myocardial Infarction: Sub- group Analysis of the Cooperative New Scandinavian Enalapril Sur- vival Study II (CONSENSUS II). The American Journal of Cardiolo- gy. 1997;79 (2):115–9. DOI:10.1016/S0002–9149 (96) 00696–0
  302. Kindsvater S, Leclerc K, Ward J. Effects of coadministration of aspi- rin or clopidogrel on exercise testing in patients with heart failure re- ceiving angiotensin-converting enzyme inhibitors**The opinions and research contained herein are exclusively those of the authors and are not to be considered as official or reflecting the views of the Depart- ment of the Army, Department of the Air Force, or the Department of Defense. The American Journal of Cardiology. 2003;91 (11):1350–2. DOI:10.1016/S0002–9149 (03) 00328-X
  303. Spaulding C, Charbonnier B, Cohen-Solal A, Juilliere Y, Kromer EP, Benhamda K et al. Acute Hemodynamic Interaction of Aspi- rin and Ticlopidine With Enalapril: Results of a Double-Blind, Ran- domized Comparative Trial. Circulation. 1998;98 (8):757–65. DOI:10.1161/01. CIR. 98.8.757
  304. Лопатин Ю. М. Совместное применение аспирина и ингибиторов АПФ при ХСН: позиция «За». Журнал Сердечная Недостаточ- ность. 2003;4 (3):149–152. [Lopatin Yu. M. The combined use of as- pirin and ACE inhibitors in CHF: position «For». Russian Heart Fail- ure Journal. 2003;4 (3):149–152.]
  305. Мареев В. Ю. Аспирин при хронической сердечной недостаточ- ности. Взаимодействие аспирина с основными средствами лечения декомпенсации. Журнал Сердечная Недостаточность. 4 (3):153– 157. [Mareev V. Yu. Aspirin in chronic heart failure. Interaction of aspi- rin with the main means of decompensation treatment. Russian Heart Failure Journal. 2003;4 (3):153–7.]
  306. Teo KK, Yusuf S, Pfeffer M, Torp-Pedersen C, Kober L, Hall A et al. Ef- fects of long-term treatment with angiotensin-converting-enzyme in- hibitors in the presence or absence of aspirin: a systematic review. Lan- cet. 2002;360 (9339):1037–43.
  307. Harjai KJ, Solis S, Prasad A, Loupe J. Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure. International Journal of Cardiology. 2003;88 (2–3):207–14. DOI:10.1016/S0167–5273 (02) 00401–1
  308. Collaboration AT. Collaborative meta-analysis of randomised tri- als of antiplatelet therapy for prevention of death, myocardial infarc- tion, and stroke in high risk patients. BMJ. 2002;324 (7329):71–86. DOI:10.1136/bmj. 324.7329.71
  309. Progress. Effects of a Perindopril-Based Blood Pressure-Lowering Regimen on Disability and Dependency in 6105 Patients With Cere- brovascular Disease: A Randomized Controlled Trial. Stroke. 2003;34 (10):2333–8. DOI:10.1161/01. STR. 0000091397.81767.40
  310. Gruppoitalianoperlostudiodell. GISSI-3: effects of lisiriopril and transdermal glyceryl trinitrate singly and together on 6-week mor- tality and ventricular function after acute myocardial infarction. The Lancet [Internet]. 1994 [cited on Febrary 12, 2018];343 (8906). DOI:10.1016/S0140–6736 (94) 90232–1
  311. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325 (5):293–302. DOI:10.1056/NEJM199108013250501
  312. Effect of Enalapril on Mortality and the Development of Heart Fail- ure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions. New England Journal of Medicine. 1992;327 (10):685–91. DOI:10.1056/NEJM199209033271003
  313. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A Comparison of Enalapril with Hydralazine – Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure. New England Journal of Medicine. 1991;325 (5):303–10. DOI:10.1056/NEJM19 9108013250502
  314. Willenheimer R. Effect on Survival and Hospitalization of Initia- ting Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112 (16):2426–35. DOI:10.1161 /CIRCULA- TIONAHA. 105.582320
  315. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rou- leau J-L et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Rando- mized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106 (8):920–6.
  316. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OP- TIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial In- farction with Angiotensin II Antagonist Losartan. Lancet. 2002;360 (9335):752–60. PMID:12241832
  317. Kleber FX, Doering W. Prognosis of mild chronic heart failure: effects of the ACE inhibitor captopril. Herz. 1991;16 Spec No 1:283–93.
  318. Kleber FX, Niemöller L. Long-term survival in the Munich Mild Heart Failure Trial (MHFT). The American Journal of Cardiology. 1993;71 (13):1237–9. DOI:10.1016/0002–9149 (93) 90657-X
  319. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in pa- tients with symptomatic heart failure: randomised trial – the Losar- tan Heart Failure Survival Study ELITE II. The Lancet. 2000;355 (9215):1582–7. DOI:10.1016/S0140–6736 (00) 02213–3
  320. Скворцов А. А., Насонова С. Н., Сычев А. В. Эффекты длительной терапии ингибитором ангиотензинпревращающего фермента квинаприлом, антагонистом рецепторов к ангиотензину II и комбинацией квинаприла и валсартана у больных с умеренной хронической сердечной недостаточностью. Основные результаты исследования САДКО – ХСН. Кардиология. 2006;46 (7):33–51. [Skvortsov A. A., Nasonova S. N., Sytchev A. V., Orlova Ya. A., Bakla- nova N. A., Masenko V. P. et al. Effects of long term therapy with an- giotensin converting enzyme inhibitor quinapril, antagonist of recep- tors to angiotensin ii valsartan, and combination of quinapril and val- sartan in patients with moderate chronic heart failure. Main results of the sadko-chf study. Kardiologiia. 2006;46 (7):33–51.]
  321. Borghi C, Marino P, Zardini P, Magnani B, Collatina S, Ambrosio- ni E. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intra- venous thrombolysis: results from the Fosinopril in Acute Myocar- dial Infarction Study. FAMIS Working Party. Am Heart J. 1998;136 (2):213–25.
  322. Erhardt L, Maclean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fos- inopril attenuates clinical deterioration and improves exercise tole- rance in patients with heart failure. European Heart Journal. 1995;16 (12):1892–9. DOI:10.1093/oxfordjournals. eurheartj. a060844
  323. Brown EJ, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP, Blumen- thal M. Effects of fosinopril on exercise tolerance and clinical dete- rioration in patients with chronic congestive heart failure not taking digitalis. The American Journal of Cardiology. 1995;75 (8):596–600. DOI:10.1016/S0002–9149 (99) 80624–9
  324. Zannad F, Chati Z, Guest M, Platc F. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Ame- rican Heart Journal. 1998;136 (4):672–80. DOI:10.1016/S0002– 8703 (98) 70015–8
  325. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Tay- lor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal. 2006;27 (19):2338–45. DOI:10.1093/eurheartj/ehl250
  326. Massie BM, Armstrong PW, Cleland JGF, Horowitz JD, Packer M, Poole-Wilson PA et al. Toleration of High Doses of Angiotensin-Con- verting Enzyme Inhibitors in Patients With Chronic Heart Failure: Re- sults From the ATLAS Trial. Archives of Internal Medicine. 2001;161 (2):165. DOI:10.1001/archinte. 161.2.165
  327. Giles TD, Katz R, Sullivan JM, Wolfson P, Haugland M, Kirlin P et al. Short- and long-acting angiotensin-converting enzyme inhibi- tors: A randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. Journal of the American College of Cardi- ology. 1989;13 (6):1240–7. DOI:10.1016/0735–1097 (89) 90294–5
  328. Sica DA, Cutler RE, Parmer RJ, Ford NF. Comparison of the Steady- State Pharmacokinetics of Fosinopril, Lisinopril and Enalapril in Pa- tients with Chronic Renal Insufficiency: Clinical Pharmacokinetics. 1991;20 (5):420–7. DOI:10.2165/00003088-199120050-00006
  329. Greenbaum R, Zucchelli P, Caspi A, Nouriel H, Paz R, Sclarovsky S et al. Comparison of the pharmacokinetics of fosinoprilat with ena- laprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol. 2000;49 (1):23–31. PMID:10606834
  330. Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: the Antihypertensive and Lipid-Lowering Treat- ment to Prevent Heart Attack Trial (ALLHAT) – Correction. JAMA. 2004;291 (18):2196. DOI:10.1001/jama. 291.18.2196
  331. Cleland JG, Erhardt L, Murray G, Hall AS, Ball SG. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial in- farction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J. 1997;18 (1):41–51. PMID:9049514
  332. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyng- borg K et al. A Clinical Trial of the Angiotensin–Converting–Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction af- ter Myocardial Infarction. New England Journal of Medicine. 1995;333 (25):1670–6. DOI:10.1056/NEJM199512213332503
  333. Ambrosioni E, Borghi C, Magnani B. The Effect of the Angiotensin- Converting – Enzyme Inhibitor Zofenopril on Mortality and Mor- bidity after Anterior Myocardial Infarction. New England Journal of Medicine. 1995;332 (2):80–5. DOI:10.1056/NEJM19950112332 0203
  334. Effects of Angiotensin-Converting Enzyme Inhibition With Perindo- pril on Left Ventricular Remodeling and Clinical Outcome: Results of the Randomized Perindopril and Remodeling in Elderly With Acute Myocardial Infarction (PREAMI) Study. Archives of Internal Medi- cine. 2006;166 (6):659. DOI:10.1001/archinte. 166.6.659
  335. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double- blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet. 2003;362 (9386):782–8. DOI:10.1016/S0140–6736 (03) 14286–9
  336. Мареев В. Ю. Ингибиторы ангиотензинпревращающего фермента в лечении больных с коронарной болезнью сердца. Взгляд 2003 года. Кардиология. 2003;43 (12):4–14. [Mareev V. Yu. ACE Inhibitors in the Treatment of Patients With Coronary Heart Disease. Overview for the Year 2003. Kardiologiia. 2003;43 (12):4–14.]
  337. Riegger GAJ. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. European Heart Journal. 1991;12 (6):705–11. DOI:10.1093/eurheartj/12.6.705
  338. Pflugfelder PW, Baird MG, Tonkon MJ, DiBianco R, Pitt B. Clinical consequences of angiotensin-converting enzyme inhibitor withdraw- al in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol. 1993;22 (6):1557–63. PMID:8227822
  339. Widimský J, Kremer HJ, Jerie P, Uhlír O. Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-con- trolled, double-blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol. 1995;49 (1–2):95–102.
  340. Мареев В. Ю., Ольбинская Л. И., Мартынов А. И. Проспективное, многоцентровое, открытое исследование эффективности и переносимости КВАдроприла у больных с Недостаточностью Кровообращения, обусловленной ишемической болезнью сердца и дилатационной кардиомиопатией (Исследование КВАНК). Журнал Сердечная Недостаточность. 2007;8 (1):42– 7. [Mareev V. Yu., Olbinskaya L. I., Martynov A. I. Prospective, mul- ticenter, open-label study of QUAdropril efficacy and tolerability in patieNts with Circulatory insufficiency due to ischemic heart disease and dilated cardiomyopathy (study QUANC). Russian Heart Failure Journal. 2007;8 (1):42–7.]
  341. Packer M. Functional Renal Insufficiency During Long-Term Thera- py with Captopril and Enalapril in Severe Chronic Heart Failure. An- nals of Internal Medicine. 1987;106 (3):346. DOI:10.7326/0003-48 19-106-3-346
  342. Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. Journal of the American College of Cardiology. 1987;10 (4):837–44. DOI:10.1016/S0735–1097 (87) 80278–4
  343. David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ace inhibitor-associated cough. American Journal of Therapeutics. 1995;2 (10):806–13. DOI:10.109 7/00045391-199510000-00013
  344. MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Heart. 1991;66 (3):206–11. DOI:10.1136/hrt. 66.3.206
  345. Navookarasu NT, Rahman AR, Abdullah I. First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac fail- ure: a Malaysian experience. Int J Clin Pract. 1999;53 (1):25–30. PMID:10344062
  346. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J. 1998;19 (3):481–9.
  347. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355 (9215):1582–7. PMID:10821361
  348. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Mar- tinez FA et al. Effects of high-dose versus low-dose losartan on clin- ical outcomes in patients with heart failure (HEAAL study): a ran- domised, double-blind trial. The Lancet. 2009;374 (9704):1840–8. DOI:10.1016/S0140–6736 (09) 61913–9
  349. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-con- verting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet. 2003;362 (9386):772–6. DOI:10.1016/S0140–6736 (03) 14284–5
  350. McMurray JJ, Östergren J, Swedberg K, Granger CB, Held P, Michel- son EL et al. Effects of candesartan in patients with chronic heart fail- ure and reduced left-ventricular systolic function taking angiotensin- converting-enzyme inhibitors: the CHARM-Added trial. The Lancet. 2003;362 (9386):767–71. DOI:10.1016/S0140–6736 (03) 14283–3
  351. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362 (9386):777–81. DOI:10.1016/S0140– 6736 (03) 14285–7
  352. Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN, et al. Effects of valsartan on morbidity and mortality in patients withheart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002;40 (8):1414–21. PMID:12392830
  353. Hollenberg NK. A randomized trial of the angiotensin-receptor block- er valsartan in chronic heart failure. Curr Hypertens Rep. 2002;4 (6):411; discussion 412. PMID:12462208
  354. Wong M, Staszewsky L, Latini R, Barlera S, Volpi A, Chiang Y-T et al. Valsartan benefits left ventricular structure and function in heart fail- ure: Val-HeFT echocardiographic study. Journal of the American Col- lege of Cardiology. 2002;40 (5):970–5. DOI:10.1016/S0735–1097 (02) 02063–6
  355. McKelvie RS, Rouleau J-L, White M, Afzal R, Young JB, Maggio- ni AP et al. Comparative impact of enalapril, candesartan or meto- prolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J. 2003;24 (19):1727–34. PMID:14522567
  356. Cohn JN, Tognoni G. A Randomized Trial of the Angiotensin-Recep- tor Blocker Valsartan in Chronic Heart Failure. New England Journal of Medicine. 2001;345 (23):1667–75. DOI:10.1056/NEJMoa010713
  357. Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75 (10):1487–96. PMID:17555141
  358. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3 (1):1–163.
  359. Mareev V. Yu., M. V. Lomonosov Moscow State University, Mareev VY. Draft conclusion of the expert Council on chronic heart failure. Rus- sian Heart Failure Journal. 2016;17 (4):291–6. DOI:10.18087/rhfj. 2016.4.2266
  360. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizka- la AR et al. Angiotensin – niprilysin Inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371 (11):993–1004. DOI:10.1056/NEJMoa1409077
  361. Packer M, McMurray JJV, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin receptor niprilysin Inhibition compared with enala- pril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131 (1):54–61. DOI:10.1161/CIRCULA- TIONAHA. 114.013748
  362. Okumura N, Jhund PS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL et al. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Pro- spective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Back- ground TherapyCLINICAL PERSPECTIVE. Circulation: Heart Fail- ure. 2016;9 (9):e003212. DOI:10.1161/CIRCHEARTFAILURE. 116.003212
  363. Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL et al Health-Related Quality of Life Outcomes in PAR- ADIGM-HF. Circulation: Heart Failure. 2017;10 (8):e003430. DOI:10.1161/CIRCHEARTFAILURE. 116.003430
  364. Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J et al An- giotensin Receptor Neprilysin Inhibition in Heart Failure With Pre- served Ejection Fraction. JACC: Heart Failure. 2017;5 (7):471–82. DOI:10.1016/j. jchf. 2017.04.013
  365. Claggett B, Packer M, McMurray JJV, Swedberg K, Rouleau J, Zile MR, et al. Estimating the Long-Term Treatment Benefits of Sacubitril – Val- sartan. New England Journal of Medicine. 2015;373 (23):2289–90. DOI:10.1056/NEJMc1509753
  366. Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chro- nic heart failure and reduced ejection fraction: results from PARA- DIGM-HF. Eur Heart J. 2017;38 (15):1132–43. DOI:10.1093/eur- heartj/ehw570
  367. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR et al. Effect of sacubitril/valsartan versus enalapril on gly- caemic control in patients with heart failure and diabetes: a post- hoc analysis from the PARADIGM-HF trial. The Lancet Diabetes & Endocrinology. 2017;5 (5):333–40. DOI:10.1016 /S2213–8587 (17) 30087–6
  368. Damman K, Testani JM. The kidney in heart failure: an update. Eu- ropean Heart Journal. 2015;36 (23):1437–44. DOI:10.1093/eur- heartj/ehv010
  369. Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF: Sacubitril/valsartan, uric acid, and heart failure. European Jour- nal of Heart Failure [Internet]. 2017 [cited on Febrary 22, 2018]; DOI:10.1002/ejhf. 1056
  370. Desai AS, McMurray JJV, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal. 2015;36 (30):1990–7. DOI:10.1093/eur- heartj/ehv186
  371. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS et al. Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure. New England Journal of Medicine. 1984;311 (13):819–23. DOI:10.1056/NEJM198409273111303
  372. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82 (5):1724–9. DOI:10.1161/01. CIR. 82.5.1724
  373. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Хроническая сердечная недостаточность: избранные лекции по кардиологии. -Москва: ГЭОТАР-Медиа; 2006. 432 с. [Belenkov Yu. N., Mareev V. Yu., Ageev F. T. Chronic heart failure: selected lectures on cardiology. – M.: GEOTAR-Media; 2006. – 423p.] ISBN: 978-5-9704-0119-4
  374. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine Stimulates Apoptosis in Adult Rat Ventricular Myocytes by Activa- tion of the -Adrenergic Pathway. Circulation. 1998;98 (13):1329–34. DOI:10.1161/01. CIR. 98.13.1329
  375. Беленков Ю. Н., Скворцов А. А., Мареев В. Ю. Клинико- гемодинамические и нейрогормональные эффекты длительной терапии β-адреноблокатором бисопрололом больных с тяжелой хронической сердечной недостаточностью. Кардиология. 2003;43 (10):10–21. [Belenkov Yu. N., Skvortsov A. A., Mareev V. Yu., Naso- nova S. N., Sytchev A. V., Narusov O. Yu. et al. Clinical, Hemodynamic and Neurohumoral Effects of Long-Term Therapy of Patients With Se- vere Chronic Heart Failure With Beta-Adrenoblocker Bisoprolol. Kar- diologiia. 2003;43 (10):10–21.]
  376. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bris- tow MR. Carvedilol improves left ventricular function and symp- toms in chronic heart failure: A double-blind randomized study. Jour- nal of the American College of Cardiology. 1995;25 (6):1225–31. DOI:10.1016/0735–1097 (95) 00012-S
  377. Беленков Ю. Н., Мареев В. Ю., Скворцов А. А. Эналаприл против Карведилола. Сравнительное рандомизированное исследование у больных хронической сердечной недостаточностью (ЭКСТАЗ). Журнал Сердечная Недостаточность. 2001;2 (2):84–91. [Belen- kov Yu. N., Mareev V. Yu., Skvortsov A. A. Enalapril against Carvedilol. A comparative randomized study in patients with chro- nic heart failure (ECSTAZ). Russian Heart Failure Journal. 2001;2 (2):84–91.]
  378. McEniery CM, Schmitt M, Qasem A, Webb DJ, Avolio AP, Wilkin- son IB et al. Nebivolol Increases Arterial Distensibility In Vi- vo. Hypertension. 2004;44 (3):305–10. DOI:10.1161/01. HYP. 0000137983.45556.6e
  379. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gil- bert EM et al. The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. New England Journal of Medicine. 1996;334 (21):1349–55. DOI:10.1056/NEJM199605233342101
  380. Pasternak B, Svanström H, Melbye M, Hviid A. Association of Treat- ment With Carvedilol vs Metoprolol Succinate and Mortality in Patients With Heart Failure. JAMA Internal Medicine. 2014;174 (10):1597. DOI:10.1001/jamainternmed. 2014.3258
  381. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Austra- lia/New Zealand Heart Failure Research Collaborative Group. Lan- cet. 1997;349 (9049):375–80. PMID:9033462
  382. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a ran- domised trial. Lancet. 1999;353 (9146):9–13.
  383. Effect of metoprolol CR/XL in chronic heart failure: Metopro- lol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). The Lancet. 1999;353 (9169):2001–7. DOI:10.1016/S0140–6736 (99) 04440–2
  384. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P et al. Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine. 2001;344 (22):1651–8. DOI:10.1056/ NEJM200105313442201
  385. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkho- menko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in el- derly patients with heart failure (SENIORS). European Heart Journal. 2005;26 (3):215–25. DOI:10.1093/eurheartj/ehi115
  386. Gaffney TE, Braunwald E. Importance of the adrenergic nervous sys- tem in the support of circulatory function in patients with congestive heart failure. The American Journal of Medicine. 1963;34 (3):320–4. DOI:10.1016/0002–9343 (63) 90118–9
  387. Cleland J, Pennell D, Ray S, Coats A, Macfarlane P, Murray G et al. Myocardial viability as a determinant of the ejection fraction re- sponse to carvedilol in patients with heart failure (CHRISTMAS tri- al): randomised controlled trial. The Lancet. 2003;362 (9377):14–21. DOI:10.1016/S0140–6736 (03) 13801–9
  388. Heart Failure Society Of America. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure. 2006;12 (1):10–38. DOI:10.1016/j. cardfail. 2005.12.001
  389. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Ревишвили А. Ш. Национальные рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр). Журнал Сердечная Недостаточность. 2007;8 (1):4–41. [Mareev V. Yu., Ageev F. T., Arutyunov G. P., Koroteev A. V., Revishvili A. Sh. RSSC and OSSN National Guidelineson diagnostics and treatment of CHF (second revision). Russian Heart Failure Journal. 2007;8 (1):4–41.]
  390. Waagstein F, Hjalmarson A, Swedberg K, Bristow MR, Gilbert EM, Camerini F et al. Beneficial effects of metoprolol in idiopathic di- lated cardiomyopathy. The Lancet. 1993;342 (8885):1441–6. DOI:10.1016/0140–6736 (93) 92930-R
  391. Hjalmarson Å, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J et al. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000;283 (10):1295. DOI:10.1001/jama. 283.10.1295
  392. Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106 (17):2194–9. DOI:10.1161/01. CIR. 0000035653.72855. BF
  393. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. The Lancet. 1997;349 (9049):375–80. DOI:10.1016/S0140–6736 (97) 80008–6
  394. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M et al. Comparison of carvedilol and metoprolol on clini- cal outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. The Lancet. 2003;362 (9377):7–13. DOI:10.1016/S0140–6736 (03) 13800–7
  395. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkho- menko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 (3):215– 25. DOI:10.1093/eurheartj/ehi115
  396. Van Veldhuisen DJ, Cohen-Solal A, Böhm M, Anker SD, Babalis D, Roughton M et al. Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejec- tion Fraction. Journal of the American College of Cardiology. 2009;53 (23):2150–8. DOI:10.1016/j. jacc. 2009.02.046
  397. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS et al. Beta-blockers for heart failure with reduced, mid- range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal. 2018;39 (1):26–35. DOI:10.1093/eurheartj/ehx564
  398. Willenheimer R. Effect on Survival and Hospitalization of Initiat- ing Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence: Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112 (16):2426–35. DOI:10.1161/CIRCULA- TIONAHA. 105.582320
  399. Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, et al. Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individu- al patient data meta-analysis. BMJ. 2016; i1855. DOI:10.1136/bmj. i1855
  400. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150 (11):784–94. PMID:19487713
  401. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long- term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and re- administration of metoprolol. Circulation. 1989;80 (3):551–63. PMID:2548768
  402. Gattis WA, O’Connor CM, Leimberger JD, Felker GM, Adams KF, Gheorghiade M. Clinical outcomes in patients on beta-blocker thera- py admitted with worsening chronic heart failure. The American Jour- nal of Cardiology. 2003;91 (2):169–74. DOI:10.1016/S0002–9149 (02) 03104–1
  403. Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decom- pensation episode. European Heart Journal. 2009;30 (18):2186–92. DOI:10.1093/eurheartj/ehp323
  404. Dorow P, Thalhofer S, Bethge H, Disselhoff G, Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol. 1990;16 Suppl 5: S36–44. PMID:11527135
  405. dal Negro RW, Tognella S, Pomari C. Once-Daily Nebivolol 5mg Does Not Reduce Airway Patency in Patients with Chronic Obstructive Pul- monary Disease and Arterial Hypertension: A Placebo-Controlled Crossover Study. Clinical Drug Investigation. 2002;22 (6):361–7. DO I:10.2165/00044011-200222060-00003
  406. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phil- lips RA et al. Differential Effects of -Blockers on Albuminuria in Pa- tients With Type 2 Diabetes. Hypertension. 2005;46 (6):1309–15. DOI:10.1161/01. HYP. 0000190585.54734.48
  407. Poirier L, Cléroux J, Nadeau A, Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive pa- tients. J Hypertens. 2001;19 (8):1429–35. PMID:11518851
  408. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients: Journal of Hypertension. 2006;24 (3):591–6. DOI:10.1097/01. hjh. 0000209993.26057. de
  409. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a ran- domised placebo-controlled study. The Lancet. 2010;376 (9744):875– 85. DOI:10.1016/S0140–6736 (10) 61198–1
  410. DiFrancesco D, Camm JA. Heart rate lowering by specific and selec- tive I (f) current inhibition with ivabradine: a new therapeutic per- spective in cardiovascular disease. Drugs. 2004;64 (16):1757–65. PMID:15301560
  411. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycard- ic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Brit- ish Journal of Pharmacology. 1996;118 (4):1051–7. DOI:10.1111/j. 1476–5381.1996. tb15505. x
  412. Виноградов АВ. Мочегонные средства в клинике внутренних болезней. Медицина; 1969. 152 с. [Vinogradov A. V. Diuretics in the clinic of internal diseases. – M.: Medicine; 1969. – 152 p.]
  413. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Хроническая сердечная недостаточность. Избранные лекции по кардиологии. 2006. 432 с. ISBN: 5-9704-0119-6
  414. Kjekshus J, Swedberg K. Tolerability of enalapril in congestive heart failure. The American Journal of Cardiology. 1988;62 (2):67A-72A. DOI:10.1016/S0002–9149 (88) 80088–2
  415. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regula- ting cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82 (5):1730–6. DOI:10.1161/01. CIR. 82.5.1730
  416. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe con- gestive heart failure during treatment with enalapril (the Coopera- tive North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). The American Journal of Cardiology. 1992;70 (4):479–87. DOI:10.1016/0002–9149 (92) 91194–9
  417. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM et al. Combination neurohormonal blockade with ACE in- hibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strat- egies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol. 1997;13 (12):1166–74. PMID:9444298
  418. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RE- SOLVD Pilot Study Investigators. Circulation. 1999;100 (10):1056– 64. DOI:10.1161/01. CIR. 100.10.1056
  419. Svensson M, Gustafsson F, Galatius Sø, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? Journal of Cardiac Failure. 2004;10 (4):297–303. DOI:10.1016/j. cardfail. 2003.10.012
  420. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates of Hyperkalemia after Publication of the Randomized Alda- ctone Evaluation Study. New England Journal of Medicine. 2004;351 (6):543–51. DOI:10.1056/NEJMoa040135
  421. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine. 1999;341 (10):709–17. DOI:10.1056/NEJM199909023411001
  422. Packer M. Identification of risk factors predisposing to the develop- ment of functional renal insufficiency during treatment with conver- ting-enzyme inhibitors in chronic heart failure. Cardiology. 1989;76 Suppl 2:50–5. DOI:10.1159/000174559
  423. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M et al Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventri- cular Systolic Dysfunction and Heart Failure. Journal of the Ameri- can College of Cardiology. 2005;46 (3):425–31. DOI:10.1016/j. jacc. 2005.04.038
  424. Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤30%. European Journal of Heart Failure. 2006;8 (3):295–301. DOI:10.1016/j. ejheart. 2005.11.008
  425. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364 (1):11–21. DOI:10.1056/NEJMoa1009492
  426. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spi- ronolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales In- vestigators. Circulation. 2000;102 (22):2700–6. PMID:11094035
  427. Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Sol- omon HA et al. Randomized, Double-Blind, Multicenter, Place- bo-Controlled Study Evaluating the Effect of Aldosterone Antag- onism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systol- ic Dysfunction. Circulation: Heart Failure. 2010;3 (3):347–53. DOI:10.1161/CIRCHEARTFAILURE. 109.906909
  428. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mor- tality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology. 2010;56 (5):392–406. DOI:10.1016/j. jacc. 2010.05.011
  429. Li X, Qi Y, Li Y, Zhang S, Guo S, Chu S et al. Impact of Mineralocorti- coid Receptor Antagonists on Changes in Cardiac Structure and Func- tion of Left Ventricular Dysfunction: A Meta-analysis of Randomized Controlled Trials. Circulation: Heart Failure. 2013;6 (2):156–65. DOI:10.1161/CIRCHEARTFAILURE. 112.000074
  430. Phelan D, Thavendiranathan P, Collier P, Marwick TH. Aldosterone antagonists improve ejection fraction and functional capacity indepen- dently of functional class: a meta-analysis of randomised controlled tri- als. Heart. 2012;98 (23):1693–700. DOI:10.1136/heartjnl-2012–30 2178
  431. Swedberg K, Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Shi H et al. Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure. Journal of the American College of Cardiology. 2012;59 (18):1598–603. DOI:10.1016/j. jacc. 2011.11.063
  432. Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J et al. Effects of Mineralocorticoid Receptor Antago- nists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction: A Meta-analysis of Randomized Controlled Trials. Circulation: Heart Failure. 2013;6 (2):166–73. DOI:10.1161/CIRCHEARTFAILURE. 112.000003
  433. Hu L, Chen Y, Deng S, Du J, She Q. Additional use of an aldoste- rone antagonist in patients with mild to moderate chronic heart fail- ure: a systematic review and meta-analysis: Additional use of aldoste- rone antagonist in mild-to-moderate CHF patients. British Journal of Clinical Pharmacology. 2013;75 (5):1202–12. DOI:10.1111/bcp. 12012
  434. Authors/Task Force Members, McMurray JJV, Adamopoulos S, An- ker SD, Auricchio A, Bohm M et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Fail- ure 2012 of the European Society of Cardiology. Developed in col- laboration with the Heart Failure Association (HFA) of the ESC. Eu- ropean Heart Journal. 2012;33 (14):1787–847. DOI:10.1093/eur- heartj/ehs104
  435. Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–163.
  436. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart fail- ure randomized trial. JAMA. 2013;310 (23):2533. DOI:10.1001/ja- ma. 2013.282190
  437. Cody RJ. Diuretic treatment for the sodium retention of congestive heart failure. Archives of Internal Medicine. 1994;154 (17):1905–14. DOI:10.1001/archinte. 154.17.1905
  438. Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investiga- tors Group. Pharmacotherapy. 1994;14 (5):514–21.
  439. Brater DC. Diuretic Therapy. Wood AJJ, редактор. New England Jour- nal of Medicine. 1998;339 (6):387–95. DOI:10.1056/NEJM199808 063390607
  440. Мухарлямов Н. М., Мареев В. Ю. Лечение хронический сердечной недостаточности. – М.: Медицина; 1985. 208 с. [Mukharly- amov N. M., Mareev V. Yu. The treatment of chronic heart failure. – M.: Medicine; – 1985. – 208p.]
  441. Vasko MR. Furosemide Absorption Altered in Decompensated Con- gestive Heart Failure. Annals of Internal Medicine. 1985;102 (3):314. DOI:10.7326/0003-4819-102-3-314
  442. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter – defibrillator for con- gestive heart failure. New England Journal of Medicine. 2005;352 (3):225–37. DOI:10.1056/NEJMoa043399
  443. Staessen JA, Wang J-G, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. The Lancet. 2001;358 (9290):1305–15. DOI:10.1016/S0140–6736 (01) 06411-X
  444. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson Å, Mc- Murray JV et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics. European Journal of Heart Failure. 2005;7 (6):1059–69. DOI:10.1016/j. ejheart. 2005.09.005
  445. GISSI-HF investigators. Effect of rosuvastatin in patients with chro- nic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372 (9645):1231–9. DOI:10.1016/S0140–6736 (08) 61240–4
  446. Horwich TB, Hamilton MA, MacLellan WR, Fonarow GC. Low se- rum total cholesterol is associated with marked increase in mortality in advanced heart failure. Journal of Cardiac Failure. 2002;8 (4):216– 24. DOI:10.1054/jcaf. 2002.0804216
  447. Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: Shift in dose-response curves. Clinical Pharmacology and Therapeutics. 1980;28 (2):182–6. DOI:10.1038/clpt. 1980.148
  448. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart fail- ure: Bolus injection versus continuous infusion. Journal of the Ameri- can College of Cardiology. 1996;28 (2):376–82. DOI:10.1016/0735– 1097 (96) 00161–1
  449. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Gold- smith SR et al. Diuretic strategies in patients with acute decompensat- ed heart failure. New England Journal of Medicine. 2011;364 (9):797– 805. DOI:10.1056/NEJMoa1005419
  450. Sharma K, Vaishnav J, Kalathiya R, Miller J, Shah N, Hill T et al. Ran- domized Evaluation of Heart Failure with Preserved Ejection Fraction Patients with Acute Heart Failure and Dopamine (Ropa-Dop) Trial. Journal of Cardiac Failure. 2017;23 (11):831. DOI:10.1016/j. card- fail. 2017.10.006
  451. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bio- availability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure*. Clinical Phar- macology & Therapeutics. 1995;57 (6):601–9. DOI:10.1016/0009– 9236 (95) 90222–8
  452. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G et al. Torasemide Inhibits Angiotensin II Induced Vasoconstriction and Intracellular Calcium Increase in the Aorta of Spontaneously Hyper- tensive Rats. Hypertension. 1999;34 (1):138–43. DOI:10.1161/01. HYP. 34.1.138
  453. Yamato M, Sasaki T, Honda K, Fukuda M, Akutagawa O, Okamoto M et al. Effects of Torasemide on Left Ventricular Function and Neuro- humoral Factors in Patients With Chronic Heart Failure. Circulation Journal. 2003;67 (5):384–90. DOI:10.1253/circj. 67.384
  454. Kasama S. Effects of torasemide on cardiac sympathetic nerve ac- tivity and left ventricular remodelling in patients with congestive heart failure. Heart. 2006;92 (10):1434–40. DOI:10.1136 / hrt. 2005.079764
  455. Агеев Ф. Т., Жубрина Е. С., Гиляревский С. Р., Мареев В. Ю., Хосева Е. Н., Голшмид М. В. Сравнительная эффективность и безопасность длительного применения торасемида и фуросемида у больных с компенсированной сердечной недостаточностью. Влияние на маркеры фиброза миокарда. Журнал Сердечная Недостаточность. 2013;14:55–62. [Ageev F. T., Zhubrina E. S., Gi- lyarevsky S. R., Mareev V. Yu., Khoseva E. N., Golshmid M. V. et al. Comparative efficacy and safety of chronic torasemide and furose- mide therapy in patients with compensated heart failure. Effect on markers of myocardial fibrosis. Russian Heart Failure Journal. 2013;14 (2):55–62.]
  456. Müller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. European Journal of Heart Failure. 2003;5 (6):793– 801. DOI:10.1016/S1388–9842 (03) 00150–8
  457. Stroupe KT, Forthofer MM, Brater DC, Murray MD. Healthcare Costs of Patients with Heart Failure Treated with Torasemide or Furose- mide: PharmacoEconomics. 2000;17 (5):429–40. DOI:10.2165/00 019053-200017050-00002
  458. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. ДиУретическая терапия Эффективными дозами перораЛЬных диуретиков торасемида (Диувер) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ – ХСН). Журнал Сердечная Недостаточность. 12 (1):3–10.
  459. Cosín J, Díez J, on behalf of the TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. European Journal of Heart Failure. 2002;4 (4):507–13. DOI:10.1016/S1388–9842 (02) 00122–8
  460. Verbrugge FH, Grieten L, Mullens W. Management of the Cardiore- nal Syndrome in Decompensated Heart Failure. Cardiorenal Medicine. 2014;4 (3–4):176–88. DOI:10.1159/000366168
  461. Jones P, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. Cochrane Airways Group, редактор. Cochrane Database of Systematic Reviews [Internet]. 2001 [cited on Febrary 1, 2018]; DOI:10.1002/14651858. CD002881
  462. Philippi H, Bieber I, Reitter B. Acetazolamide Treatment for Infantile Central Sleep Apnea. Journal of Child Neurology. 2001;16 (8):600– 3. DOI:10.1177/088307380101600813
  463. Javaheri S. Acetazolamide Improves Central Sleep Apnea in Heart Failure: A Double-Blind, Prospective Study. American Journal of Respiratory and Critical Care Medicine. 2006;173 (2):234–7. DOI:10.1164/rccm. 200507-1035OC
  464. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O’Connor CM, Bull DA et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal of Medicine. 2012;367 (24):2296– 304. DOI:10.1056/NEJMoa1210357
  465. Bastien N, Haddad H, Bergeron S, Ignaszewski A, Searles G. The para- sail study: patient reported outcomes from the Canadian real world ex- perience use of sacubitril/valsartan in patients with heart failure and reduced ejection fraction. Canadian Journal of Cardiology. 2017;33 (10):S162–3. DOI:10.1016/j. cjca. 2017.07.316
  466. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than tar- get doses in heart failure with reduced ejection fraction: the PARA- DIGM-HF trial: Angiotensin receptor neprilysin inhibitor and heart failure. European Journal of Heart Failure. 2016;18 (10):1228–34. DOI:10.1002/ejhf. 580
  467. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of Venous Congestion for Worsening of Renal Func- tion in Advanced Decompensated Heart Failure. Journal of the Ameri- can College of Cardiology. 2009;53 (7):589–96. DOI:10.1016/j. jacc. 2008.05.068
  468. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuis- en DJ et al. Congestion in chronic systolic heart failure is related to re- nal dysfunction and increased mortality. European Journal of Heart Failure. 2010;12 (9):974–82. DOI:10.1093/eurjhf/hfq118
  469. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. Circu- lation. 1989;80 (1):65–77. DOI:10.1161/01. CIR. 80.1.65
  470. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation. 1991;84 (5):2181–6. DOI:10.1161/01. CIR. 84.5.2181
  471. Нарусов О. В., Мареев В. Ю., Скворцов А. А. Клинические, гемодинамические и нейрогуморальные эффекты дигоксина у больных ХСН. ЖСН. 2000;1 (1):26–30. [Narusov O. V., Mare- ev V. Yu., Skvortsov A. A. Clinical, hemodynamic and neurohumor- al effects of digoxin in patients with CHS. Russian Heart Failure Jour- nal. 2000;1 (1):26–30.]
  472. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Asso- ciation of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871–8. DOI:10.1001/jama. 289.7.871
  473. Adams KF, Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA et al. Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trial. Journal of the American College of Cardiology. 2005;46 (3):497–504. DOI:10.1016/j. jacc. 2005.02.091
  474. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure. New England Journal of Medicine. 1997;336 (8):525– 33. DOI:10.1056/NEJM199702203360801
  475. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cle- land JGF et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. The Lancet. 2014;384 (9961):2235–43. DOI:10.1016 / S0140–6736 (14) 61373–8
  476. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JGF, But- ler J, Epstein AE et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. European Heart Journal. 2013;34 (20):1489–97. DOI:10.1093/eurheartj/eht120
  477. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH et al. Safety and efficacy of digoxin: systematic review and meta-analy- sis of observational and controlled trial data. BMJ. 2015; h4451. DOI:10.1136/bmj. h4451
  478. Jorge E, Baptista R, Martins H, Saraiva F, Costa S, Vieira H et al. Di- goxin in advanced heart failure patients: A question of rhythm. Revis- ta Portuguesa de Cardiologia. 2013;32 (4):303–10. DOI:10.1016/j. repc. 2012.11.007
  479. Mareev V. Yu., Mareev Yu. V., Mareev YV, Federal State Budgetary Insti- tution, «Russian Cardiology Science and Production Center» of the Ministry of Health of the Russian Federation. Role of heart rate in mechanisms of compensation and decompensation in CHF patients with sinus rhythm and atrial fibrillation and methods for safe and effi- cient control of heart rhythm. Part 2. Atrial fibrillation. Kardiologiia. 2017;17 (S2):351–66. DOI:10.18087/cardio. 2401
  480. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF et al. Effect of oral digoxin in high-risk heart failure pa- tients: a pre-specified subgroup analysis of the DIG trial. Europe- an Journal of Heart Failure. 2013;15 (5):551–9. DOI:10.1093/eur- jhf/hft010
  481. Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of iv- abradine, a new selective If inhibitor, compared with atenolol in pa- tients with chronic stable angina. European Heart Journal. 2005;26 (23):2529–36. DOI:10.1093/eurheartj/ehi586
  482. Tardif J-C, Ponikowski P, Kahan T, for the ASSOCIATE study Inves- tigators. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, ran- domized, placebo-controlled trial. European Heart Journal. 2009;30 (5):540–8. DOI:10.1093/eurheartj/ehn571
  483. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery dis- ease and left-ventricular systolic dysfunction (BEAUTIFUL): a sub- group analysis of a randomised controlled trial. The Lancet. 2008;372 (9641):817–21. DOI:10.1016/S0140–6736 (08) 61171-X
  484. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L. Ratio- nale and design of a randomized, double-blind, placebo-controlled out- come trial of ivabradine in chronic heart failure: the Systolic Heart Fail- ure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT). Euro- pean Journal of Heart Failure. 2010;12 (1):75–81. DOI:10.1093/eur- jhf/hfp154
  485. Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL et al. Ef- fect of ivabradine on recurrent hospitalization for worsening heart fail- ure in patients with chronic systolic heart failure: the SHIFT Study. European Heart Journal. 2012;33 (22):2813–20. DOI:10.1093/eur- heartj/ehs259
  486. Böhm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez- Sendon J et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clinical Research in Cardiology. 2013;102 (1):11–22. DOI:10.1007/s00392-012-0467-8
  487. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Bra- ma A et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. The Lancet. 2010;376 (9744):886–94. DOI:10.1016/S0140–6736 (10) 61259–7
  488. Cucherat M. Quantitative relationship between resting heart rate re- duction and magnitude of clinical benefits in post-myocardial infarc- tion: a meta-regression of randomized clinical trials. European Heart Journal. 2007;28 (24):3012–9. DOI:10.1093/eurheartj/ehm489
  489. Marchioli R. Early Protection Against Sudden Death by n-3 Polyunsa- turated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) – Prevenzione. Circulation. 2002;105 (16):1897–903. DOI:10.1161/01. CIR. 0000014682.14181. F2
  490. Macchia A, Levantesi G, Franzosi MG, Geraci E, Maggioni AP, Marfi- si R et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. European Journal of Heart Failure. 2005;7 (5):904–9. DOI:10.1016/j. ejheart. 2005.04.008
  491. Poole CD, Halcox JP, Jenkins-Jones S, Carr ESM, Schifflers MG, Ray KK et al. Omega-3 Fatty Acids and Mortality Outcome in Pa- tients With and Without Type 2 Diabetes After Myocardial Infarc- tion: A Retrospective, Matched-Cohort Study. Clinical Therapeutics. 2013;35 (1):40–51. DOI:10.1016/j. clinthera. 2012.11.008
  492. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM et al. Effects of n-3 Polyunsaturated Fatty Acids on Left Ventricular Function and Functional Capacity in Patients With Dilated Cardio- myopathy. Journal of the American College of Cardiology. 2011;57 (7):870–9. DOI:10.1016/j. jacc. 2010.11.017
  493. Finzi AA, Latini R, Barlera S, Rossi MG, Ruggeri A, Mezzani A et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular ar- rhythmias in patients with chronic heart failure and implantable car- dioverter-defibrillators: A substudy of the Gruppo Italiano per lo Stu- dio della Sopravvivenza nell’ Insufficienza Cardiaca (GISSI-HF) trial. American Heart Journal. 2011;161 (2):338–343. e1. DOI:10.1016/j. ahj. 2010.10.032
  494. Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M et al. Ef- fects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI- HF trial. European Journal of Heart Failure. 2010;12 (12):1345–53. DOI:10.1093/eurjhf/hfq172
  495. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berg- er R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin. Ameri- can Heart Journal. 2011;161 (5):915. e1–915. e9. DOI:10.1016/j. ahj. 2011.02.011
  496. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Stud- ies Group. Circulation. 1993;87 (6 Suppl): VI102–110.
  497. Dunkman WB. Thromboembolism and antithrombotic therapy in con- gestive heart failure: Journal of Cardiovascular Risk. 1995;2 (2):107– 17. DOI:10.1097/00043798-199504000-00005
  498. Katz SD. Left ventricular thrombus and the incidence of thromboem- bolism in patients with congestive heart failure: can clinical factors identify patients at increased risk?: Journal of Cardiovascular Risk. 1995;2 (2):97–102. DOI:10.1097/00043798-199504000-00003
  499. Cioffi G, Pozzoli M, Forni G, Franchini M, Opasich C, Cobelli F et al. Systemic thromboembolism in chronic heart failure: A prospective study in 406 patients. European Heart Journal. 1996;17 (9):1381–9. DOI:10.1093/oxfordjournals. eurheartj. a015073
  500. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. The Ameri- can Journal of Cardiology. 1981;47 (3):525–31. DOI:10.1016/0002– 9149 (81) 90534–8
  501. Stratton JR, Nemanich JW, Johannessen KA, Resnick AD. Fate of left ventricular thrombi in patients with remote myocardial infarction or idiopathic cardiomyopathy. Circulation. 1988;78 (6):1388–93. DOI:10.1161/01. CIR. 78.6.1388
  502. Spyropoulos AC. Emerging Strategies in the Prevention of Venous Thromboembolism in Hospitalized Medical Patients. Chest. 2005;128 (2):958–69. DOI:10.1378/chest. 128.2.958
  503. Howell M. Congestive heart failure and outpatient risk of venous thromboembolism A retrospective, case-control study. Journal of Clin- ical Epidemiology. 2001;54 (8):810–6. DOI:10.1016/S0895–4356 (00) 00373–5
  504. Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C et al. A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. New England Journal of Medicine. 1999;341 (11):793–800. DOI:10.105 6/NEJM199909093411103
  505. Turpie AGG. Thrombosis prophylaxis in the acutely ill medical pa- tient: insights from the prophylaxis in medical patients with enoxapa- rin (MEDENOX) trial. The American Journal of Cardiology. 2000;86 (12):48–52. DOI:10.1016/S0002–9149 (00) 01481–8
  506. Ageno W, Turpie AGG. Clinical trials of deep vein thrombosis pro- phylaxis in medical patients. Clinical Cornerstone. 2005;7 (4):16–22. DOI:10.1016/S1098–3597 (05) 80099–7
  507. 2014 ESC Guidelines on the diagnosis and management of acute pul- monary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiolo- gy (ESC) Endorsed by the European Respiratory Society (ERS). Eu- ropean Heart Journal. 2014;35 (43):3033–73. DOI:10.1093/eur- heartj/ehu283
  508. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA et al. Comparison of Low-Intensity Warfarin Therapy with Conven- tional-Intensity Warfarin Therapy for Long-Term Prevention of Re- current Venous Thromboembolism. New England Journal of Medi- cine. 2003;349 (7):631–9. DOI:10.1056/NEJMoa035422
  509. Nunnelee JD. Review of an Article: Dabigatran versus warfarin in the treatment of acute venous thromboembolism (2009). Schulman S, Ke- aron C, Kakkar A et al., N Engl J Med 361;2342–2352. Journal of Vas- cular Nursing. 2010;28 (2):84. DOI:10.1016/j. jvn. 2010.03.002
  510. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for Extended Treatment of Venous Thromboembo- lism. New England Journal of Medicine. 2013;368 (8):699–708. DOI:10.1056/NEJMoa1207541
  511. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral Apixaban for the Treatment of Acute Venous Thromboem- bolism. New England Journal of Medicine. 2013;369 (9):799–808. DOI:10.1056/NEJMoa1302507
  512. The EINSTEIN – PE Investigators. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Med- icine. 2012;366 (14):1287–97. DOI:10.1056/NEJMoa1113572
  513. Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Mem- bers, Camm AJ, Kirchhof P, Lip GYH et al. Guidelines for the man- agement of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eu- ropean Heart Journal. 2010;31 (19):2369–429. DOI:10.1093/eur- heartj/ehq278
  514. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic Therapy in Atrial Fibrillation. Chest. 2004;126 (3):429S-456S. DOI:10.1378/chest. 126.3_suppl. 429S
  515. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S et al. Clopidogrel plus as- pirin versus oral anticoagulation for atrial fibrillation in the Atrial fi- brillation Clopidogrel Trial with Irbesartan for prevention of Vas- cular Events (ACTIVE W): a randomised controlled trial. Lan- cet. 2006;367 (9526):1903–12. DOI:10.1016/S0140–6736 (06) 68845–4
  516. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV et al. Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation. New England Journal of Medicine. 2003;349 (11):1019–26. DOI:10.1056/NEJMoa022913
  517. Baker DW. Management of Heart Failure: IV. Anticoagulation for Patients With Heart Failure Due to Left Ventricular Systol- ic Dysfunction. JAMA. 1994;272 (20):1614. DOI:10.1001/jama. 1994.03520200070038
  518. Dries DL, Domanski MJ, Waclawiw MA, Gersh BJ. Effect of Anti- thrombotic Therapy on Risk of Sudden Coronary Death in Patients With Congestive Heart Failure. The American Journal of Cardiology. 1997;79 (7):909–13. DOI:10.1016/S0002–9149 (97) 00013–1
  519. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N et al. Should Patient Characteristics Influence Target Anticoagulation Intensity for Stroke Prevention in Nonvalvular Atri- al Fibrillation?: The ATRIA Study. Circulation: Cardiovascular Qual- ity and Outcomes. 2009;2 (4):297–304. DOI:10.1161/CIRCOUT- COMES. 108.830232
  520. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A et al. Dabigatran versus warfarin in patients with atrial fibril- lation. New England Journal of Medicine. 2009;361 (12):1139–51. DOI:10.1056/NEJMoa0905561
  521. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al. Ri- varoxaban versus warfarin in nonvalvular atrial fibrillation. New Eng- land Journal of Medicine. 2011;365 (10):883–91. DOI:10.1056/NEJ- Moa1009638
  522. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golit- syn S et al. Apixaban in Patients with Atrial Fibrillation. New Eng- land Journal of Medicine. 2011;364 (9):806–17. DOI:10.1056/NEJ- Moa1007432
  523. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibril- lation. New England Journal of Medicine. 2011;365 (11):981–92. DOI:10.1056/NEJMoa1107039
  524. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. The Lancet. 2009;374 (9689):534– 42. DOI:10.1016/S0140–6736 (09) 61343-X
  525. Reddy VY, Holmes D, Doshi SK, Neuzil P, Kar S. Safety of Percuta- neous Left Atrial Appendage Closure: Results From the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Reg- istry. Circulation. 2011;123 (4):417–24. DOI:10.1161/CIRCULA- TIONAHA. 110.976449
  526. Grygier M, Wojakowski W, Smolka G, Demkow M, Wąsek W, So- rysz D et al. Przezcewnikowe zamykanie uszka lewego przedsionka -stanowisko grupy ekspertów powołanej przez Asocjację Interwencji Sercowo-Naczyniowych oraz Sekcję Rytmu Serca Polskiego Towar- zystwa Kardiologicznego. Kardiologia Polska [Internet]. 2014 [cit- ed on Febrary 25, 2018]; DOI:10.5603/KP. a2018.0057
  527. Dai Y-L, Luk T-H, Yiu K-H, Wang M, Yip PMC, Lee SWL et al. Rever- sal of mitochondrial dysfunction by coenzyme Q10 supplement im- proves endothelial function in patients with ischaemic left ventricular systolic dysfunction: A randomized controlled trial. Atherosclerosis. 2011;216 (2):395–401. DOI:10.1016/j. atherosclerosis. 2011.02.013
  528. Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M et al. Coenzyme Q10. Journal of the American Col- lege of Cardiology. 2008;52 (18):1435–41. DOI:10.1016/j. jacc. 2008.07.044
  529. Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis. American Jour- nal of Clinical Nutrition. 2013;97 (2):268–75. DOI:10.3945/ajcn. 112.040741
  530. Каленикова Е. И., Городецкая Е. А., Медведев О. С. Фармакокинетика коэнзима Q10. РМЖ. 2008; (5):338–40. [Kalenikova E. I., Gorodets- kaya E. A., Medvedev O. S. The pharmacokinetics of coenzyme Q10. RMJ. 2008;5:338–40]
  531. Мареев В. Ю., Минина Ю. В., Беграмбекова Ю. Л. КУДЕсан® (капли 3% для приема внутрь) в лечении больных Сердечной Недостаточностью: эффективность И безопасность в Комбинации со стандартной терапией (КУДЕСНИК). Дизайн и результаты проспективного рандомизированного двойного слепого исследования КУДЕСНИК. Журнал Сердечная Недостаточность. 2016;17 (4):236–49. [Mareev V. Yu., Minina Yu. V., Begrambeko- va Yu. L. KUDESan® (3% drops for oral use) in treatment of patieNts with heart failure: efficacy and safety In Combination with standard therapy (KUDESNIC). Design and resultsof a prospective, rando- mized, double-blind KUDESNIC study. Russian Heart failure Jour- nal. 2016;17 (4):236–49.] DOI:10.18087/rhfj. 2016.4.2257
  532. Токарева ОГ, Харитонова ЕВ, Мареев ВЮ. Влияние коэнзима Q₁₀ в составе стандартной терапии больных хронической сердечной недостаточностью на плазменные уровни мозгового натрийуретического пептида. Журнал Сердечная Недостаточ- ность. 2014;15 (4):232–7. [Tokareva O. G., Kharitonova E. V., Mareev V. Yu., Kalenikova E. I., Medvedev O. S. Effect of coenzyme Q10 used as a part of standard therapyon plasma levels of brain na- triuretic peptide in patients with chronic heart failure. Russian Heart Failure Journal. 2014;15 (4):232–7.]
  533. Alehagen U, Johansson P, Björnstedt M, Rosén A, Dahlström U. Car- diovascular mortality and N-terminal-proBNP reduced after com- bined selenium and coenzyme Q10 supplementation: A 5-year pro- spective randomized double-blind placebo-controlled trial among el- derly Swedish citizens. International Journal of Cardiology. 2013;167 (5):1860–6. DOI:10.1016/j. ijcard. 2012.04.156
  534. Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pel- la D et al. The Effect of Coenzyme Q10 on Morbidity and Mortali- ty in Chronic Heart Failure. JACC: Heart Failure. 2014;2 (6):641–9. DOI:10.1016/j. jchf. 2014.06.008
  535. Kannel WB, Plehn JF, Cupples LA. Cardiac failure and sudden death in the Framingham Study. American Heart Journal. 1988;115 (4):869– 75. DOI:10.1016/0002–8703 (88) 90891–5
  536. Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. Diverse mechanisms of unexpected cardiac arrest in advanced heart fail- ure. Circulation. 1989;80 (6):1675–80. DOI:10.1161 /01. CIR. 80.6.1675
  537. Poole-Wilson PA. Mode of death in heart failure: findings from the AT- LAS trial. Heart. 2003;89 (1):42–8. DOI:10.1136/heart. 89.1.42
  538. Chen Z-M. CAST: randomised placebo-controlled trial of early as- pirin use in 20000 patients with acute ischaemic stroke. The Lancet. 1997;349 (9066):1641–9. DOI:10.1016/S0140–6736 (97) 04010–5
  539. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. European Heart Journal. 2009;30 (10):1245–53. DOI:10.1093/eur- heartj/ehp100
  540. Boutitie F, Boissel J-P, Connolly SJ, Camm AJ, Cairns JA, Julian DG et al. Amiodarone Interaction With -Blockers: Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) Da- tabases. Circulation. 1999;99 (17):2268–75. DOI:10.1161/01. CIR. 99.17.2268
  541. Свириденко Н. Ю., Платонова Н. М., Молашенко Н. В., Голицин С. П., Бакалов С. А., Сердюк С. Е. Эндокринные аспекты применения амиодарона в клинической практике. (Алгоритм наблюдения и лечения функциональных расстройств щитовидной железы). Российский Кардиологический Журнал. 2012;2:63–71. [Sviridenko N. Yu., Platonova N. M., Molashenko N. V., Golitsyn S. P., Bakalov S. A., Serdyuk S. E. Endocrine aspects of amiodarone therapy in clinical practice (Follow-up and treatment algorithm for patients with thyroid dysfunction). Russian Journal of Cardiology. 2012;2:63–71.]
  542. Kovoor P. Comparison of sotalol with amiodarone for long-term treat- ment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. European Heart Journal. 1999;20 (5):364– 74. DOI:10.1053/euhj. 1998.1279
  543. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 1993;72 (4):44A-50A. PMID:8346726
  544. Stevenson WG, Stevenson LW. Atrial Fibrillation in Heart Failure. New England Journal of Medicine. 1999;341 (12):910–1. DOI:10.10 56/NEJM199909163411209
  545. Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibril- lation is associated with a lower exercise capacity in male chronic heart failure patients. Heart. 1997;78 (6):564–8. DOI:10.1136/hrt. 78.6.564
  546. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA et al. Temporal relations of atrial fibrillation and congestive heart fail- ure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107 (23):2920–5. DOI:10.1161/01. CIR. 0000072767.89944.6E
  547. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI:10.1093/eurheartj/ehw210
  548. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347 (23):1825– 33. DOI:10.1056/NEJMoa021328
  549. Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Ti- jssen JGP, Alings AM et al. Lenient versus strict rate control in pa- tients with atrial fibrillation. N Engl J Med. 2010;362 (15):1363–73. DOI:10.1056/NEJMoa1001337
  550. Hagens VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAte Control versus Electrical cardio- version (RACE) study. American Heart Journal. 2005;149 (6):1106– 11. DOI:10.1016/j. ahj. 2004.11.030
  551. Lundström T, Rydén L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand. 1988;223 (1):53–9. PMID:3348103
  552. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Mainte- nance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42 (1):20–9. PMID:12849654
  553. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of Amiodarone for Conversion of Atrial Fibrillation to Sinus Rhythm: A Meta-analysis. Archives of Internal Medicine. 2003;163 (7):777. DOI:10.1001/archinte. 163.7.777
  554. Singh SN, Poole J, Anderson J, Hellkamp AS, Karasik P, Mark DB et al. Role of amiodarone or implantable cardioverter/defibrilla- tor in patients with atrial fibrillation and heart failure. American Heart Journal. 2006;152 (5):974. e7–974. e11. DOI:10.1016/j. ahj. 2006.08.012
  555. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M et al. Amiodarone to Prevent Recurrence of Atrial Fibrillation. New Eng- land Journal of Medicine. 2000;342 (13):913–20. DOI:10.1056/NE JM200003303421302
  556. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, King- ma T et al. A Comparison of Rate Control and Rhythm Control in Pa- tients with Recurrent Persistent Atrial Fibrillation. New England Journal of Medicine. 2002;347 (23):1834–40. DOI:10.1056/NEJ- Moa021375
  557. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An Analysis of the Lowest Effective Intensity of Prophylactic Anticoagulation for Pa- tients with Nonrheumatic Atrial Fibrillation. New England Journal of Medicine. 1996;335 (8):540–6. DOI:10.1056/NEJM19960822 3350802
  558. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic Thera- py To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Ana- lysis. Annals of Internal Medicine. 1999;131 (7):492. DOI:10.7326/ 0003-4819-131-7-199910050-00003
  559. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yu- suf S et al. Prevention of Atrial Fibrillation With Angiotensin-Con- verting Enzyme Inhibitors and Angiotensin Receptor Blockers. Jour- nal of the American College of Cardiology. 2005;45 (11):1832–9. DOI:10.1016/j. jacc. 2004.11.070
  560. Fang W, Li H, Zhang H, Jiang S. The role of statin therapy in the pre- vention of atrial fibrillation: a meta-analysis of randomized controlled trials: Statin therapy in prevention of atrial fibrillation. British Journal of Clinical Pharmacology. 2012;74 (5):744–56. DOI:10.1111/j. 1365–2125.2012.04258. x
  561. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L et al. Valsartan for prevention of recurrent atrial fibril- lation. N Engl J Med. 2009;360 (16):1606–17. DOI:10.1056/NEJ- Moa0805710
  562. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydro- piridine calcium channel blocker in the treatment of paroxysmal atri- al fibrillation with hypertension ( J-RHYTHM II Study). Europace. 2011;13 (4):473–9. DOI:10.1093/europace/euq439
  563. Irbesartan in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;364 (10):928–38. DOI:10.1056/NEJMoa1008816
  564. Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (AN- TIPAF) Trial. Circulation: Arrhythmia and Electrophysiology. 2012;5 (1):43–51. DOI:10.1161/CIRCEP. 111.965178
  565. Matsuda M, Matsuda Y, Yamagishi T, Takahashi T, Haraguchi M, Ta- da T et al. Effects of digoxin, propranolol, and verapamil on exercise in patients with chronic isolated atrial fibrillation. Cardiovascular Re- search. 1991;25 (6):453–7. DOI:10.1093/cvr/25.6.453
  566. David D, Di Segni E, Klein HO, Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: Bene- ficial effect of an added beta adrenergic blocking agent. The American Journal of Cardiology. 1979;44 (7):1378–82. DOI:10.1016/0002– 9149 (79) 90456–9
  567. Farshi R, Kistner D, Sarma JS., Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and pro- grammed exercise: a crossover open-label study of five drug regimens. Journal of the American College of Cardiology. 1999;33 (2):304–10. DOI:10.1016/S0735–1097 (98) 00561–0
  568. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? Journal of the Ame- rican College of Cardiology. 2003;42 (11):1944–51. DOI:10.1016/j. jacc. 2003.07.020
  569. Mareev Y, Cleland JGF. Should β-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther. 2015;37 (10):2215–24. DOI:10.1016/j. clinthera. 2015.08.017
  570. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H et al. Effect of the calcium antagonist felodipine as supplementary vasodila- tor therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation. 1997;96 (3):856–63. PMID:9264493
  571. Thackray S, Witte K, Clark AL, Cleland JGF. Clinical trials update: OP- TIME-CHF, PRAISE-2, ALL-HAT. European Journal of Heart Fail- ure. 2000;2 (2):209–12. DOI:10.1016/S1388–9842 (00) 00080–5
  572. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Bel- kin RN et al. Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. New England Journal of Med- icine. 1996;335 (15):1107–14. DOI:10.1056 / NEJM19961010 3351504
  573. O’Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neu- berg GW et al. Effect of amlodipine on mode of death among patients with advanced heart failure in the praise trial. The American Journal of Cardiology. 1998;82 (7):881–7. DOI:10.1016/S0002–9149 (98) 00496–2
  574. Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т. Медикаментозные пути улучшения прогноза больных хронической сердечной недостаточностью. – М.: Инсайт; 1997. 77 с. [Belenkov Yu. N., Mareev V. Yu., Ageev F. T. Medical ways to improve the prognosis of patients with chronic heart failure. – M.: Insait; 1997–77p.]
  575. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associ- ated with improved survival in ischemic and non-ischemic heart fail- ure. Journal of the American College of Cardiology. 2004;43 (4):642– 8. DOI:10.1016/j. jacc. 2003.07.049
  576. O’Meara E. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Can- desartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113 (7):986–94. DOI:10.1161/CIRCULATIONAHA. 105.582577
  577. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG et al. Etiology of anemia in patients with advanced heart failure. Journal of the American College of Cardiology. 2006;48 (12):2485–9. DOI:10.1016/j. jacc. 2006.08.034
  578. Node K. Short-Term Statin Therapy Improves Cardiac Function and Symptoms in Patients With Idiopathic Dilated Cardiomyop- athy. Circulation. 2003;108 (7):839–43. DOI:10.1161/01. CIR. 0000084539.58092. DE
  579. Liao JK. Statin Therapy for Cardiac Hypertrophy and Heart Failure: Journal of Investigative Medicine. 2004;52 (4):248–53. DOI:10.109 7/00042871-200405000-00033
  580. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R et al. The relationship between cholesterol and survival in patients with chronic heart failure. Journal of the American College of Cardiology. 2003;42 (11):1933–40. DOI:10.1016/j. jacc. 2003.07.016
  581. Leeper NJ, Ardehali R, deGoma EM, Heidenreich PA. Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is As- sociated With Improved Survival. Circulation. 2007;116 (6):613–8. DOI:10.1161/CIRCULATIONAHA. 107.694117
  582. Davie A. Even low-dose aspirin inhibits arachidonic acid – induced vasodilation in heart failure. Clinical Pharmacology & Therapeutics. 2000;67 (5):530–7. DOI:10.1067/mcp. 2000.106290
  583. Lindenfeld J, Robertson AD, Lowes BD, Bristow MR. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. Journal of the American College of Cardiology. 2001;38 (7):1950–6. DOI:10.1016/S0735–1097 (01) 01641–2
  584. Latini R, Tognoni G, Maggioni AP, Franzosi M, Santoro E, Baigent C et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. Journal of the American College of Cardiolo- gy. 2000;35 (7):1801–7. DOI:10.1016/S0735–1097 (00) 00638–0
  585. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324 (7329):71–86. PMID:11786451
  586. Jones CG, Cleland JGF. The LIDO, HOPE, MOXCON and WASH studies. European Journal of Heart Failure. 1999;1 (4):425–31. DOI:10.1016/S1388–9842 (99) 00059–8
  587. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliter- no DJ et al. Prevention of Premature Discontinuation of Dual Anti- platelet Therapy in Patients With Coronary Artery Stents: A Science Advisory From the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Inter- ventions, American College of Surgeons, and American Dental As- sociation, With Representation From the American College of Phy- sicians. Circulation. 2007;115 (6):813–8. DOI:10.1161/CIRCULA- TIONAHA. 106.180944
  588. Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G et al. Long- term ACE-inhibitor therapy in patients with heart failure or left-ven- tricular dysfunction: a systematic overview of data from individual pa- tients. The Lancet. 2000;355 (9215):1575–81. DOI:10.1016/S0140– 6736 (00) 02212–1
  589. Takkouche B, Etminan M, Caama?? o F, Rochon PA. Interaction Be- tween Aspirin and ACE Inhibitors: Resolving Discrepancies Using a Meta-Analysis. Drug Safety. 2002;25 (5):373–8. DOI:10.2165/0000 2018-200225050-00005
  590. Authors/Task Force Members, Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E et al. ESC Guidelines for the management of acute coro- nary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syn- dromes (ACS) in patients presenting without persistent ST-segment el- evation of the European Society of Cardiology (ESC). European Heart Journal. 2011;32 (23):2999–3054. DOI:10.1093/eurheartj/ehr236
  591. Lopatin YM, Rosano GMC, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LHW et al. Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. International Journal of Cardiology. 2016;203:909–15. DOI:10.1016/j. ijcard. 2015.11.060
  592. McCarthy CP, Mullins KV, Kerins DM. The role of trimetazidine in cardiovascular disease: beyond an anti-anginal agent. European Heart Journal – Cardiovascular Pharmacotherapy. 2016;2 (4):266–72. DOI:10.1093/ehjcvp/pvv051
  593. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angi- na. The Cochrane Collaboration, редактор. Cochrane Database of Systematic Reviews [Internet]. 2005 [cited on Febrary 1, 2018]; DOI:10.1002/14651858. CD003614. pub2
  594. Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy Compa- rison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-Analysis. Cardiology. 2011;120 (2):59–72. DOI:10.1159/000332369
  595. Iyengar SS, Rosano GMC. Effect of Antianginal Drugs in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial Infarction: A Preliminary Study (METRO). American Journal Cardiovascular Drugs. 2009;9 (5):293–7. DOI:10.2165/11316840-000000000-00000
  596. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W et al. Myocardial Phosphocreatine-to-ATP Ratio Is a Predictor of Mortal- ity in Patients With Dilated Cardiomyopathy. Circulation. 1997;96 (7):2190–6. DOI:10.1161/01. CIR. 96.7.2190
  597. Fragasso G. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. European Heart Journal. 2005;27 (8):942–8. DOI:10.1093/eurheartj/ehi816
  598. Napoli PD, Giovanni PD, Gaeta MA, Taccardi AA, Barsot- ti A. Trimetazidine and Reduction in Mortality and Hospitalization in Patients With Ischemic Dilated Cardiomyopathy: A Post Hoc Anal- ysis of the Villa Pini D`Abruzzo Trimetazidine Trial: Journal of Car- diovascular Pharmacology. 2007;50 (5):585–9. DOI:10.1097/FJC. 0b013e31814fa9cb
  599. Hu B, Li W, Xu T, Chen T, Guo J. Evaluation of Trimetazidine in An- gina Pectoris by Echocardiography and Radionuclide Angiography: A Meta-Analysis of Randomized, Controlled Trials. Clinical Cardiol- ogy. 2011;34 (6):395–400. DOI:10.1002/clc. 20888
  600. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-anal- ysis of randomised controlled trials in heart failure. Heart. 2011;97 (4):278–86. DOI:10.1136/hrt. 2010.208751
  601. Васюк Ю. А., Шальнова С. А., Школьник Е. Л., Куликов К. Г. Ис- следование ПРИМА. Сравнение клинического эффекта три- метазидина МВ у мужчин и женщин. Кардиология. 2011;51 (6):11– 5. [Vasyuk Yu. A., Shalnova S. A., Shkolnik E. L., Kulikov K. G. The ПРИМА (PRIMA) Study. Comparison of Clinical Effect of Trimeta- zidine MR in Men and Women. Kardiologiia. 2011;51 (6):11–5.]
  602. Glezer GMG, on on behalf of the C- study par, Sechenov First Mos- cow State Medical University, Moscow, Russia. Treatment of Patients With Stable Ischemic Heart Disease in Real Clinical Practice in Rus- sia. The CHOICE-2 Program. Kardiologiia. 2016;5_2016:5–11. DOI:10.18565/cardio. 2016.5.5–11
  603. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y et al. Additional Use of Trimetazidine in Patients With Chronic Heart Failure. Jour- nal of the American College of Cardiology. 2012;59 (10):913–22. DOI:10.1016/j. jacc. 2011.11.027
  604. Fragasso G, Rosano G, Baek SH, Sisakian H, Di Napoli P, Alberti L et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an interna- tional multicentre retrospective cohort study. International Journal of Cardiology. 2013;163 (3):320–5. DOI:10.1016/j. ijcard. 2012.09.123
  605. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. New England Journal of Medicine. 1986;314 (24):1547–52. DOI:10.1056/NEJM198606123142404
  606. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Ferdinand K et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine. 2004;351 (20):2049–57. DOI:10.1056/NEJMoa042934
  607. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in re- sponse to therapy for heart failure: Analysis of the vasodilator- heart failure trials. Journal of Cardiac Failure. 1999;5 (3):178–87. DOI:10.1016/S1071–9164 (99) 90001–5
  608. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zel- dis SM et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325 (21):1468–75. DOI:10.1056/NEJM199111213252103
  609. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Po- cock SJ et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial. JA- MA. 2007;297 (17):1883. DOI:10.1001/jama. 297.17.1883
  610. Metra M, Eichhorn E, Abraham WT, Linseman J, Bohm M, Corbalan R et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart fail- ure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. European Heart Journal. 2009;30 (24):3015–26. DOI:10.1093/eurheartj/ehp338
  611. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gil- bert EM et al. Effects of Vesnarinone on Morbidity and Mortality in Pa- tients with Heart Failure. New England Journal of Medicine. 1993;329 (3):149–55. DOI:10.1056/NEJM199307153290301
  612. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical Presentation, Management, and In-Hospital Outcomes of Pa- tients Admitted With Acute Decompensated Heart Failure With Pre- served Systolic Function. Journal of the American College of Cardio- logy. 2006;47 (1):76–84. DOI:10.1016/j. jacc. 2005.09.022
  613. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD et al New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eu- ropean Heart Journal. 2014;35 (40):2797–815. DOI:10.1093/eur- heartj/ehu204
  614. Ferrari R, Böhm M, Cleland JGF, Paulus WJS, Pieske B, Rapezzi C et al. Heart failure with preserved ejection fraction: uncertainties and dilemmas: Uncertainties and dilemmas of HFpEF. European Journal of Heart Failure. 2015;17 (7):665–71. DOI:10.1002/ejhf. 304
  615. Nanayakkara S, Patel HC, Kaye DM. Hospitalisation in Pa- tients With Heart Failure With Preserved Ejection Fraction. Clin- ical Medicine Insights: Cardiology. 2018;12:117954681775160. DOI:10.1177/1179546817751609
  616. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA et al. Impact of noncardiac comorbidities on morbidity and mortal- ity in a predominantly male population with heart failure and pre- served versus reduced ejection fraction. J Am Coll Cardiol. 2012;59 (11):998–1005. DOI:10.1016/j. jacc. 2011.11.040
  617. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail. 2008;1 (2):91–7. DOI:10.1161/CIRCHEARTFAILURE. 107.743146
  618. Fukuta H, Goto T, Wakami K, Ohte N. Effects of drug and exercise intervention on functional capacity and quality of life in heart fail- ure with preserved ejection fraction: A meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology. 2016;23 (1):78–85. DOI:10.1177/2047487314564729
  619. Lewis EF, Lamas GA, O’Meara E, Granger CB, Dunlap ME, Mc- Kelvie RS et al. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9 (1):83–91. DOI:10.1016/j. ej- heart. 2006.10.012
  620. Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Ameri- can Heart Journal. 1997;134 (2):188–95. DOI:10.1016/S0002–8703 (97) 70123–6
  621. Fu M, Zhou J, Sun A, Zhang S, Zhang C, Zou Y et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction? A meta analysis of 7 prospective clinical studies. International Jour- nal of Cardiology. 2012;155 (1):33–8. DOI:10.1016 / j. ijcard. 2011.01.081
  622. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in es- sential hypertension. The American Journal of Medicine. 2003;115 (1):41–6. DOI:10.1016/S0002–9343 (03) 00158-X
  623. Bergström A, Andersson B, Edner M, Nylander E, Persson H, Dahl- ström U. Effect of carvedilol on diastolic function in patients with dia- stolic heart failure and preserved systolic function. Results of the Swed- ish Doppler-echocardiographic study (SWEDIC). European Jour- nal of Heart Failure. 2004;6 (4):453–61. DOI:10.1016/j. ejheart. 2004.02.003
  624. Lund LH, Benson L, Dahlström U, Edner M, Friberg L. Association Between Use of β-Blockers and Outcomes in Patients With Heart Fail- ure and Preserved Ejection Fraction. JAMA. 2014;312 (19):2008. DOI:10.1001/jama. 2014.15241
  625. Kristensen SL, Kober L, Jhund PS, Solomon SD, Kjekshus J, McKel- vie RS et al. International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Cir- culation. 2015;131 (1):43–53. DOI:10.1161/CIRCULATIONAHA. 114.012284
  626. Свирида О. Н., Овчинников А. Г., Агеев Ф. Т. Влияние кандесартана и его комбинации со спиронолактоном на диастолическую функцию левого желудочка и содержание биохимических маркеров баланса коллагена у пациентов с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2010;11 (5):263–75. [Svirida O. N., Ovchinnikov A. G., Ageev F. T. Influence of candesartan and its combination with spironolactone on left ven- tricular diastolic function and level of collagen balance’s biochemi- cal markers in patients with chronic heart failure and preserved left ventricular systolic function. Russian Heart Failure Journal. 2010;11 (5):263–75.]
  627. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for Heart Failure with Preserved Ejection Frac- tion. New England Journal of Medicine. 2014;370 (15):1383–92. DOI:10.1056/NEJMoa1313731
  628. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clau- sell N et al. Regional variation in patients and outcomes in the Treat- ment of Preserved Cardiac Function Heart Failure With an Aldoste- rone Antagonist (TOPCAT) trial. Circulation. 2015;131 (1):34–42. DOI:10.1161/CIRCULATIONAHA. 114.013255
  629. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Ef- fects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. Journal of the American Col- lege of Cardiology. 2004;43 (11):2028–35. DOI:10.1016 /j. jacc. 2003.12.052
  630. Овчинников А. Г., Агеев Ф. Т., Азизова А. Г. Сравнительное влияние торасемида и фуросемида на клинический статус и диастолическую функцию левого желудочка у больных с компенсированной сердечной недостаточностью и высоким давлением наполнения левого желудочка. Журнал Сердечная Недостаточность. 2011;12 (6):326–32. [Azizova A. G., Ovchinnikov A. G., Ageev F. T. Compara- tive study of Torasemide vs. Furosemide effects on clinical status and di- astolic function of the left ventricle in patients with compensated heart failure and high ventricular filling pressure. Russian Heart Failure Jour- nal. 2011;12 (6):326–32.]
  631. Secondary prevention with verapamil after myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction. Am J Car- diol. 1990;66 (21):33I-40I. PMID:2147813
  632. Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikows- ki P et al. Effect of ivabradine in patients with heart failure with pre- served ejection fraction: the EDIFY randomized placebo-controlled trial: Ivabradine in HFpEF. European Journal of Heart Failure. 2017;19 (11):1495–503. DOI:10.1002/ejhf. 876
  633. Belenkov Yu. N., At’kov O. Yu., Tsibekmakher T. D. Effect of rap- id digitalization on the left-ventricular myocardial function accord- ing to the echocardiographic data. Kardiologiia. 1977;17 (9):46–50. PMID:926600
  634. Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of Treat- ment on Exercise Tolerance, Cardiac Function, and Mortality in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology. 2011;57 (16):1676–86. DOI:10.1016/j. jacc. 2010.10.057
  635. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind ran- domised controlled trial. The Lancet. 2012;380 (9851):1387–95. DOI:10.1016/S0140–6736 (12) 61227–6
  636. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation devel- oped in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50 (5):e1–88. DOI:10.1093/ejcts/ezw313
  637. Authors/Task Force Members, Mancia G, Fagard R, Narkiewicz K, Re- don J, Zanchetti A et al. 2013 ESH/ESC Guidelines for the manage- ment of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal. 2013;34 (28):2159–219. DOI:10.1093/eurheartj/eht151
  638. Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure us- ing olmesartan (SUPPORT) trial. European Heart Journal. 2015;36 (15):915–23. DOI:10.1093/eurheartj/ehu504
  639. Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mat- theus M et al. Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease. Jour- nal of the American College of Cardiology. 2018;71 (3):364–7. DOI:10.1016/j. jacc. 2017.11.022
  640. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Tho- racic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interven- tions (EAPCI). European Heart Journal. 2014;35 (37):2541–619. DOI:10.1093/eurheartj/ehu278
  641. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH et al. Isosorbide Mononitrate in Heart Failure with Pre- served Ejection Fraction. New England Journal of Medicine. 2015;373 (24):2314–24. DOI:10.1056/NEJMoa1510774
  642. Taylor RS, Davies EJ, Dalal HM, Davis R, Doherty P, Cooper C, et al. Effects of exercise training for heart failure with preserved ejec- tion fraction: A systematic review and meta-analysis of comparative studies. International Journal of Cardiology. 2012;162 (1):6–13. DOI:10.1016/j. ijcard. 2012.05.070
  643. Edelmann F, Gelbrich G, Düngen H-D, Fröhling S, Wachter R, Stahrenberg R et al. Exercise Training Improves Exercise Capacity and Diastolic Function in Patients With Heart Failure With Preserved Ejec- tion Fraction. Journal of the American College of Cardiology. 2011;58 (17):1780–91. DOI:10.1016/j. jacc. 2011.06.054
  644. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J et al. EURObservational Research Programme: region- al differences and 1-year follow-up results of the Heart Failure Pi- lot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15 (7):808–17. DOI:10.1093/eurjhf/hft050
  645. Мареев В. Ю., Арутюнов Г. П., Асташкин Е. И., Вёрткин А. Л., Глезер М. Г., Лопатин Ю. М. и др. Острая декомпенсированная сердечная недостаточность. Согласованная позиция российских экспертов – 2014. Журнал Сердечная Недостаточность. 2014;15 (5):321–36. [Mareev V. Yu., Arutyunov G. P., Astashkin E. I., Vert- kin A. L., Glezer M. G., Lopatin Yu. M. et al. Acute decompensated heart failure. Consensus of Russian experts, 2014. Russian Heart Fail- ure Journal. 2014;15 (5):321–6.] DOI:10.18087/rhfj. 2014.5.2024
  646. Chakko S, Woska D, Martinez H, de Marchena E, Futterman L, Kes- sler KM et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to in- appropriate care. Am J Med. 1991;90 (3):353–9.
  647. Wang CS. Does This Dyspneic Patient in the Emergency Depart- ment Have Congestive Heart Failure? JAMA. 2005;294 (15):1944. DOI:10.1001/jama. 294.15.1944
  648. Sarasin FP. Acute dyspnea: what is the diagnostic role of B-type natri- uretic peptide? Rev Med Suisse. 2005;1 (29):1888–91.
  649. Martindale JL, Wakai A, Collins SP, Levy PD, Diercks D, Hies- tand BC et al. Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis. Carpenter C, редактор. Academic Emergency Medicine. 2016;23 (3):223–42. DOI:10.1111/acem. 12878
  650. Newby LK, Jesse RL, Babb JD, Christenson RH, De Fer TM, Dia- mond GA et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012;60 (23):2427–63. DOI:10.1016/j. jacc. 2012.08.969
  651. Januzzi JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin el- evation in patients with heart failure: on behalf of the third Univer- sal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. European Heart Journal. 2012;33 (18):2265–71. DOI:10.1093/eurheartj/ehs191
  652. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al. Third universal definition of myocardial infarction. European Heart Journal. 2012;33 (20):2551–67. DOI:10.1093/eur- heartj/ehs184
  653. Felker GM, Hasselblad V, Tang WHW, Hernandez AF, Armstrong PW, Fonarow GC et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. European Journal of Heart Fail- ure. 2012;14 (11):1257–64. DOI:10.1093/eurjhf/hfs110
  654. Felker GM, Mentz RJ, Teerlink JR, Voors AA, Pang PS, Ponikowski P et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study: Troponin in Acute Heart Failure. European Journal of Heart Failure. 2015;17 (12):1262– 70. DOI:10.1002/ejhf. 341
  655. Adams KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT et al. Characteristics and outcomes of patients hospita- lized for heart failure in the United States: Rationale, design, and pre- liminary observations from the first 100,000 cases in the Acute Decom- pensated Heart Failure National Registry (ADHERE). American Heart Journal. 2005;149 (2):209–16. DOI:10.1016/j. ahj. 2004.08.005
  656. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syn- dromes in patients presenting without persistent ST-segment eleva- tion: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37 (3):267– 315. DOI:10.1093/eurheartj/ehv320
  657. Forrester JS, Diamond GA, Swan HJ. Correlative classification of cli- nical and hemodynamic function after acute myocardial infarction. Am J Cardiol. 1977;39 (2):137–45. DOI:10.1016/S0002–9149 (77) 80182–3
  658. Nohria A, Mielniczuk LM, Warner Stevenson L. Evaluation and Mon- itoring of Patients with Acute Heart Failure Syndromes. The Ameri- can Journal of Cardiology. 2005;96 (6):32–40. DOI:10.1016/j. amj- card. 2005.07.019
  659. Park JH, Balmain S, Berry C, Morton JJ, McMurray JJV. Potential- ly detrimental cardiovascular effects of oxygen in patients with chro- nic left ventricular systolic dysfunction. Heart. 2010;96 (7):533–8. DOI:10.1136/hrt. 2009.175257
  660. Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicat- ed myocardial infarction. Br Med J. 1976;1 (6018):1121–3.
  661. Vital FMR, Ladeira MT, Atallah AN. Non-invasive positive pres- sure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmo- nary oedema. Cochrane Database Syst Rev. 2013; (5):CD005351. DOI:10.1002/14651858. CD005351. pub3
  662. Park M, Sangean MC, Volpe M de S, Feltrim MIZ, Nozawa E, Leite PF et al. Randomized, prospective trial of oxygen, continuous posi- tive airway pressure, and bilevel positive airway pressure by face mask in acute cardiogenic pulmonary edema. Crit Care Med. 2004;32 (12):2407–15.
  663. Eapen ZJ, Reed SD, Li Y, Kociol RD, Armstrong PW, Starling RC et al. Do countries or hospitals with longer hospital stays for acute heart fail- ure have lower readmission rates?: Findings from ASCEND-HF. Circ Heart Fail. 2013;6 (4):727–32. DOI:10.1161/CIRCHEARTFAIL- URE. 112.000265
  664. Hernandez AF. Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. JAMA. 2010;303 (17):1716. DOI:10.1001/jama. 2010.533
  665. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA et al. Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. JAMA Cardiology. 2017;2 (9):950. DOI:10.1001/jamacardio. 2017.2198
  666. Мареев В. Ю., Выгодин В. А., Беленков Ю. Н. ДиУретическая терапия Эффективными дозами перораЛЬных диуретиков торасемида (Диувер®) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности (ДУЭЛЬ-ХСН). Журнал Сердечная Недостаточность. 2011;12 (1):3–10. [Mareev V. Y., Vygo- din V. A., Belenkov Y. N. DiUretic therapy with Effective doses of oraL diuretics: torasemide (Diuver®) and furosemide in patientswith acute exacerbation of Chronic Heart Failure (DUEL–CHF). Russian Heart Failure Journal. 2011;12 (1):3–10.]
  667. DiNicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiology. 2012;8 (5):707–28. DOI:10.2217/fca. 12.54
  668. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Per- kins SM et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111 (7):513–20.
  669. Martens P, Nijst P, Mullens W. Current Approach to Deconges- tive Therapy in Acute Heart Failure. Current Heart Failure Reports. 2015;12 (6):367–78. DOI:10.1007/s11897-015-0273-5
  670. van Vliet A, Donker AJM, Nauta JJP, Verheugt FWA. Spironolac- tone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. The Ameri- can Journal of Cardiology. 1993;71 (3):A21–8. DOI:10.1016/0002– 9149 (93) 90241–4
  671. Butler J, Hernandez AF, Anstrom KJ, Kalogeropoulos A, Redfield MM, Konstam MA et al. Rationale and Design of the ATHENA-HF Tri- al. JACC: Heart Failure. 2016;4 (9):726–35. DOI:10.1016/j. jchf. 2016.06.003
  672. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29 (3):367–72.
  673. Farag M, Shoaib A, Gorog DA. Nitrates for the Management of Acute Heart Failure Syndromes, A Systematic Review. Journal of Car- diovascular Pharmacology and Therapeutics. 2017;22 (1):20–7. DOI:10.1177/1074248416644345
  674. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Di- ercks DB et al. Nitrates for acute heart failure syndromes. Co- chrane Database of Systematic Reviews. 2013;6 (8):CD005151. DOI:10.1002/14651858. CD005151. pub2
  675. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A et al. Randomised trial of high-dose isosorbide dinitrate plus low- dose furosemide versus high-dose furosemide plus low-dose isosor- bide dinitrate in severe pulmonary oedema. The Lancet. 1998;351 (9100):389–93. DOI:10.1016/S0140–6736 (97) 08417–1
  676. Belletti A, Castro ML, Silvetti S, Greco T, Biondi-Zoccai G, Pa- sin L et al. The Effect of inotropes and vasopressors on mor- tality: a meta-analysis of randomized clinical trials. Myles PS, редактор. British Journal of Anaesthesia. 2015;115 (5):656–75. DOI:10.1093/bja/aev284
  677. Mebazaa A, Parissis J, Porcher R, Gayat E, Nikolaou M, Boas FV et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensi- ty scoring methods. Intensive Care Medicine. 2011;37 (2):290–301. DOI:10.1007/s00134-010-2073-4
  678. Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Amer- ican Heart Journal. 2007;153 (1):98–104. DOI:10.1016 / j. ahj. 2006.09.005
  679. Kivikko M, Pollesello P, Tarvasmäki T, Sarapohja T, Nieminen MS, Harjola V-P. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. Internation- al Journal of Cardiology. 2016;215:26–31. DOI:10.1016/j. ijcard. 2016.04.064
  680. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jas- ki BE et al. A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure. New England Journal of Medicine. 1998;339 (25):1810–6. DOI:10.1056/NEJM199812173 392503
  681. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al. Comparison of Dopamine and Norepinephrine in the Treatment of Shock. New England Journal of Medicine. 2010;362 (9):779–89. DOI:10.1056/NEJMoa0907118
  682. Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C et al. Impact of Dopamine Infusion on Renal Function in Hospital- ized Heart Failure Patients: Results of the Dopamine in Acute Decom- pensated Heart Failure (DAD-HF) Trial. Journal of Cardiac Failure. 2010;16 (12):922–30. DOI:10.1016/j. cardfail. 2010.07.246
  683. Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G, Wolski K et al. Efficacy and safety of high dose versus low dose furo- semide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. International Journal of Cardiology. 2014;172 (1):115–21. DOI:10.1016/j. ijcard. 2013.12.276
  684. Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J et al. Effect of levosimendan on the short-term clinical course of pa- tients with acutely decompensated heart failure. JACC: Heart Failure. 2013;1 (2):103–11. DOI:10.1016/j. jchf. 2012.12.004
  685. The Consensus Trial Study Group*. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. New England Journal of Medicine. 1987;316 (23):1429–35. DOI:10.1056/NEJM198706043162301
  686. Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decom- pensation episode. European Heart Journal. 2009;30 (18):2186–92. DOI:10.1093/eurheartj/ehp323
  687. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta- analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146 (4):278–88.
  688. Агеев Ф. Т., Мареев В. Ю., Середенина Е. М., Беленков Ю. Н. Перс- пективы внедрения специализированных форм активного амбулаторного ведения больных с сердечной недостаточностью: структура, методика и предварительные результаты Российской программы «ШАНС». Журнал Сердечная Недостаточность. 2004;5 (6):268–71. [Ageev F. T., Mareev V. Yu., Seredenina E. M., Belen- kov Yu. N. Prospects for introducing specialized forms of active outpa- tient management in patients with heart failure: structure, methodolo- gy and preliminary results of the Russian program «SHANS». Russian heart failure journal. 2004;5 (6):268–71.]
  689. Ревишвили А. Ш., Ардашев А. В., Бойцов С. А., Бокерия Л. А., Голухова Е. З., Давтян К. В. и др. Клинические рекомендации по про- ведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. ГОЭТАР-медиа. – Москва; 2013. 597 с. [Revishvi- li A. SH. i dr., «Klinicheskie rekomendacii po provedeniyu ehlektro- fiziologicheskih issledovanij, kateternoj ablyacii i primeneniyu implan- tiruemyh antiaritmicheskih ustrojstv», 2013.] ISBN: 5-7887-0106-6
  690. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Im- plantable Defibrillator (DAVID) Trial. JAMA. 2002;288 (24):3115– 23. PMID:12495391
  691. Yu C–M, Chan JY-S, Zhang Q, Omar R, Yip GW-K, Hussin A et al Bi- ventricular pacing in patients with bradycardia and normal ejection fraction. New England Journal of Medicine. 2009;361 (22):2123–34. DOI:10.1056/NEJMoa0907555
  692. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L et al. Biventricular pacing for atrioventricular block and systolic dys- function. New England Journal of Medicine. 2013;368 (17):1585–93. DOI:10.1056/NEJMoa1210356
  693. Doshi RN, Daoud EG, Fellows C, Turk K, Duran A, Hamdan MH et al. Left ventricular-based cardiac stimulation Post AV nodal ab- lation Evaluation (The PAVE Study). Journal of Cardiovascular Electrophysiology. 2005;16 (11):1160–5. DOI:10.1111/j. 1540– 8167.2005.50062. x
  694. Brignole M, Botto G, Mont L, Iacopino S, De Marchi G, Oddone D et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: a randomized trial. European Heart Journal. 2011;32 (19):2420–9. DOI:10.1093/eurheartj/ehr162
  695. Saba MM, Donahue TP, Panotopoulos PTH, Ibrahim SS, Abi-Sam- ra FM. Long-term mortality in patients with pauses in ventricular electrical activity. Pacing and Clinical Electrophysiology. 2005;28 (11):1203–7. DOI:10.1111/j. 1540–8159.2005.50189. x
  696. Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour holter recor- dings. The American Journal of Cardiology. 1985;55 (8):1005–8. DOI:10.1016/0002–9149 (85) 90735–0
  697. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization ther- apy of the European Society of Cardiology (ESC). Developed in col- laboration with the European Heart Rhythm Association (EHRA). European Heart Journal. 2013;34 (29):2281–329. DOI:10.1093/eur- heartj/eht150
  698. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM, Freedman RA, Gettes LS et al. ACC/AHA/HRS 2008 Guidelines for device- based therapy of cardiac rhythm abnormalities. Journal of the Ameri- can College of Cardiology. 2008;51 (21):e1–62. DOI:10.1016/j. jacc. 2008.02.032
  699. Мареев Ю. В., Шитов В. Н., Саидова М. А. Сердечная ресинхронизирующая терапия. Отбор пациентов иихведение после имплантации бивентрикулярного электрокардиостимулятора. Кардиология. 2013;53 (3):81–7. [Mareev Yu. V., Shitov V. N., Said- ova M. A. Cardiac resynchronizing therapy. Selection of patients and their management after implantation of biventricular heart pacemaker. Kardiologiia. 2013;53 (3):81–7.]
  700. Stavrakis S, Lazzara R, Thadani U. The benefit of cardiac resynchro- nization therapy and QRS duration: a meta-analysis. Journal of Car- diovascular Electrophysiology. 2012;23 (2):163–8. DOI:10.1111/j. 1540–8167.2011.02144. x
  701. Sipahi I, Chou JC, Hyden M, Rowland DY, Simon DI, Fang JC. Effect of QRS morphology on clinical event reduction with cardiac resyn- chronization therapy: meta-analysis of randomized controlled trials. American Heart Journal. 2012;163 (2):260–267. e3. DOI:10.1016/j. ahj. 2011.11.014
  702. Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J et al. An individual patient meta-analysis of five random- ized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. European Heart Journal. 2013;34 (46):3547–56. DOI:10.1093/eur- heartj/eht290
  703. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. New England Journal of Medicine. 2013;369 (15):1395– 405. DOI:10.1056/NEJMoa1306687
  704. Beshai JF, Grimm RA, Nagueh SF, Baker JH, Beau SL, Greenberg SM et al. Cardiac-resynchronization therapy in heart failure with nar- row QRS complexes. New England Journal of Medicine. 2007;357 (24):2461–71. DOI:10.1056/NEJMoa0706695
  705. on behalf of the ESTEEM–CRT Investigators, Donahue T, Niazi I, Leon A, Stucky M, Herrmann K. Acute and chronic response to CRT in narrow QRS patients. Journal of Cardiovascular Translational Re- search. 2012;5 (2):232–41. DOI:10.1007/s12265-011-9338-3
  706. Thibault B, Harel F, Ducharme A, White M, Ellenbogen KA, Frasure- Smith N et al. Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the evaluation of resyn- chronization therapy for heart failure (LESSER-EARTH) trial. Circu- lation. 2013;127 (8):873–81. DOI:10.1161/CIRCULATIONAHA. 112.001239
  707. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M et al. Effectiveness of cardiac resynchronization therapy by QRS mor- phology in the Multicenter Automatic Defibrillator Implantation Tri- al-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;123 (10):1061–72. DOI:10.1161 / CIRCULATIONAHA. 110.960898
  708. Birnie DH, Ha A, Higginson L, Sidhu K, Green M, Philippon F et al. Impact of QRS morphology and duration on outcomes after cardiac re- synchronization therapy: results from the Resynchronization-Defibril- lation for Ambulatory Heart Failure Trial (RAFT). Circulation: Heart Failure. 2013;6 (6):1190–8. DOI:10.1161/CIRCHEARTFAILURE. 113.000380
  709. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. New England Journal of Medicine. 2009;361 (14):1329–38. DOI:10.1056/NEJMoa0906431
  710. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. New England Journal of Medicine. 2010;363 (25):2385–95. DOI:10.1056/NEJMoa1009540
  711. Linde C, Abraham WT, Gold MR, Daubert C. Cardiac resynchroniza- tion therapy in asymptomatic or mildly symptomatic heart failure pa- tients in relation to etiology. Journal of the American College of Car- diology. 2010;56 (22):1826–31. DOI:10.1016/j. jacc. 2010.05.055
  712. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappen- berger L et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. European Heart Journal. 2006;27 (16):1928–32. DOI:10.1093/eurheartj/ehl099
  713. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine. 2004;350 (21):2140–50. DOI:10.1056/NEJMoa032423
  714. Healey JS, Hohnloser SH, Exner DV, Birnie DH, Parkash R, Connol- ly SJ et al. Cardiac resynchronization therapy in patients with perma- nent atrial fibrillation: results from the Resynchronization for Ambu- latory Heart Failure Trial (RAFT). Circulation: Heart Failure. 2012;5 (5):566–70. DOI:10.1161/CIRCHEARTFAILURE. 112.968867
  715. Koplan BA, Kaplan AJ, Weiner S, Jones PW, Seth M, Christman SA. Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure. Jour- nal of the American College of Cardiology. 2009;53 (4):355–60. DOI:10.1016/j. jacc. 2008.09.043
  716. Cheng A, Landman SR, Stadler RW. Reasons for loss of cardiac re- synchronization therapy pacing: insights from 32844 patients. Cir- culation: Arrhythmia and Electrophysiology. 2012;5 (5):884–8. DOI:10.1161/CIRCEP. 112.973776
  717. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ab- lation in patients with permanent atrial fibrillation. European Heart Journal. 2008;29 (13):1644–52. DOI:10.1093/eurheartj/ehn133
  718. Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, San- tini M et al. Cardiac resynchronization therapy in patients with atrial fibrillation. JACC: Heart Failure. 2013;1 (6):500–7. DOI:10.1016/j. jchf. 2013.06.003
  719. Delnoy PPHM, Ottervanger JP, Luttikhuis HO, Elvan A, Misier ARR, Beukema WP et al. Comparison of usefulness of cardiac resynchroni- zation therapy in patients with atrial fibrillation and heart failure ver- sus patients with sinus rhythm and heart failure. The American Jour- nal of Cardiology. 2007;99 (9):1252–7. DOI:10.1016/j. amjcard. 2006.12.040
  720. Tolosana JM, Arnau AM, Madrid AH, Macias A, Lozano IF, Osca J et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response? European Journal of Heart Failure. 2012;14 (6):635–41. DOI:10.1093/eurjhf/hfs024
  721. Kamath GS, Cotiga D, Koneru JN, Arshad A, Pierce W, Aziz EF et al. The utility of 12-lead holter monitoring in patients with permanent atrial fibrillation for the identification of nonresponders after cardiac resynchronization therapy. Journal of the American College of Car- diology. 2009;53 (12):1050–5. DOI:10.1016/j. jacc. 2008.12.022
  722. Мареев Ю. В., Шитов В. Н., Киктев В. Г., Сапельников О. В., Латы- пов Р. С., Гришин И. Р. и др. Сердечная ресинхронизирующая тера- пия при постоянной форме мерцательной аритмии. Кардиология. 2013;53 (5):43–9. [Mareev Yu. V., Shitov V. N., Kiktev V. G., Sapel- nicov O. V., Latipov R. S., Grishin I. R. et al. Cardiac resynchroniza- tion therapy in patients with permanent atrial fibrillation. Kardiologi- ia. 2013;53 (5):43–9.]
  723. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUS- TIC) study. J Am Coll Cardiol. 2002;40 (1):111–8. PMID:12103264
  724. Kang S-H, Oh I-Y, Kang D-Y, Cha M-J, Cho Y, Choi E-K et al. Cardiac resynchronization therapy and QRS uration: systematic review, me- ta-analysis, and meta-regression. Journal of Korean Medical Science. 2015;30 (1):24–33. DOI:10.3346/jkms. 2015.30.1.24
  725. Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS et al. The effect of QRS duration on cardiac resynchronization ther- apy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. European Heart Journal. 2015;36 (30):1983–9. DOI:10.1093/eurheartj/ehv242
  726. Barsheshet A, Moss AJ, McNitt S, Jons C, Glikson M, Klein HU et al. Long-term implications of cumulative right ventricular pacing among patients with an implantable cardioverter-defibrillator. Heart Rhythm. 2011;8 (2):212–8. DOI:10.1016/j. hrthm. 2010.10.035
  727. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. и др. Национальные рекомен- дации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14 (7):379–472. [Mareev V. Yu., Ageev F. T., Arutyunov G. P., Koroteev A. V., Mareev Yu. V., Ovchin- nikov A. G. SEHF, RSC and RSMSIM national guidelines on CHF diagnostics and treatment (fourth revision) Approved at the SEHF Congress on December 7, 2012, at the SEHF Board of Directors meeting on March 31, 2013, and at the RSC Congress on Septem- ber 25, 2013. Russian Heart Failure Journal. 2013;14 (7):379–472.] DOI:10.18087/rhfj. 2013.7.1860
  728. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al. Defibrillator implantation in patients with nonischemic systolic heart failure. New England Journal of Medicine. 2016;375 (13):1221–30. DOI:10.1056/NEJMoa1608029
  729. Al-Khatib SM, Fonarow GC, Joglar JA, Inoue LYT, Mark DB, Lee KL et al. Primary prevention implantable cardioverter defibrillators in pa- tients with nonischemic cardiomyopathy: a meta-analysis. JAMA Car- diology. 2017;2 (6):685. DOI:10.1001/jamacardio. 2017.0630
  730. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non- ischaemic cardiomyopathy, sudden death and implantable defibrilla- tors: a review and meta-analysis. Heart. 2018;104 (2):144–50. DOI:1 0.1136/heartjnl-2016–310850
  731. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF et al. Declining risk of sudden death in heart failure. New England Journal of Medicine. 2017;377 (1):41–51. DOI:10.1056/NEJMoa1609758
  732. Connolly S. Meta-analysis of the implantable cardioverter defibril- lator secondary prevention trials. European Heart Journal. 2000;21 (24):2071–8. DOI:10.1053/euhj. 2000.2476
  733. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocar- dial infarction and reduced ejection fraction. New England Journal of Medicine. 2002;346 (12):877–83. DOI:10.1056/NEJMoa013474
  734. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrilla- tors for the prevention of mortality in patients with nonischemic car- diomyopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292 (23):2874–9. DOI:10.1001/jama. 292.23.2874
  735. Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Ferrer JBM et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309 (18):1903. DOI:10.1001/jama. 2013.4598
  736. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP et al. Reduction in inappropriate therapy and mortality through ICD programming. New England Journal of Medicine. 2012;367 (24):2275–83. DOI:10.1056/NEJMoa1211107
  737. Scott PA, Silberbauer J, McDonagh TA, Murgatroyd FD. Impact of prolonged implantable cardioverter-defibrillator arrhythmia de- tection times on outcomes: A meta-analysis. Heart Rhythm. 2014;11 (5):828–35. DOI:10.1016/j. hrthm. 2014.02.009
  738. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dys- function. New England Journal of Medicine. 2011;364 (17):1607–16. DOI:10.1056/NEJMoa1100356
  739. Bangalore S, Pursnani S, Kumar S, Bagos PG. Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spon- taneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease. Circulation. 2013;127 (7):769–81. DOI:10.1161/CIRCU- LATIONAHA. 112.131961
  740. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary ar- tery disease: a quantitative 20-year synopsis and a network meta-analy- sis. The Lancet. 2009;373 (9667):911–8. DOI:10.1016/S0140–6736 (09) 60319–6
  741. Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomy- opathy. New England Journal of Medicine. 2016;374 (16):1511–20. DOI:10.1056/NEJMoa1602001
  742. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guy- ton RA et al. 2014 AHA/ACC Guideline for the Management of Pa- tients With Valvular Heart Disease. Journal of the American Col- lege of Cardiology. 2014;63 (22):e57–185. DOI:10.1016/j. jacc. 2014.02.536
  743. Latib А, Giannini А. Cardiac Interventions Today – The Next Frontier of Percutaneous Tricuspid Valve Repair. Cardiac Interventions Today. 2016;10 (4):54–9.
  744. Готье С. В., Иткин Г. П., Шемакин С. Ю., Саитгареев Р. Ш., Поп- цов В. Н., Захаревич В. М. и др. Первый опыт клинического при- менения отечественного аппарата вспомогательного крово- обращения на базе имплантируемого осевого насоса для двухэтап- ной трансплантации сердца. Вестник трансплантологии и искус- ственных органов. 2014;15 (3):92–101. [Gautier S. V., Itkin G. P., Shemakin S. Y., Saitgareev R. S., Poptsov V. N., Zakharevich V. M. et al. The first experience in clinical application of domestic circulato- ry support device on basis of implantable axial pump for two stage heart transplantation. Russian Journal of Transplantology and Arti- ficial Organs. 2013;15 (3):92–101.] DOI:10.15825/1995-1191-20 13-3-92-101
  745. Готье С. В., Попцов В. Н., Захаревич В. М., Шевченко А. О., Спирина Е. А., Ухренков С. Г. и др. Пятилетний опыт применения периферической вено-артериальной экстракорпоральной мембранной оксигенации как метода механической поддержки кровообращения у потенциальных реципиентов сердца. Вестник трансплантологии и искусственных органов. 2016;18 (4):16–25. [Gautier S. V., Poptsov V. N., Zakharevich V. M., Shevchenko A. O., Spirina E. A., Ukhrenkov S. G. et al. Five-year experience in peripheral venoarterial extracorporeal membrane oxygenation as a method of mechanical circulatory support in po- tential heart transplant recipients. Russian Journal of Transplan- tology and Artificial Organs. 2016;18 (4):16–25.] DOI:10.1582 5 /1995-1191-2016-4-16-32
  746. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA et al. The 2013 International Society for Heart and Lung Transplanta- tion Guidelines for mechanical circulatory support: Executive summa- ry. The Journal of Heart and Lung Transplantation. 2013;32 (2):157– 87. DOI:10.1016/j. healun. 2012.09.013
  747. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dem- bitsky W et al. Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart Failure. New England Journal of Medicine. 2001;345 (20):1435–43. DOI:10.1056/NEJMoa012175
  748. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feld- man D et al. Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device. New England Journal of Medicine. 2009;361 (23):2241–51. DOI:10.1056/NEJMoa0909938
  749. Estep JD, Starling RC, Horstmanshof DA, Milano CA, Selzman CH, Shah KB et al. Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients. Journal of the American College of Cardiolo- gy. 2015;66 (16):1747–61. DOI:10.1016/j. jacc. 2015.07.075
  750. Готье С. В., Иткин Г. П., Шевченко А. О., Халилулин Т. А., Коз- лов В. А. Длительная механическая поддержка кровообраще- ния как альтернатива трансплантации сердца. Вестник транс- плантологии и искусственных органов. 2016;18 (3):128–36. [Gautier S. V., Itkin G. P., Shevchenko A. O., Khalilulin T. A., Ko- zlov V. A. Durable mechanical circulation support as an alternative to heart transplantation. Russian Journal of Transplantology and Artifi- cial Organs. 2016;18 (3):128–136.] DOI:10.15825/1995-1191-201 6-3-128-136
  751. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Ba- ran DA et al. The 2016 International Society for Heart Lung Trans- plantation listing criteria for heart transplantation: A 10-year update. The Journal of Heart and Lung Transplantation. 2016;35 (1):1–23. DOI:10.1016/j. healun. 2015.10.023
  752. Попцов В. Н., Спирина Е. А., Ухренков С. Г., Устин С. Ю., Алиев Э. З., Масютин С. А. и др. Периоперационный период при трансплантации сердца у реципиентов 60 лет и старше. Вестник трансплантологии и искусственных органов. 2016;18 (4):56–65. [Poptsov V. N., Spirina E. A., Ukhrenkov S. G., Ustin S. Y., Aliev E. Z., Masyutin S. A. et al. Early postoperative period after ortho- topic heart transplantation in recipients of 60 years and older. Russian Journal of Transplantology and Artificial Organs. 2016;18 (4):56–65.] DOI:10.15825/1995-1191-2016-4-56-65
  753. Goldstein DJ, Bello R, Shin JJ, Stevens G, Zolty R, Maybaum S et al. Outcomes of cardiac transplantation in septuagenarians. The Journal of Heart and Lung Transplantation. 2012;31 (7):679–85. DOI:10.1016/j. healun. 2012.03.019
  754. Weiss ES, Allen JG, Russell SD, Shah AS, Conte JV. Impact of Re- cipient Body Mass Index on Organ Allocation and Mortality in Orthotopic Heart Transplantation. The Journal of Heart and Lung Transplantation. 2009;28 (11):1150–7. DOI:10.1016/j. healun. 2009.06.009
  755. Готье С. В., Шевченко А. О., Попцов В. Н. Пациент с транс- плантированным сердцем. Руководство для врачей по ведению пациентов, перенесших трансплантацию сердца. ООО «Из- дательство «Триада». – М. – Тверь; 2014. 144 с. [Gautier S. V., Shevchenko A. O., Poptsov V. N. Patient with a transplanted heart. A guide for physicians in the management of patients undergoing heart transplantation. – M. – Tver.:«Triada», 2014. – 144p.] ISBN: 978-5-94789-648-0
  756. Шевченко А. О., Туняева И. Ю., Насырова А. А., Миронков Б. Л., Ильинский И. М., Можейко Н. П. и др. Отторжение сердечного трансплантата и неинвазивные показатели функционального состояния стенки общей сонной артерии. Вестник трансплантологии и искусственных органов. 2015;17 (1):5–11. [Shevchenko A. O., Tunjaieva I. U., Nasyrova A. A., Mironkov B. L., Ilinsky I. M., Mozhejko N. P. et al. Cardiac transplant rejection and non-invasive comon carotid artery wall functional indices. Russian Journal of Transplantology and Artificial Organs. 2015;17 (1):5– 11.] DOI:10.15825/1995-1191-2015-1-5-11
  757. Готье С. В., Шевченко А. О., Кормер А. Я., Попцов В. Н., Шевчен- ко О. П. Перспективы улучшения отдаленных результатов трансплантации сердца. Вестник трансплантологии и искус- ственных органов. 2014;16 (3):23–30. [Gautier S. V., Shevchen- ko A. O., Kormer A. Y., Poptsov V. N., Shevchenko O. P. Prospects to improve long-term outcomes of cardiac transplantation. Rus- sian Journal of Transplantology and Artificial Organs. 2014;16 (3):23–30.] DOI:10.15825 / 1995-1191-2014-3-23-30
  758. Шевченко А. О. Гиполипидемическая терапия у реципиентов сердца: статины. Вестник трансплантологии и искусственных органов. 2016;18 (2):171–6. [Shevchenko A. О. Hypolipidemic ther- apy in patients after heart transplantation: statins. Russian Journal of Transplantology and Artificial Organs. 2016;18 (2):171–176.] DOI: 10.15825/1995-1191-2016-2-171-176
  759. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. The American Journal of Cardi- ology. 1974;34 (1):29–34. DOI:10.1016/0002–9149 (74) 90089–7
  760. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an in- dependent risk factor for cardiovascular disease: a 26- year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67 (5):968–77. DOI:10.1161/01. CIR. 67.5.968
  761. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function. Journal of the American College of Car- diology. 2004;43 (3):317–27. DOI:10.1016/j. jacc. 2003.07.046
  762. Sakata Y, Miyata S, Nochioka K, Miura M, Takada T, Tadaki S et al. Gender differences in clinical characteristics, treatment and long-term outcome in patients with stage C/D heart failure in Ja- pan. Report from the CHART-2 study. Circ J. 2014;78 (2):428–35. PMID:24317114
  763. Lenzen MJ, Rosengren A, Scholte op Reimer WJM, Follath F, Boers- ma E, Simoons ML et al. Management of patients with heart failure in clinical practice: differences between men and women. Heart. 2008;94 (3):e10. DOI:10.1136/hrt. 2006.099523
  764. Kannel WB. Incidence and Epidemiology of Heart Failure. Heart Fail- ure Reviews. 2000;5 (2):167–73. DOI:10.1023/A:1009884820941
  765. Rusinaru D, Mahjoub H, Goissen T, Massy Z, Peltier M, Tribouil- loy C. Clinical features and prognosis of heart failure in women. A 5-year prospective study. International Journal of Cardiology. 2009;133 (3):327–35. DOI:10.1016/j. ijcard. 2007.12.113
  766. Adams KF, Sueta CA, Gheorghiade M, O’Connor CM, Schwartz TA, Koch GG et al. Gender Differences in Survival in Advanced Heart Fail- ure: Insights From the FIRST Study. Circulation. 1999;99 (14):1816– 21. DOI:10.1161/01. CIR. 99.14.1816
  767. Mullens W, Abrahams Z, Sokos G, Francis GS, Starling RC, Young JB et al. Gender Differences in Patients Admitted With Advanced Decom- pensated Heart Failure. The American Journal of Cardiology. 2008;102 (4):454–8. DOI:10.1016/j. amjcard. 2008.04.009
  768. Roger VL. Trends in Heart Failure Incidence and Survival in a Commu- nity-Based Population. JAMA. 2004;292 (3):344. DOI:10.1001/ja- ma. 292.3.344
  769. Barker WH. Changing Incidence and Survival for Heart Failure in a Well-Defined Older Population, 1970–1974 and 1990–1994. Circu- lation. 2006;113 (6):799–805. DOI:10.1161/CIRCULATIONAHA. 104.492033
  770. Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. Sex dif- ferences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J. 1999;138 (5 Pt 1):835–42. PMID:10539813
  771. Ohlsson A, Lindahl B, Hanning M, Westerling R. Inequity of access to ACE inhibitors in Swedish heart failure patients: a register-based study. Journal of Epidemiology and Community Health. 2016;70 (1):97– 103. DOI:10.1136/jech-2015–205738
  772. Lupón J, Urrutia A, González B, Díez C, Altimir S, Albaladejo C et al. Does Heart Failure Therapy Differ According to Patient Sex? Clinical Cardiology. 2007;30 (6):301–5. DOI:10.1002/clc. 20098
  773. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37 (5):1199–208. PMID:11358929
  774. Shekelle PG, Rich MW, Morton SC, Atkinson CSW, Tu W, Maglione M et al. Efficacy of angiotensin-converting enzyme inhibitors and beta- blockers in the management of left ventricular systolic dysfunction ac- cording to race, gender, and diabetic status. Journal of the American College of Cardiology. 2003;41 (9):1529–38. DOI:10.1016/S0735– 1097 (03) 00262–6
  775. Oparil S, Miller AP. Gender and Blood Pressure. The Journal of Clin- ical Hypertension. 2005;7 (5):300–9. DOI:10.1111 / j.1524– 6175.2005.04087. x
  776. Rathore SS, Wang Y, Krumholz HM. Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure. New England Journal of Medicine. 2002;347 (18):1403–11. DOI:10.1056/NEJ- Moa021266
  777. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Fu- rie KL et al. Guidelines for the Prevention of Stroke in Women: A State- ment for Healthcare Professionals From the American Heart Associ- ation/American Stroke Association. Stroke. 2014;45 (5):1545–88. DOI:10.1161/01. str. 0000442009.06663.48
  778. Levitan EB, Wolk A, Mittleman MA. Consistency With the DASH Diet and Incidence of Heart Failure. Archives of Internal Medicine. 2009;169 (9):851. DOI:10.1001/archinternmed. 2009.56
  779. Rautiainen S, Levitan EB, Mittleman MA, Wolk A. Fruit and vegeta- ble intake and rate of heart failure: a population-based prospective co- hort of women: Fruit and vegetables and rate of heart failure. Europe- an Journal of Heart Failure. 2015;17 (1):20–6. DOI:10.1002/ejhf. 191
  780. Bleeker GB, Schalij MJ, Boersma E, Steendijk P, Van Der Wall EE, Bax JJ. Does a Gender Difference in Response to Cardiac Resynchroniza- tion Therapy Exist? Pacing and Clinical Electrophysiology. 2005;28 (12):1271–5. DOI:10.1111/j. 1540–8159.2005.00267. x
  781. Zabarovskaja S, Gadler F, Braunschweig F, Ståhlberg M, Hörnsten J, Linde C et al. Women have better long-term prognosis than men after cardiac resynchronization therapy. Europace. 2012;14 (8):1148–55. DOI:10.1093/europace/eus039
  782. Kelarijani RB, Saleh DK, Chalian M, Kabir A, Ahmadzad Asl M, Dadjoo Y. Gender- and age-related outcomes of cardiac resynchroni- zation therapy: A pilot observational study. Gender Medicine. 2008;5 (4):415–22. DOI:10.1016/j. genm. 2008.10.005
  783. Xu Y-Z, Friedman PA, Webster T, Brooke K, Hodge DO, Wiste HJ et al. Cardiac Resynchronization Therapy: Do Women Benefit More Than Men? Journal of Cardiovascular Electrophysiology. 2012;23 (2):172–8. DOI:10.1111/j. 1540–8167.2011.02168. x
  784. Ghani A, Maas AHEM, Delnoy PPHM, Ramdat Misier AR, Otter- vanger JP, Elvan A. Sex-Based Differences in Cardiac Arrhythmias, ICD Utilisation and Cardiac Resynchronisation Therapy. Netherlands Heart Journal. 2011;19 (1):35–40. DOI:10.1007/s12471-010-0050-8
  785. Solomon SD, Foster E, Bourgoun M, Shah A, Viloria E, Brown MW, et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implan- tation trial: cardiac resynchronization therapy. Circulation. 2010;122 (10):985–92. DOI:10.1161/CIRCULATIONAHA. 110.955039
  786. Russo AM, Poole JE, Mark DB, Anderson J, Hellkamp AS, Lee KL et al. Primary Prevention with Defibrillator Therapy in Women: Results from the Sudden Cardiac Death in Heart Failure Trial. Journal of Car- diovascular Electrophysiology. 2008;19 (7):720–4. DOI:10.1111/j. 1540–8167.2008.01129. x
  787. Zeitler EP, Hellkamp AS, Schulte PJ, Fonarow GC, Hernandez AF, Peterson ED et al. Comparative Effectiveness of Implantable Cardio- verter Defibrillators for Primary Prevention in WomenCLINICAL PERSPECTIVE. Circulation: Heart Failure. 2016;9 (1):e002630. DOI:10.1161/CIRCHEARTFAILURE. 115.002630
  788. Fornaro A, Castelli G, Ciaccheri M, Tomberli B, Olivotto I, Gensini GF. Improving survival of chemotherapy-induced cardiomyopathy in the modern heart failure therapy era. European Heart Journal. 2013;34 (suppl_1):P2968 – P2968. DOI:10.1093/eurheartj/eht309. P2968
  789. Kalam K, Marwick TH. Role of cardioprotective therapy for preven- tion of cardiotoxicity with chemotherapy: A systematic review and meta-analysis. European Journal of Cancer. 2013;49 (13):2900–9. DOI:10.1016/j. ejca. 2013.04.030
  790. Васюк ЮА, Школьник ЕВ, Несветов ВВ, Школьник ЛД, Варлан ГВ, Пильщиков АВ. Нарушения метаболизма миокарда на фоне химиотерапевтического лечения, а также возможности их коррекции. CardioСоматика. 2013; (4):20–4. [Vasyuk Yu. A., Shkolnik E. L., Nesvetov V. V., Shkolnik L. D., Varlan G. V., Pils- chikov A. V. Myocardial metabolic background on chemotherapy and means of their correction. CardioSomatika. 2013;4:20–4.]
  791. Amann K. Cross-Talk between the Kidney and the Cardiovascu- lar System. Journal of the American Society of Nephrology. 2006;17 (8):2112–9. DOI:10.1681/ASN. 2006030204
  792. Zoccali C, Goldsmith D, Agarwal R, Blankestijn PJ, Fliser D, Wiecek A et al. The complexity of the cardio – renal link: taxonomy, syndromes, and diseases. Kidney International Supplements. 2011;1 (1):2–5. DOI:10.1038/kisup. 2011.4
  793. Zhang Q-L, Rothenbacher D. Prevalence of chronic kidney dis- ease in population-based studies: Systematic review. BMC Pub- lic Health [Internet]. 2008 [cited on March 21, 2018];8 (1). DOI:10.1186/1471-2458-8-117
  794. Zoccali C, Kramer A, Jager KJ. Epidemiology of CKD in Europe: an uncertain scenario. Nephrology Dialysis Transplantation. 2010;25 (6):1731–3. DOI:10.1093/ndt/gfq250
  795. Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bag- shaw SM et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2010;31 (6):703–11. DOI:10.1093/eurheartj/ehp507
  796. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and po- tential targets for clinical management. Nature Reviews Nephrology. 2013;9 (2):99–111. DOI:10.1038/nrneph. 2012.279
  797. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: A Report From the ADHERE Database. Journal of Cardi- ac Failure. 2007;13 (6):422–30. DOI:10.1016/j. cardfail. 2007.03.011
  798. Campbell RC, Sui X, Filippatos G, Love TE, Wahle C, Sanders PW, et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study. Nephrology Dialysis Trans- plantation. 2008;24 (1):186–93. DOI:10.1093/ndt/gfn445
  799. Hillege HL. Renal Function as a Predictor of Outcome in a Broad Spec- trum of Patients With Heart Failure. Circulation. 2006;113 (5):671– 8. DOI:10.1161/CIRCULATIONAHA. 105.580506
  800. Gigante A, Liberatori M, Gasperini ML, Sardo L, Di Mario F, Dorel- li B et al. Prevalence and Clinical Features of Patients with the Cardio- renal Syndrome Admitted to an Internal Medicine Ward. Cardiorenal Medicine. 2014;4 (2):88–94. DOI:10.1159/000362566
  801. Clementi A, Virzì GM, Goh CY, Cruz DN, Granata A, Vescovo G et al. Cardiorenal Syndrome Type 4: A Review. Cardiorenal Medi- cine. 2013;3 (1):63–70. DOI:10.1159/000350397
  802. Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuis- en DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European Heart Journal. 2014;35 (7):455–69. DOI:10.1093/eur- heartj/eht386
  803. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, eva- luation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD–MBD). Kidney Int Suppl. 2009; (113):S1– 130. DOI:10.1038/ki. 2009.188
  804. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Re- nal Disease Study Group. Ann Intern Med. 1999;130 (6):461–70. PMID:10075613
  805. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS et al. Association of estimated glomerular filtration rate and albuminuria with all- cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375 (9731):2073–81. DOI:10.1016/S0140–6736 (10) 60674–5
  806. O’Seaghdha CM, Hwang S-J, Upadhyay A, Meigs JB, Fox CS. Pre- dictors of Incident Albuminuria in the Framingham Offspring Co- hort. American Journal of Kidney Diseases. 2010;56 (5):852–60. DOI:10.1053/j. ajkd. 2010.04.013
  807. Ishani A. Association of Single Measurements of Dipstick Proteinuria, Estimated Glomerular Filtration Rate, and Hematocrit with 25-Year Incidence of End-Stage Renal Disease in the Multiple Risk Factor Intervention Trial. Journal of the American Society of Nephrology. 2006;17 (5):1444–52. DOI:10.1681/ASN. 2005091012
  808. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH et al. Characteristics, Treatments, and Outcomes of Pa- tients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology. 2007;50 (8):768–77. DOI:10.1016/j. jacc. 2007.04.064
  809. Clark H, Krum H, Hopper I. Worsening renal function during renin- angiotensin-aldosterone system inhibitor initiation and long-term out- comes in patients with left ventricular systolic dysfunction. Eur J Heart Fail. 2014;16 (1):41–8. DOI:10.1002/ejhf. 13
  810. Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velaz- quez EJ et al. Chronic obstructive pulmonary disease is an indepen- dent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardi- al Infarction Trial (VALIANT). European Journal of Heart Failure. 2009;11 (3):292–8. DOI:10.1093/eurjhf/hfp001
  811. Apostolovic S, Jankovic-Tomasevic R, Salinger-Martinovic S, Djord- jevic-Radojkovic D, Stanojevic D, Pavlovic M et al. Frequency and sig- nificance of unrecognized chronic obstructive pulmonary disease in el- derly patients with stable heart failure. Aging Clinical and Experimen- tal Research. 2011;23 (5–6):337–42. DOI:10.1007/BF03337759
  812. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piña IL et al. Clin- ical characteristics, response to exercise training, and outcomes in pa- tients with heart failure and chronic obstructive pulmonary disease: Findings from Heart Failure and A Controlled Trial Investigating Out- comes of Exercise TraiNing (HF-ACTION). American Heart Journal. 2013;165 (2):193–9. DOI:10.1016/j. ahj. 2012.10.029
  813. Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G. The prog- nostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. European Journal of Heart Fail- ure. 2007;9 (9):942–8. DOI:10.1016/j. ejheart. 2007.06.004
  814. Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis D, Di- mopoulou I et al. Differences in clinical characteristics, manage- ment and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co- morbidity. Clinical Research in Cardiology. 2014;103 (9):733–41. DOI:10.1007/s00392-014-0708-0
  815. Mentz RJ, Fiuzat M, Wojdyla DM, Chiswell K, Gheorghiade M, Fon- arow GC et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF. European Journal of Heart Failure. 2012;14 (4):395–403. DOI:10.1093/eurjhf/hfs009
  816. Mentz RJ, Schmidt PH, Kwasny MJ, Ambrosy AP, O’Connor CM, Konstam MA et al. The Impact of Chronic Obstructive Pulmonary Disease in Patients Hospitalized for Worsening Heart Failure With Re- duced Ejection Fraction: An Analysis of the EVEREST Trial. Jour- nal of Cardiac Failure. 2012;18 (7):515–23. DOI:10.1016/j. cardfail. 2012.04.010
  817. Rutten FH. Diagnosis and management of heart failure in COPD. Rabe KF, Wedzicha JA, Wouters EFM, editor. COPD and Comorbid- ity [Internet]. European Respiratory Society; 2013 [cited on Febrary 1, 2018]. p. 50–63. ISBN: 978-1-84984-032-3
  818. Naeije R, Boerrigter BG. Pulmonary hypertension at exercise in COPD: does it matter? European Respiratory Journal. 2013;41 (5):1002–4. DOI:10.1183/09031936.00173512
  819. Iversen KK, Kjaergaard J, Akkan D, Kober L, Torp-Pedersen C, Has- sager C et al. Chronic obstructive pulmonary disease in patients admit- ted with heart failure. Journal of Internal Medicine. 2008;264 (4):361– 9. DOI:10.1111/j. 1365–2796.2008.01975. x
  820. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and Therapeutic Chal- lenges in Patients With Coexistent Chronic Obstructive Pulmo- nary Disease and Chronic Heart Failure. Journal of the American College of Cardiology. 2007;49 (2):171–80. DOI:10.1016/j. jacc. 2006.08.046
  821. Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J Thorac Dis. 2012;4 (3):310–5. DOI:10.3978/j. issn. 2072–1439.2012.01.09
  822. Чучалин А. Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Терапевтический архив. 2013;85 (8):43–8. [Chuchalin A. G. Chronic obstructive pulmonary disease and comorbidities. Therapeutic Archive. 2013;85 (8):43–8.]
  823. Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Bro- phy JM. Reduction of Morbidity and Mortality by Statins, Angioten- sin-Converting Enzyme Inhibitors, and Angiotensin Receptor Block- ers in Patients With Chronic Obstructive Pulmonary Disease. Jour- nal of the American College of Cardiology. 2006;47 (12):2554–60. DOI:10.1016/j. jacc. 2006.04.039
  824. Mortensen EM, Copeland LA, Pugh MJV, Restrepo MI, de Mo- lina RM, Nakashima B et al. Impact of statins and ACE in- hibitors on mortality after COPD exacerbations. Respirato- ry Research [Internet]. 2009 [cited on Febrary 1, 2018];10 (1). DOI:10.1186/1465-9921-10-45
  825. Finnerty JP, Keeping I, Bullough I, Jones J. The Effectiveness of Out- patient Pulmonary Rehabilitation in Chronic Lung Disease. Chest. 2001;119 (6):1705–10. DOI:10.1378/chest. 119.6.1705
  826. Федотов П. А., Ситникова М. Ю., Сафьянова Н. В., Шапоро- ва Н. Л. Хроническая сердечная недостаточность ишемического генеза и хроническая обструктивная болезнь легких: возможности комбинированной терапии, включающей небиволол. Клиницист. 2013; (3–4):40–7. [Fedotov P. A., Sitnikova M. Yu., Safyanova N. V., Shaporova N. L. Chronic heart failure of ischemic genesis and chron- ic obstructive pulmonary disease: Possibilities of combination thera- py including nebivolol. Klinitsist. 2013;3–4:40–7.]
  827. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenau- er PK. Association between β-blocker therapy and outcomes in pa- tients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67 (11):977–84. DOI:10.1136/tho- raxjnl-2012–201945
  828. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pul- monary Medicine [Internet]. 2012 [cited on Febrary 1, 2018];12 (1). DOI:10.1186/1471-2466-12-48
  829. Rutten FH. β-Blockers May Reduce Mortality and Risk of Exacerba- tions in Patients With Chronic Obstructive Pulmonary Disease. Ar- chives of Internal Medicine. 2010;170 (10):880. DOI:10.1001/archin- ternmed. 2010.112
  830. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Ana- lysis of Observational Studies. Chalmers JD, редактор. PLoS ONE. 2014;9 (11):e113048. DOI:10.1371/journal. pone. 0113048
  831. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker Use and Incidence of Chronic Obstructive Pulmonary Dis- ease Exacerbations. Annals of Pharmacotherapy. 2013;47 (5):651–6. DOI:10.1345/aph. 1R600
  832. Ekström MP, Hermansson AB, Ström KE. Effects of Cardiovascular Drugs on Mortality in Severe Chronic Obstructive Pulmonary Dis- ease: A Time-Dependent Analysis. American Journal of Respiratory and Critical Care Medicine. 2013;187 (7):715–20. DOI:10.1164/rc- cm. 201208-1565OC
  833. Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M et al. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: An efficacy and safety analysis of SHIFT study. International Journal of Cardiology. 2013;170 (2):182–8. DOI:10.1016/j. ijcard. 2013.10.068
  834. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of Mortality and Heart Failure Exacerbations Associated With In- haled β-Adrenoceptor Agonists Among Patients With Known Left Ventricular Systolic Dysfunctiona. Chest. 2003;123 (6):1964–9. DOI:10.1378/chest. 123.6.1964
  835. Levy D. The progression from hypertension to congestive heart failure. JAMA: The Journal of the American Medical Association. 1996;275 (20):1557–62. DOI:10.1001/jama. 275.20.1557
  836. Effect of intensive blood-glucose control with metformin on complica- tions in overweight patients with type 2 diabetes (UKPDS 34). The Lan- cet. 1998;352 (9131):854–65. DOI:10.1016/S0140–6736 (98) 07037–8
  837. Masoudi FA. Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study. Circulation. 2005;111 (5):583–90. DOI:10.1161/01. CIR. 0000154542.13412. B1
  838. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidin- ediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials. Ameri- can Journal Cardiovascular Drugs. 2011;11 (2):115–28. DOI:10.216 5/11587580-000000000-00000
  839. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2017;377 (13):1228–39. DOI:10.1056/NEJMoa1612917
  840. Barzilay J. Risk and impact of incident glucose disorders in hyperten- sive older adults treated with an ace inhibitor, a diuretic, or a calcium channel blocker: a report from the allhat trial. American Journal of Hy- pertension. 2004;17 (5):S1. DOI:10.1016/j. amjhyper. 2004.03.002
  841. Gottlieb SS, McCarter RJ, Vogel RA. Effect of Beta-Blockade on Mor- tality among High-Risk and Low-Risk Patients after Myocardial Infarc- tion. New England Journal of Medicine. 1998;339 (8):489–97. DOI: 10.1056/NEJM199808203390801
  842. Heinemann L, Heise T, Ampudia J, Sawicki P, Sindelka G, Brunner G et al. Four week administration of an ACE inhibitor and a cardioselec- tive beta-blocker in healthy volunteers: no influence on insulin sensi- tivity. Eur J Clin Invest. 1995;25 (8):595–600. PMID:7589016
  843. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ra- gone R et al. Metabolic and cardiovascular effects of carvedilol and at- enolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med. 1997;126 (12):955– 9. PMID:9182472
  844. Мареев В. Ю., Даниелян М. О., Осмаловская Ю. Ф., Агеев Ф. Т., Серединина Е. М., Жубрина Е. С. и др. НЕбиволол против МЕтопролола: сравнительное рандомиЗированное ИсслеДовАние у больных Хронической Сердечной Недостаточностью (НЕМЕЗИДА – ХСН). ЖСН. 2013;14 (2):63–74. [Mareev V. Yu., Danielyan M. O., Osmolovskaya Yu. F., Ageev F. T., Seredenina E. M., Zhubrina E. S. et al. NEbivolol vs. MEtoprolol: comparative random- ized Study In patientS with Chronic Heart Failure (NEMESIS-CHF). Russian Heart Failure Journal. 2013;14 (2):63–74.]
  845. Torp-Pedersen C, Metra M, Charlesworth A, Spark P, Lukas MA, Poole-Wilson PA et al. Effects of metoprolol and carvedilol on pre- existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93 (8):968–73. DOI:10.1136/hrt. 2006.092379
  846. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phil- lips RA et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial. JAMA. 2004;292 (18):2227. DOI:10.1001/jama. 292.18.2227
  847. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in Heart Failure. Journal of the American College of Cardiology. 2006;48 (8):1527–37. DOI:10.1016/j. jacc. 2006.06.055
  848. Оганов Р. Г., Ольбинская Л. И., Смулевич А. Б., Вейн А. М., Дробижев М. Ю., Шальнова С. А. и др. Депрессии и расстройства депрессивного спектра в общемедицинской практике. Результаты программы КОМПАС. Кардиология. 2004;44 (1):48. [Oganov R. G., Olbinskaya L. I., Smulevich A. B., Vein A. M., Drobi- zhev M. Yu., Shalnova S. A. et al. Depressions and Disorders of Depres- sive Spectrum in General Medical Practice. Results of the COMPAS program. Kardiologiia. 2004;44 (1):48–54.]
  849. Jiménez JA, Redwine LL, Rutledge TR, Dimsdale JE, Pung MA, Ziegler MG et al. Depression Ratings and Antidepressant Use among Outpatient Heart Failure Patients: Implications for the Screening and Treatment of Depression. The International Journal of Psychiatry in Medicine. 2012;44 (4):315–34. DOI:10.2190/PM. 44.4. c
  850. DeWolfe A, Gogichaishvili I, Nozadze N, Tamariz L, Quevedo HC, Ju- lian E et al. Depression and Quality of Life Among Heart Failure Pa- tients in Georgia, Eastern Europe: depression and quality of life among heart failure patients. Congestive Heart Failure. 2012;18 (2):107–11. DOI:10.1111/j. 1751–7133.2011.00226. x
  851. Feola M, Garnero S, Vallauri P, Salvatico L, Vado A, Leto L et al. Relation- ship between Cognitive Function, Depression/Anxiety and Functional Parameters in Patients Admitted for Congestive Heart Failure. Open Car- diovasc Med J. 2013;7:54–60. DOI:10.2174/1874192401307010054
  852. Jiang W, Kuchibhatla M, Cuffe MS, Christopher EJ, Alexander JD, Clary GL et al. Prognostic value of anxiety and depression in pa- tients with chronic heart failure. Circulation. 2004;110 (22):3452–6. DOI:10.1161/01. CIR. 0000148138.25157. F9
  853. Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Her- bert R et al. Noncardiac comorbidity increases preventable hospitaliza- tions and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42 (7):1226–33. PMID:14522486
  854. Newhouse A, Jiang W. Heart Failure and Depression. Heart Failure Clinics. 2014;10 (2):295–304. DOI:10.1016/j. hfc. 2013.10.004
  855. Katon W, Lin EHB, Kroenke K. The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. General Hospital Psychiatry. 2007;29 (2):147–55. DOI:10.1016/j. genhosppsych. 2006.11.005
  856. Egede LE. Major depression in individuals with chronic medical dis- orders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. General Hospi- tal Psychiatry. 2007;29 (5):409–16. DOI:10.1016/j. genhosppsych. 2007.06.002
  857. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lesperance F et al. Depression and Coronary Heart Disease: Rec- ommendations for Screening, Referral, and Treatment: A Science Ad- visory From the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardi- ology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Psychiatric Association. Circulation. 2008;118 (17):1768– 75. DOI:10.1161/CIRCULATIONAHA. 108.190769
  858. U. S. Preventive Services Task Force*. Screening for Depression: Rec- ommendations and Rationale. Annals of Internal Medicine. 2002;136 (10):760. DOI:10.7326/0003-4819-136-10-200205210-00012
  859. Thombs BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JP. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Medicine [Internet]. 2014 [cited on Febrary 1, 2018];12 (1). DOI:10.1186/1741-7015-12-13
  860. Whooley MA. To Screen or Not to Screen? Journal of the American College of Cardiology. 2009;54 (10):891–3. DOI:10.1016/j. jacc. 2009.05.034
  861. Оганов Р. Г., Погосова Г. В., Шальнова С. А., Деев А. Д. Депрессивные расстройства в общемедицинской практике по данным исследова- ния КОМПАС: взгляд кардиолога. Кардиология. 2005;45 (8):37– 43. [Oganov R. G., Pogosova G. V., Shalnova S. A., Deev A. D. Depres- sive Disorders in General Medical Practice in KO-MPAS Study: Out- look of a Cardiologist. Kardiologiia. 2005;45 (8):37–43.]
  862. Васюк Ю. А., Довженко Т. В. Хроническая сердечная недостаточ- ность и расстройства депрессивного спектра. Журнал Сердечная Недостаточность. 2009;10 (6):342–8. [Vasyuk Y. A., Dovjen- ko T. V. Chronic heart failure and depressive disorders. Russian Heart Failure Journal. 2009;10 (6):342–8.]
  863. Васюк Ю. А., Довженко Т. В., Школьник Е. Л. Депрессии при хро- нической сердечной недостаточности ишемического гене- за. Журнал Сердечная Недостаточность. 2004;5 (3):140–6. [Vasyuk Yu. A., Dovzhenko T. V., Shkolnik E. L. Depressions in chroni- cheart failure of ischemic genesis. Russian Heart Failure Journal. 2004;5 (3):140–6.]
  864. Faller H, Störk S, Gelbrich G, Schowalter M, Ertl G, Angermann CE. Depressive symptoms in heart failure: Independent prognostic factor or marker of functional status? Journal of Psychosomatic Research. 2015;78 (6):569–72. DOI:10.1016/j. jpsychores. 2015.02.015
  865. Lahlou-Laforêt K, Ledru F, Niarra R, Consoli SM. Validity of Beck De- pression Inventory for the assessment of depressive mood in chronic heart failure patients. Journal of Affective Disorders. 2015;184:256– 60. DOI:10.1016/j. jad. 2015.05.056
  866. DiMatteo MR, Lepper HS, Croghan TW. Depression Is a Risk Fac- tor for Noncompliance With Medical Treatment: Meta-analysis of the Effects of Anxiety and Depression on Patient Adherence. Archives of Internal Medicine. 2000;160 (14):2101. DOI:10.1001/archinte. 160.14.2101
  867. Ski CF, Thompson DR, Hare DL, Stewart AG, Watson R. Car- diac Depression Scale: Mokken scaling in heart failure pa- tients. Health and Quality of Life Outcomes. 2012;10 (1):141. DOI:10.1186/1477-7525-10-141
  868. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hos- pital Anxiety and Depression Scale. An updated literature review. J Psy- chosom Res. 2002;52 (2):69–77. PMID:11832252
  869. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Ac- ta Psychiatr Scand. 1983;67 (6):361–70. PMID:6880820
  870. Savard LA, Thompson DR, Clark AM. A meta-review of evi- dence on heart failure disease management programs: the chal- lenges of describing and synthesizing evidence on complex inter- ventions. Trials [Internet]. 2011 [cited on Febrary 1, 2018];12 (1). DOI:10.1186/1745-6215-12-194
  871. de la Porte PWFB-A, Lok DJA, van Veldhuisen DJ, van Wijngaarden J, Cornel JH, Zuithoff NPA et al. Added value of a physician-and-nurse- directed heart failure clinic: results from the Deventer – Alkmaar heart failure study. Heart. 2007;93 (7):819–25. DOI:10.1136/hrt. 2006.095810
  872. Clark AM, Thompson DR. The future of management pro- grammes for heart failure. The Lancet. 2008;372 (9641):784–6. DOI:10.1016/S0140–6736 (08) 61317–3
  873. Андрющенко А. В., Дробижев М. Ю., Добровольский А. В. Сравни- тельная оценка шкал CES-D, BDI и HADS (d) в диагностике депрессий в общемедицинской практике. Журнал неврологии и психиатрии им СС Корсакова. 2003;103 (5):11–8. [Andrushen- ko A. V., Drobizhev M. Yu., Dobrovolskiy A. V. Sravnitel’naya ocen- ka shkal CES-D, BDI i HADS (d) v diagnostike depressij v obshche- medicinskoj praktike. Zhurnal nevrologii i psikhiatrii imeni S. S. Kor- sakova. 2003;103 (5):11–8.]
  874. Беленков Ю. Н., Агеев Ф. Т., Банщиков Г. Т., Волкова Е. Г., Гиля- ревский С. Р., Донова И. Г. и др. Влияние специализированных форм активного амбулаторного ведения на функциональный статус, качество жизни и показатели гемодинамики больных с выраженной сердечной недостаточностью. Результаты Российской программы «ШАНС». Журнал Сердечная Недостаточность. 2007;8 (3):112–6. [Belenkov Yu. N., on behalf of the «CHANCE» research group. Effect of specialized forms of ac- tive out-patient management on the functional status, quality of life and hemodynamic parameters in patients with advanced heart fail- ure. Results of the Russian Program «CHANCE». Russian Heart Failure Journal. 2007;8 (3):112–6.]
  875. Беграмбекова Ю. Л., Мареев В. Ю., Дробижев М. Ю. Школы для пациентов с сердечной недостаточностью. Есть ли ШАНС повлиять на депрессию и тревогу? Вторичный (Post-hoc) анализ исследования ШАНС (Школа и Амбулаторное Наблюдение больных Сердечной недостаточностью). Журнал Сердечная Недостаточность. 2016;17 (6):433–42. [Begrambekova Yu. L., Mareev V. Yu., Drobizhev M. Yu. Disease management programs for the heart failure patients. Is thereany CHANCE to defeat depres- sion and anxiety Post-hoc analysis of CHANCE trial (Congestive Heart Failure: A multidisciplinaryNon-pharmacological approach for Changing in rE-hospitalizat. Russian Heart Failure Journal. 2016;17 (6):433–442] DOI:10.18087/rhfj. 2016.6.2281
  876. Dekker RL. Cognitive Therapy for Depression in Patients with Heart Failure: A Critical Review. Heart Failure Clinics. 2011;7 (1):127–41. DOI:10.1016/j. hfc. 2010.10.001
  877. Gary RA, Dunbar SB, Higgins MK, Musselman DL, Smith AL. Com- bined exercise and cognitive behavioral therapy improves outcomes in patients with heart failure. Journal of Psychosomatic Research. 2010;69 (2):119–31. DOI:10.1016/j. jpsychores. 2010.01.013
  878. Tu R-H, Zeng Z-Y, Zhong G-Q, Wu W-F, Lu Y-J, Bo Z-D et al. Ef- fects of exercise training on depression in patients with heart fail- ure: a systematic review and meta-analysis of randomized controlled trials: Effects of exercise training on depression in HF: a systema- tic review. European Journal of Heart Failure. 2014;16 (7):749–57. DOI:10.1002/ejhf. 101
  879. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Call- wood DD et al. Safety and Efficacy of Sertraline for Depression in Pa- tients With Heart Failure. Journal of the American College of Cardiol- ogy. 2010;56 (9):692–9. DOI:10.1016/j. jacc. 2010.03.068
  880. Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA. 2016;315 (24):2683. DOI:10.1001/jama. 2016.7635
  881. Glassman AH. Cardiovascular Effects of Tricyclic Antidepressants. Annual Review of Medicine. 1984;35 (1):503–11. DOI:10.1146/an- nurev. me. 35.020184.002443
  882. Goldberg RJ, Capone RJ, Hunt JD. Cardiac complications following tricyclic antidepressant overdose. Issues for monitoring policy. JAMA. 1985;254 (13):1772–5. PMID:4032678
  883. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem. 1999;6 (6):469–80. PMID:10213794
  884. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al. Aripip- razole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302 (1):381–9. PMID:12065741
  885. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The anti- psychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441 (3):137–40. PMID:12063084
  886. Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) «cachexia-an- orexia in chronic wasting diseases» and «nutrition in geriatrics». Cli- nical Nutrition. 2010;29 (2):154–9. DOI:10.1016/j. clnu. 2009.12.004
  887. Beaudart C, Reginster J-Y, Slomian J, Buckinx F, Locquet M, Bru- yère O. Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. J Musculoskelet Neuronal Interact. 2014;14 (4):425– 31. PMID:25524968
  888. Collamati A, Marzetti E, Calvani R, Tosato M, D’Angelo E, Sisto AN et al. Sarcopenia in heart failure: mechanisms and therapeutic strate- gies. J Geriatr Cardiol. 2016;13 (7):615–24. DOI:10.11909/j. issn. 1671–5411.2016.07.004
  889. Hajahmadi M, Shemshadi S, Khalilipur E, Amin A, Taghavi S, Male- ki M et al. Muscle wasting in young patients with dilated cardiomy- opathy: Muscle wasting in young patients with dilated cardiomyopa- thy. Journal of Cachexia, Sarcopenia and Muscle. 2017;8 (4):542–8. DOI:10.1002/jcsm. 12193
  890. Massy-Westropp NM, Gill TK, Taylor AW, Bohannon RW, Hill CL. Hand Grip Strength: age and gender stratified normative data in a population-based study. BMC Research Notes. 2011;4 (1):127. DOI:10.1186/1756-0500-4-127
  891. Landi F, Marzetti E, Martone AM, Bernabei R, Onder G. Exercise as a remedy for sarcopenia: Current Opinion in Clinical Nutrition and Metabolic Care. 2013;1. DOI:10.1097/MCO. 0000000000000018
  892. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise train- ing. Journal of Cachexia, Sarcopenia and Muscle. 2010;1 (1):9–21. DOI:10.1007/s13539-010-0007-1
  893. Binder EF, Yarasheski KE, Steger-May K, Sinacore DR, Brown M, Schechtman KB et al. Effects of Progressive Resistance Training on Body Composition in Frail Older Adults: Results of a Rando- mized, Controlled Trial. The Journals of Gerontology Series A: Bi- ological Sciences and Medical Sciences. 2005;60 (11):1425–31. DOI:10.1093/gerona/60.11.1425
  894. Smart NA, Steele M. The Effect of Physical Training on System- ic Proinflammatory Cytokine Expression in Heart Failure Patients: A Systematic Review: physical training and cytokine levels. Con- gestive Heart Failure. 2011;17 (3):110–4. DOI:10.1111/j. 1751– 7133.2011.00217. x
  895. Daly RM. Exercise and nutritional approaches to prevent frail bones, falls and fractures: an update. Climacteric. 2017;20 (2):119–24. DOI :10.1080/13697137.2017.1286890
  896. Pinto CL, Botelho PB, Carneiro JA, Mota JF. Impact of creatine supple- mentation in combination with resistance training on lean mass in the elderly: Creatine and resistance training in the elderly. Journal of Ca- chexia, Sarcopenia and Muscle. 2016;7 (4):413–21. DOI:10.1002/jc- sm. 12094
  897. Арутюнов Г. П., Чернявская Т. К., Костюкевич О. И., Волги- на О. Н. Сердечная кахексия. Фарматека. 2008; (11):68–71. [Arutyunov G. P., Chernyavskaya T. K., Kostyukevich O. I., Volgi- na O. N. Cardiac cachexia. Pharmateca. 2008;11:68–71.]
  898. Арутюнов Г. П., Костюкевич О. И. Питание больных с хронической сердечной недостаточностью, проблемы нутритивной поддержки, решенные и нерешенные аспекты. ЖСН. 2002;3 (5):245–8. [Aru- tyunov G. P., Kostyukevich O. I. Nutrition of patients with heart fail- ure. Problems of nutritive support. Solved and unsolved aspects. Rus- sian Heart Failure Journal. 2002;3 (5):245–8.]
  899. Арутюнов АГ, Костюкевич ОИ, Звонова ЕВ, Топильская НВ. Исследование распространенности и клинической значимости гипотрофии у терапевтических больных (САТУРН). ЖСН. 2007;8 (3):144–9. [Arutyunov A. G., Kostyukevich O. I., Zvonova E. V., To- pilskaya N. V. Study on prevalence and clinical significance of hypot- rophy in therapeutic patients (SATURN). Russian Heart Failure Jour- nal. 2007;8 (3):144–9.]
  900. Арутюнов Г. П., Костюкевич О. И., Звонова Е. В., Топильская Н. В. Клиническая эффективноСть питАтельной смеси ПепТамен У пациентов с хронической сеРдечной недостаточностью III–IV ФК по NYHA и призНаками гипотрофии (САТУРН-II), предварительные результаты. Журнал Сердечная Недостаточность. 2007;8 (5):239–43. [Arutyunov G. P., Kostyuke- vichO. I., Zvonova E. V., Topilskaya N. V. Clinical efficacy of the nu- tritive mixture Peptamen in patientS with III–IV NYHA FC chronic heArT failURe and sigNs of hypotrophy (SATURN-II): preliminary data. Russian Heart Failure Journal. 2007;8 (5):239–43.]
  901. Zamboni M, Rossi AP, Corzato F, Bambace C, Mazzali G, Fan- tin F. Sarcopenia, cachexia and congestive heart failure in the elder- ly. Endocr Metab Immune Disord Drug Targets. 2013;13 (1):58–67. PMID:23369138
  902. Von Haehling S. The wasting continuum in heart failure: from sar- copenia to cachexia. Proceedings of the Nutrition Society. 2015;74 (04):367–77. DOI:10.1017/S0029665115002438
  903. Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials: Weight loss in the GISSI-HF and Val-HeFT trials. European Journal of Heart Failure. 2015;17 (4):424–33. DOI:10.1002/ejhf. 240
  904. Арутюнов Г. П. Кахексия у больных с хронической сердечной недостаточностью. Каков масштаб проблемы? Что мы знаем и что нам делать? ЖСН. 2001;2 (3):101. [Arutyunov G. P. Cachexia in patients with chronic heart failure. What is the scale of the problem? What do we know and what do we do? Russian Heart Failure Journal. 2001;2 (3):101.]
  905. Clark AL, Coats AJS, Krum H, Katus HA, Mohacsi P, Salekin D et al. Effect of beta-adrenergic blockade with carvedilol on cachexia in se- vere chronic heart failure: results from the COPERNICUS trial: Ca- chexia and beta blockers in chronic heart failure. Journal of Cachex- ia, Sarcopenia and Muscle. 2017;8 (4):549–56. DOI:10.1002/jcsm. 12191
  906. Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG et al. Iron deficiency impairs contractility of hu- man cardiomyocytes through decreased mitochondrial function: Im- paired contractility in iron-deficient cardiomyocytes. European Jour- nal of Heart Failure. 2018;20 (5):910–9. DOI:10.1002/ejhf. 1154
  907. Núñez J, Comín-Colet J, Miñana G, Núñez E, Santas E, Mollar A et al. Iron deficiency and risk of early readmission following a hos- pitalization for acute heart failure: Iron deficiency and rehospital- ization. European Journal of Heart Failure. 2016;18 (7):798–802. DOI:10.1002/ejhf. 513
  908. Pozzo J, Fournier P, Delmas C, Vervueren P-L, Roncalli J, Elbaz M et al. Absolute iron deficiency without anaemia in patients with chronic systolic heart failure is associated with poorer functional ca- pacity. Archives of Cardiovascular Diseases. 2017;110 (2):99–105. DOI:10.1016/j. acvd. 2016.06.003
  909. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ et al. Anemia and Mortality in Heart Fail- ure Patients. Journal of the American College of Cardiology. 2008;52 (10):818–27. DOI:10.1016/j. jacc. 2008.04.061
  910. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R et al. Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Fail- ure. New England Journal of Medicine. 2013;368 (13):1210–9. DOI:10.1056/NEJMoa1214865
  911. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Ole kowska-Florek W et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eu- ropean Heart Journal. 2014;35 (36):2468–76. DOI:10.1093/eur- heartj/ehu235
  912. Von Haehling S, Gremmler U, Krumm M, Mibach F, Schön N, Tagge- selle J et al. Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clinical Research in Cardiology. 2017;106 (6):436–43. DOI:10.1007/s00392-016-1073-y
  913. Yeo TJ, Yeo PSD, Ching-Chiew Wong R, Ong HY, Leong KTG, Jaufeerally F et al. Iron deficiency in a multi-ethnic Asian popula- tion with and without heart failure: prevalence, clinical correlates, functional significance and prognosis: Iron deficiency in Asian heart failure. European Journal of Heart Failure. 2014;16 (10):1125–32. DOI:10.1002/ejhf. 161
  914. Weiss G, Goodnough LT. Anemia of chronic disease. New England Journal of Medicine. 2005;352 (10):1011–23. DOI:10.1056/NEJM- ra041809
  915. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation. 2003;107 (2):223–5. DOI:10.1161/01. CIR. 0000052622.51963. FC
  916. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in se- vere heart failure: the prospective randomized amlodipine surviv- al evaluation (PRAISE). J Am Coll Cardiol. 2003;41 (11):1933–9. PMID:12798560
  917. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheo- rghiade M et al. Usefulness of anemia as a predictor of death and re- hospitalization in patients with decompensated heart failure. Am J Car- diol. 2003;92 (5):625–8. PMID:12943893
  918. Solomakhina NI, Nakhodnova ES, Gitel EP, Belenkov YN. Hepcidin and its relationship with inflammation in old and older patients with anemia of chronic disease associated with CHF. Kardiologiia. 2018;17 (S2):4–11. DOI:10.18087/cardio. 2457
  919. Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felk- er GM et al. Effect of Oral Iron Repletion on Exercise Capacity in Pa- tients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017;317 (19):1958. DOI:10.1001/jama. 2017.5427
  920. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V et al. Beneficial effects of long-term intravenous iron thera- py with ferric carboxymaltose in patients with symptomatic heart fail- ure and iron deficiency. European Heart Journal. 2015;36 (11):657– 68. DOI:10.1093/eurheartj/ehu385
  921. Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Wil- lenheimer R et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanaly- sis of the FAIR-HF trial. European Journal of Heart Failure. 2013;15 (11):1267–76. DOI:10.1093/eurjhf/hft099
  922. Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R et al. Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure. Journal of the American College of Car- diology. 2006;48 (6):1225–7. DOI:10.1016/j. jacc. 2006.07.015
  923. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous Iron Reduc- es NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency. Journal of the American College of Cardiology. 2007;50 (17):1657–65. DOI:10.1016/j. jacc. 2007.07.029
  924. Usmanov RI, Zueva EB, Silverberg DS, Shaked M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol. 2008;21 (2):236–42.
  925. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H et al. Ferric Carboxymaltose in Patients with Heart Fail- ure and Iron Deficiency. New England Journal of Medicine. 2009;361 (25):2436–48. DOI:10.1056/NEJMoa0908355
  926. Beshara S, Sorensen J, Lubberink M, Tolmachev V, Langstrom B, An- toni G et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe- labelled iron polymaltose in anaemic patients using positron emission tomography. British Journal of Haematology. 2003;120 (5):853–9. DOI:10.1046/j. 1365–2141.2003.03590. x
  927. Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-rela- ted heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21 Suppl 5: v277–282. DOI:10.1093/annonc/mdq200
  928. Hochhaus A, Kantarjian H. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial stu- dies to application in newly diagnosed patients. Journal of Can- cer Research and Clinical Oncology. 2013;139 (12):1971–84. DOI:10.1007/s00432-013-1488-z
  929. Под ред. Н. И. Переводчиковой. Руководство по химиотерапии опухолевых заболеваний. -М.: Практическая медицина; 2011. 512 с. [Guide for chemotherapy of neoplastic diseases. ed. by Perevod- chikova N. I. – M.: Practical medicine, 2011. – 512p. (p. 435–436)] ISBN: 978-5-98811-180-1
  930. Gendlin GE, Emelina EI, Nikitin IG, Vasyuk YA. Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracy- clines. Russian Journal of Cardiology. 2017; (3):145–54. DOI:10.158 29/1560-4071-2017-3-145-154
  931. Vejpongsa P, Yeh ETH. Prevention of Anthracycline-Induced Car- diotoxicity. Journal of the American College of Cardiology. 2014;64 (9):938–45. DOI:10.1016/j. jacc. 2014.06.1167
  932. Raj S, Franco VI, Lipshultz SE. Anthracycline-induced car- diotoxicity: a review of pathophysiology, diagnosis, and treat- ment. Curr Treat Options Cardiovasc Med. 2014;16 (6):315. DOI:10.1007/s11936-014-0315-4
  933. Матяш М. Г., Кравчук Т. Л., Высоцкая В. В., Чернов В. И., Гольд- берг В. Е. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский Онкологический Журнал. 2008; (6):66–75. [Matyash M. G., Krav- chuk T. L., Vysotskaya V. V., Chernov V. I., Goldberg V. E. Anthracy- cline-induced cardiac toxicity: mechanisms of development and clini- cal manifestations. Sibirskii onkologicheskii zhurnal. 2008;6:66–75.]
  934. Shakir D. Chemotherapy Induced Cardiomyopathy: Pathogene- sis, Monitoring and Management. Journal of Clinical Medicine Re- search [Internet]. 2009 [cited on June 1, 2018]; DOI:10.4021/joc- mr2009.02.1225
  935. Shuykova KV, Emelina EI, Gendlin GE, Storojakov GI. Сhange of the left ventricle functioning in lymphoma treated with anthracycline an- tibiotics. Russian Journal of Cardiology. 2016; (1):41–6. DOI:10.158 29/1560-4071-2016-1-41-46
  936. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS et al. Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malig- nancies in Pediatric Hodgkin’s Disease. Journal of Clinical Oncology. 2007;25 (5):493–500. DOI:10.1200/JCO. 2005.02.3879
  937. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Can- cer Institute ALL Consortium. European Journal of Cancer. 2011;47 (9):1373–9. DOI:10.1016/j. ejca. 2011.03.022
  938. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children’s oncology group. Leukemia. 2010;24 (2):355–70. DOI:10.1038/leu. 2009.261
  939. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Pro- tective Effects of Carvedilol Against Anthracycline-Induced Cardio- myopathy. Journal of the American College of Cardiology. 2006;48 (11):2258–62. DOI:10.1016/j. jacc. 2006.07.052
  940. Правдивцева Е. В., Потешкина Н. Г., Сванадзе А. М., Рыль- ский Д. С. Профилактика кардиотоксического действия антрацикли- нового антибиотика доксорубицина: роль ингибитора ангиотензин- превращающего фермента периндоприла. Клиницист. 2011; (3):55–61. [Pravdivtseva E. V., Poteshkina N. G., Svanadze A. M., Rilskiy D. S. Preven- tion of antracyclin antibiotic doxorubicin сardiotoxicity: a role of ace-in- hibitor perindopril. Clinician. 2011;3:55–60]
  941. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al. Enalapril and Carvedilol for Preventing Che- motherapy-Induced Left Ventricular Systolic Dysfunction in Pa- tients With Malignant Hemopathies. Journal of the American Col- lege of Cardiology. 2013;61 (23):2355–62. DOI:10.1016/j. jacc. 2013.02.072
  942. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342 (15):1077–84. DOI:10.1056/NEJM200004133421502
  943. Стенина М. Б., Фролова М. А. Рак молочной железы: наиболее важные научные события и выводы последних лет. Практическая Онкология. 2011;12 (1 (45)): 6–11. [Stenina M. B., Frolo- va M. A. Breast cancer: the most important scientific events and con- clusions of recent years. Practical Oncology. 2011;12 (1):6–11]
  944. Abi Aad S, Pierce M, Barmaimon G, Farhat FS, Benjo A, Mou- hayar E. Hypertension induced by chemotherapeutic and immunosup- presive agents: A new challenge. Critical Reviews in Oncology/Hema- tology. 2015;93 (1):28–35. DOI:10.1016/j. critrevonc. 2014.08.004
  945. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol ADG et al. Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma. JNCI: Journal of the National Cancer Institute [Internet]. 2015 [cited on June 1, 2018];107 (4). DOI:10.1093/jn- ci/djv008
  946. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340–9. DOI:10.1001/jama.2012.12559

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы/REFERENCES
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*